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Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic 
and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion 
reported in 2017. A popular framework widely used in pharmaceutical industries for designing 
manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured 
and systematic approach in investigation and screening process parameters that might influence 
the product quality. However, due to the large number of product quality attributes (CQAs) and 
process parameters that exist in an mAb process platform, extensive investigation is needed to 
characterise their impact on the product quality which makes the process development costly 
and time consuming. There is thus an urgent need for methods and tools that can be used for 
early risk-based selection of critical product properties and process factors to reduce the number 
of potential factors that have to be investigated, thereby aiding in speeding up the process 
development and reduce costs. 
In this study, a framework for predictive model development based on Quantitative Structure-
Activity Relationship (QSAR) modelling was developed to link structural features and 
properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and 
expressed mAb yield from HEK cells. Model development was based on a structured approach 
for incremental model refinement and evaluation that aided in increasing model performance 
until becoming acceptable in accordance to the OECD guidelines for QSAR models. 
The resulting models showed that it was possible to predict HIC retention times of mAbs based 
on their inherent structure. Further improvements of the models are suggested due to 
performance being adequate but not sufficient for implementation as a risk assessment tool in 
QbD. However, the described methodology and workflow has been proven to work for retention 
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Monoclonal antibodies (mAbs) are therapeutic proteins that have gained increasing popularity 
and importance over the last three decades mainly due to their clinical specificity and safety as 
treatments, but also because they can be applied to a wide spectrum of different ailments. The 
Process Analytical Technology (PAT) initiative and the Quality by Design (QbD) paradigm 
have become an integral part of process development of mAbs in today’s pharmaceutical 
industries with the goal of increasing process understanding and control in order to deliver a 
consistent product quality (Rathore, 2014, Zurdo et al., 2015). Continuous improvements are 
constantly being made to increase the effectiveness and applicability of these frameworks for 
the production of biopharmaceuticals (Glassey et al., 2011). However, many challenges still 
impede the successful implementation of QbD due to limited process and product 
understanding in early process development. This has led to an increased need of tools to aid in 
risk assessment of mAb candidates in order to speed up process development but also to 
evaluate their manufacturing feasibility.  
In the last decade, much focus has been directed to the development of in silico methods that 
can aid in risk assessment and speed up the process development. The Quantitative structure-
activity relationships (QSAR) framework, which can use knowledge from previous mAb 
production processes, appears to be one of the most promising frameworks for the development 
of predictive tools. The main strength of the QSAR framework is its ability to effectively link 
structural properties and features of the protein structure, which are commonly known as 
descriptors, to those of the biological response or mAb behaviour in unit operations. This 
therefore has the potential of increasing the product understanding of new mAb candidates in 
early process development by aiding in the risk assessment and process route selection and 
allowing for a more efficient process development. 
The aim of this project was therefore to explore the available methods in the QSAR framework 
that could be used to address the lack of process and product knowledge in early process 
development. A list of project objectives has been presented below:  
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1. Generation and exploration of suitable structural descriptors that can be used for 
predictive QSAR models. 
2. Development of a robust and structured framework with critical evaluation of 
classification and regression methods to determine their applicability in relevant process 
development settings. 
3. Testing the proposed modelling framework and descriptors generation workflow on 
relevant process development data. In this research HIC retention times and mAb yields 
of 137 mAbs was used and acquired from a data set published by Jain et al. (2017).  
Thesis structure 
The thesis starts with an extensive review of the QbD and QSAR frameworks in Chapter 1. 
Methodology and implementation of predictive modelling methods and techniques are 
overviewed in Chapter 2. The remaining chapters of the thesis can logically be divided into two 
parts based on the methodology used to acquire structural descriptors that were used in the 
predictive modelling. The first part investigates structural descriptors derived directly from the 
primary sequence (amino acid sequences) of the mAbs and is described in Chapter 3, Chapter 
4 and Chapter 5. The second part investigates structural descriptors derived from the 3D 
structure of the mAbs and is described in Chapter 6 and Chapter 7. 
Chapter 1: Literature Review 
The literature review provides a background of the current state-of-the-art in process 
development of mAbs according to the QbD paradigm. Attrition and current challenges in the 
paradigm are addressed which mainly originates in the limited knowledge of both the process 
and product available in early process development. The QSAR methodology was proposed for 
predictive model development of mAb behaviour in unit operations. 
Chapter 2: Modelling Development and Assessment 
This chapter provides an overview of the multivariate techniques used in this research to 
develop and test predictive QSAR models. Examples of successful implementation of these 
methods and their applicability to specific problems are highlighted and reviewed.  
Chapter 3: Primary Sequence-based Descriptors 
In this chapter the structure and sources of sequence variation in a mAb are assessed and 
reviewed. The methodology for generating descriptors based on the primary sequence is 
presented with the corresponding software used in this research.  
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Chapter 4: Impact of mAb isotypes and species origins on primary sequence-based 
descriptors 
The generated descriptors from Chapter 3 are investigated with exploratory methods with 
regards to structural variations related to the heavy and light chain isotype as well as the species 
origins. This provided insight into sources of variations that were present in the primary 
sequence-based descriptors sets and was used for identifying systematic structural variation that 
negatively impacted model performance in Chapter 5. 
Chapter 5: QSAR model development: Primary sequence-based descriptors 
In this chapter the applicability of the primary sequence-based descriptors in predictive 
modelling of HIC retention times and mAb yields was assessed. A statistical analysis 
investigating the impact of the heavy and light chain isotypes as well as species origins on the 
two responses was performed. The statistical analysis coupled with the exploratory analysis in 
Chapter 4 was used as a foundation for sample selection in order to reduce systematic variation 
in the descriptors that was detrimental to the performance of the developed models. 
Chapter 6: 3D Structure Descriptors 
In this chapter a methodology for generating descriptors from the 3D structure of mAbs is 
presented. To this end, methods for generating 3D structures from the primary sequence is 
assessed as well as options for protein dynamics simulations for structure relaxation and 
modifications are reviewed and covered in detail.  
Chapter 7: QSAR model development: 3D Structure Descriptors 
The applicability of the 3D structure descriptors from Chapter 7 is assessed in predictive 
modelling of HIC retention times and mAb yields. Exploration of structural variations related 
to the light chain isotypes as well as the species origins are performed to investigate potential 
systematic variation that may be detrimental to the performance of the developed models. A 
comparison between models developed using the primary sequence-based descriptors and the 
3D structure descriptors was carried out to evaluate their applicability in an industrial setting. 
Chapter 8: Conclusion and Future Perspectives 
This chapter concludes the work presented in this thesis as well as providing suggestions for 







Chapter 1  
 
Literature review 
1.1 Antibody Market 
The increasing popularity of mAbs can be seen in Figure 1.1a where the number of approved 
mAbs by the European Medicine Agency (EMA) in EU (blue line) and the Food and Drug 
Administration (FDA) in US (green line) has drastically increased over the last 30 years 
(ACTIP, 2017, May 15, Reichert, 2012). In the last five years a new trend has emerged where 
manufacturing of generic mAbs, known as biosimilars, has gained more attention due to the 
expiration of patents on mAbs introduced to the market earlier. The first biosimilar of 
infliximab (better known as Remicade) was first approved and then marketed in 2013 by the 
EMA and later approved by FDA in 2016, thus opening the door for manufacturing of generic 
mAbs. As of 2017, a total number of 11 biosimilars has been approved by either EMA, FDA or 
both. These are biosimilars of infliximab, adalimumab, trastuzumab and rituximab (Grilo and 
Mantalaris, 2019). A list of currently approved mAbs is presented in Table A.1 in Appendix A. 
The market sales have enjoyed an increasing growth ever since the first mAb was launched in 
1986. Recent reports on the mAb market show an increase in revenue from around $39 billion 
in 2008 to around $89 billion in 2017 illustrated in Figure 1.1b, making mAbs one of the fastest 
growing bioproduct groups (Ecker et al., 2015, Grilo and Mantalaris, 2019). The market is 
expected to grow further with a predicted worldwide revenue of between $130-200 billion by 




Figure 1.1. Approval and market trends of mAbs. (a) History of approved mAbs by EMA (blue) and FDA (green) 
annually (bars) and cumulative (lines) as well as approved biosimilars by either EMA, FDA or both shown in red. 
(b) History of market revenue from 2008 to 2018 (green bars) and prognosis of the expected market revenue 
between 2019 and 2022 (red bars) where an optimistic revenue prognosis has been included (grey bars). Based on 
market data from EvaluatePharma® (2018) and Grilo and Mantalaris (2019). 
Due to their popularity and market revenue, many advances in improving the mAb 
manufacturing processes have been made including process optimisation (Fischer et al., 2015, 
Kunert and Reinhart, 2016) and process control (Karst et al., 2017). Frameworks, such as QbD, 
have gained popularity during recent years due to their ability to expedite the process 
development of mAbs through increased process understanding (Rathore et al., 2018). 
However, the manufacturing of mAbs is cost-intensive due to the high product quality and 
regulatory requirements that must be met to make the product clinically safe. This is especially 
pronounced in the downstream processes due to the need of high product purity of the end 
product (Hammerschmidt et al., 2014, Hou et al., 2011). Industries still struggle with the 
development of the manufacturing processes due to high complexity of both the underlying 
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biological system and the behaviour of the mAb molecules, which hampers the implementation 
of PAT and QbD (Krummen, 2013, Mercier et al., 2014). In particular, the sensitivity of the 
product quality in mAbs to changes in the processing conditions requires a high level of 
understanding of the product and process in order to implement effective control. There is thus 
an increased need for better tools to aid process development. Due to its popularity in 
pharmaceutical industries, the QbD framework is reviewed in detail in this chapter and some 
of its limitations and challenges are highlighted.  
1.2 State of the Art in mAb manufacturing 
In 2004, FDA introduced a new regulatory initiative called Process Analytical Technology 
(PAT) with the aim to design and develop well understood processes that consistently ensure a 
predefined quality of a drug at the end of the manufacturing process (U.S. Department of of 
Health and Human Services, 2004). The PAT principles are used to gain information relating 
to physical, chemical and biological attributes of the product to increase process understanding 
to create a foundation for the implementation of monitoring, optimisation and control of the 
process (Glassey et al., 2011). The QbD paradigm was introduced in 2004 and is a systematic 
approach that aligns with the PAT principles and aims to build quality into the product through 
product and process understanding. The framework is especially useful for process 
development of mAbs, which consists of many different steps (unit operations). A typical mAb 
process can be divided into two parts: The upstream (USP) or the cell culture where the mAbs 
are expressed and the downstream (DSP) or purification where the mAbs are isolated and 
contaminants removed. Typically, a mAb process will consist of between 15-20 different unit 
operations which must be characterised in order to deliver consistent quality and safety of use 
(Rathore et al., 2018). The guideline for implementation of QbD is outlined in the International 
Conference on Harmonisation Guidelines: ICH Q8 (ICH Harmonised Tripartite Guideline, 
2009), ICH Q9 (ICH Harmonised Tripartite Guideline, 2005) and ICH Q10(ICH Harmonised 
Tripartite Guideline, 2008). The general outline and the nomenclature of the QbD methodology 




Figure 1.2. General outline of the QbD methodology. The process design space is shown as the dashed box where 
the effects of process parameters and raw material input (blue box) on the product quality is characterised. Steps 
highlighted in red indicate risk assessment of either product quality attributes, process parameters or raw materials. 
The green box indicates availability of clinical data which can be used to better define the QTPP (adapted from 
Chatterjee (2012)).  
1.2.1 Implementation of QbD 
The implementation of QbD starts by defining the Quality Target Product Profile (QTPP) which 
forms the basis of the design for the development and contains information about the drug 
quality criteria such as delivery mechanisms, intended use, route of administration for the 
intended product to ensure clinical safety and efficacy. The QTPP is generated from knowledge 
based on literature research, clinical trials and existing experience from industry or academia 
(Herwig et al., 2015, Rathore, 2014). For mAbs, the QTPP relates to the product’s intended use 
and properties that can affect patients and need to be clearly stated in order to avoid adverse 
effects in patients. These should include antigen binding, pharmacokinetics, effector function, 
stability and half-life of the mAb (Rathore, 2009, Alt et al., 2016). However, much of this 
information does not become available until later when clinical data has been obtained. Thus, 
instead many aspects of the QTPP are based on prior knowledge in early process development 
of an mAb. Recently, computational prediction and simulation of the mAb structure have been 
shown to be a valuable tool for mAb design due to their ability to provide estimates of behaviour 
and protein stability which can aid in more accurate QTPP specification (Yamashita, 2018, 
Tiller and Tessier, 2015). 
Based on the QTPP, the Critical Quality Attributes (CQAs) are identified from a list of Quality 
Attributes (QAs) using risk-based analysis in accordance with the ICH Q9 guideline to 
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investigate properties that might affect product quality. The CQAs are physical, chemical or 
biological properties of the drug product that need to be within appropriate ranges to ensure the 
desired product quality. These ranges, similarly to the generation of QTPP, are obtained through 
literature research, clinical data and previous experience but they are also updated during the 
process development as new information from characterisation studies becomes available. The 
most frequently used method for risk assessment in industries is Failure Mode and Effect 
Analysis (FMEA) where the impact of different unit operations in the process on the QAs are 
listed. Each effect is ranked according to a Severity rating (S), an Occurrence rating (O) and a 
Detectability rating (D). A final Risk Priority Number (RPN) is calculated by multiplying the 
ratings which are then ranked to identify the effects that potentially affect the product quality 
and efficacy (Zimmermann and Hentschel, 2011, Harms et al., 2008). Tailored risk assessment 
methods have also been proposed for biopharmaceuticals by Zalai et al (2013) where the authors 
argued that traditional methods do not take into account the “complexity” of how a process 
might affect the product or the “uncertainty” which includes the quality of the input material as 
a possible source of risk and which need to be added as additional factors to the risk assessment 
(Zalai et al., 2013). A list of potential CQAs adapted from the work of Alt et al (2016) is 
presented in Table 1.1 which gives a non-exhaustive overview of the different structural 
variants that can occur in mAbs and can affect their structure, stability and activity. It is 
therefore important that the CQAs are controlled in order to achieve the desired product quality 
(Alt et al., 2016).  
All categories of variants in Table 1.1, except the “structure” category, are caused by so-called 
post-translational modifications (PTMs). This means that modifications of the protein structure 
occurs after the mAb has been expressed in the cells and which are therefore highly dependent 
on the environment (Yang et al., 2013). For clarification, a few of the PTMs are described in 
more detail. The low molecular weight species (LMW) is an incomplete mAb structure where 
a part or parts of the structure are missing. This is most commonly caused by missing disulphide 
bonds between chains (see Section 3.1 for description of mAb structure) or enzymatic/non-
enzymatic cleavage of the amino acid sequence (Wang et al., 2018). Additionally, if cleavage 
occurs at the C-terminal residue, which is most often a lysine in mAbs, a basic charge variant 
will be produced as well, due to loss of a basic residue. However, other charge variants can still 
occur without the sequence cleavage. For example, deamidation of sterically free asparagine 
into aspartate is one such PTM which is promoted if the asparagine is followed by a glycine 
(Khawli et al., 2010). It is important to remember that the majority of the PTMs require the site 
or the residue that is modified to be accessible on the surface of the mAb structure and therefore 
in contact with the solvent (Sydow et al., 2014). It should be noted that Table 1.1 does not take 
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into consideration the quality of the input material and its effect on the product quality as well 
as various process related QAs, such as contaminants e.g. host cell proteins (HCPs) and DNA, 
which also need to be characterised. 
Table 1.1. List of potential CQAs related to common structural variants in mAbs (adapted from Alt et al. (2016)). 
Category Quality Attribute 
Size related High Molecular Weight Species (HMWs) 
 Low Molecular Weight Species (LMWs) 
Acidic Charge Variants Deamidation in CDRs regions 
 Deamidation in non-CDR regions 
 Glycation in CDR regions 
 Glycation in non-CDR regions 
Basic Charge Variants Aspartic Acid isomerisation in CDR regions 
 Aspartic Acid isomerisation in non-CDR regions 
 C-terminal Lysine cleavage 
 N-terminal leader sequence 
 N-terminal pyroglutamic acid 
Oxidation Oxidation of Methionine and Tryptophan in CDR regions 
 Oxidation of Methionine in non-CDR regions 




 Non-glycosylated Heavy chain 
Structure Cysteine variants 
 Sequences variants 
 Protein structure 
 
Once the CQAs have been selected, a process design space is defined by screening process 
parameters (PPs) for each of the unit operations in the process that have a significant effect on 
the CQAs. PPs that have a significant impact on the CQAs are called Critical Process 
Parameters (CPPs) and are identified and controlled through the use of the following steps:  
1. Similar to identification of CQAs, risk analysis methods, such as FMEA, are used to 
reduce the large number of PPs to those that may affect CQAs. 
2. Systematic experimental studies using Design of Experiments (DoE) over a range of PP 
settings are carried out in small scale to obtain experimental data for process 
characterisation to identify CPPs and their optimal ranges which. This is referred to as 
the control space.  
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3. Multivariate data analysis (MVDA) is used for implementation of appropriate real-time 
monitoring and control strategies needed for the defined CQAs and CPPs to ensure 
product quality. Movement outside of the defined control space would cause the product 
quality to drop below that of the desired quality stated in the QTPP.  
The use of statistical DoE is preferred in process development of pharmaceuticals over 
univariate analysis as it can generate qualitative and quantitative information about important 
process parameters and their impact on the product quality (Leardi, 2009). Response Surface 
Modelling (RSM) and leverage plots are often used on generated DoE data to investigate the 
significance of PPs on the explored CQAs as well as define allowed ranges for the identified 
CPPs (Rathore, 2016). Several different experimental designs exists and selecting an 
appropriate design is critical in order to maximise the information gained from the experiments. 
Kumar et al. (2014) compared different experimental designs for the DoE of downstream unit 
operations to demonstrate how these affect the response surface of each unit operation (Kumar 
et al., 2014).  Tai et al. (2015) showed that a well-chosen experimental design can lead to diverse 
and informative data about the system and when combined with high-throughput 
experimentation techniques, can be a powerful tool when defining the process design space.  
Process validation is performed when the design space has been characterised to demonstrate 
that the desired product quality is delivered when operated within the design space and is 
usually performed on larger scale. In order to ensure consistent quality, the CQAs need to be 
within the defined control space of the process. This is done through monitoring and control of 
identified CPPs that have a dynamic behaviour and effect on the CQAs e.g. pH, temperature, 
flow rates etc. (Read et al., 2010, Golabgir et al., 2015). MVDA methods such as Principal 
Component Analysis (PCA) and Partial Least Square (PLS) are commonly employed in order 
to monitor and control CQAs (Ferreira and Tobyn, 2015). For examples of MVDA 
implementations for monitoring and control, refer to “modelling based approaches” under 
Section 1.2.3. However, implementation of monitoring and control strategies is usually not 
necessary for all CPPs e.g. trace elements in the basal media might need to be characterised, 
depending on the product, to achieve the desired product quality, but they do not necessarily 
need to be monitored in real time.  The control of the CPPs should always be in the form of a 
dynamic control scheme to ensure that product quality is kept constant, even if there is 
variability introduced by the input raw materials used in the process. The QbD framework is an 
iterative process where the QTTP, CQAs and CPPs need to be constantly revaluated in order to 
characterise all sources of variability that can impact the final product quality. 
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As mentioned previously, many aspects of the QTPP might not be known in early process 
development and only become available once clinical trials have been performed. This means 
that the process development is closely linked to the clinical phases, as illustrated in Figure 1.3. 
Once clinical data becomes available, better decisions regarding the potential redesign of the 
product and re-evaluation of the QTPP, CQAs and CPPs can be made (Cooney et al., 2016). A 
short summary of investigation goals and scope of each trial phase is presented in Table 1.2 




Figure 1.3. Overview of the parallelisation between the clinical trials and the process development (adapted from 
Li and Easton (2018) as well as Mercier et al. (2013)) 
Generally, early process development always starts in small scale and is subsequently scaled 
up as the mAb advances through the different clinical phases which provides two benefits: 1) it 
provides an economic safety if the mAb product fails in the clinical trial and termination of the 
drug candidate is likely, 2) it is more cost-effective due to the early clinical trials (pre-clinical 
and phase I) not requiring large quantities of the mAb for clinical testing. Process knowledge 
gained from earlier trials is used to build a foundation of process understanding and is applied 
when scaling up the process which aids in reducing uncertainty in subsequent process 
characterisation steps. Control and monitoring strategies for characterised CQAs and CPPs also 
starts to be implemented in Phase II and III (Li and Easton, 2018). If a mAb passes Phase III in 
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the clinical trials, enough evidence is usually available to start a Biologics Licensing 
Application (BLA) in the US or a Market Authorisation Application (MAA) in the EU. The 
process is then transferred to full production, which is also known as Phase VI or manufacturing 
phase and is implemented according to Good Manufacturing Practice (GMP). Additional 
clinical data is gathered after the mAbs have been marketed in order to investigate additional 
adverse effects that were not apparent during the Phase I to Phase III.  
Table 1.2. Overview of the clinical phases for an mAb candidate with their corresponding research goals and scope 
(adapted from the ICH E8 guidelines). 
Phase Goals Scope 
Pre-clinical Animal Testing 
Assessment of safety  
Estimation of biological activity 
Laboratory and animal studies 
I human Pharmacology 
Assessment of tolerance and safety 
Estimation of biological activity 
Estimation of pharmacodynamics and 
pharmacokinetics. 
20-100 (healthy or with 
disease/condition) 
II Therapeutic Exploratory 
Estimate dosage for subsequent studies 
Further assessment of safety and efficacy 
Side effects 
Hundreds (with condition/disease) 
III Therapeutic Confirmatory 
Confirmation of efficacy 
Establish safety profile 
Establish dose-response relationship 
Provide basis for benefits and risks to support 
licensing 
300-3000 (with condition/disease) 
VI (M) Therapeutic Use 
Refine understanding of benefits and risks 
Identify less common side effects 
Refinement of dosage 
Thousands (with condition/disease) 
 
Throughout the process development it is important to note that scale-up can have an impact 
on the product quality. More generally, CPPs that have been identified to have an effect on 
product quality in small scale might not necessarily have that same effect in larger scale and 
may therefore impact the product quality differently. This was thoroughly investigated in the 
works of Le et al. (2012) and Mercier et al. (2013), where scale dependent effects on CPPs were 
characterised and had a significant effect on the product quality. This shows that the importance 
and the ranges of CPPs determined in smaller scales cannot necessarily be transferred to larger 
scales directly. Consequently, this implies that characterisation of these CPPs needs to be 
performed every time the scale is increased.  
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A case study of QbD implementation was published in 2009 by CASSS and ISPE on A-mAb 
bioprocess development (CASSS and ISPE, 2009). The study gave a broad overview from 
identification and risk assessment of CQAs to the construction of the design space for both 
upstream and downstream unit operations. It presented a systematic approach to designing a 
well-controlled process which assures high product quality and has been used as a foundation 
for applying the QbD framework to other biopharmaceutical products. Further details on the 
implementation of QbD in biopharmaceutical manufacture can be found in literature (Rathore 
and Winkle, 2009, Rathore, 2009, Rathore, 2014, Sadowski et al., 2016).  
1.2.2 Challenges in QbD implementation 
Effective implementation of QbD and PAT is still a significant challenge in biopharmaceutical 
industries due to the complex relationships between PPs and product quality. This becomes 
more apparent when considering the potential structural variants presented in Table 1.1 that 
commonly occur during the process development. It is therefore important that sources causing 
structural variability are investigated in order to minimise the risk of harmful effects on patients. 
However, this requires extensive experimental studies to characterise the CPPs and ranges 
(Eon-Duval et al., 2012, Mercier et al., 2014).  
The glycan in the mAb structure is a good example of this due to being very important for the 
efficacy and stability of the protein. It is therefore important to determine the impacting factors 
which need to be monitored and controlled, but this proved to be challenging (Boyd et al., 1995, 
Raju and Jordan, 2012, Costa et al., 2014). It has been shown that the glycan structure can be 
controlled through changing the composition of the basal and feed media (Kildegaard et al., 
2016, Rathore et al., 2015) or optimisation of the mammalian cell line used for expression (del 
Val et al., 2010) in order to drive the glycosylation towards the desired structure. 
As previously described, heuristic approaches are often used by industries for process 
development based on experience gained from previous process implementations. However, 
these rarely succeed in delivering good correlation between PPs and QAs (Zalai et al., 2015). 
An example of this was the QbD application filing of the mAb Perjeta (pertuzumab) at the end 
of 2012 by Genentech & Roche (Krummen, 2013). This application was rejected due to the 
design space not being properly characterised as demonstrated by the following: 
1. Not all CQAs, such as the effect of different glycosylation patterns on the Antibody-
Dependent Cell-mediated Cytotoxicity (ADCC) which introduced residual clinical risks 
from different glycosylation variants, were identified. This was mainly due to the 
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previous ranges from an existing mAb process being used and other CQAs not being 
considered. 
2. Not all CPPs were identified and the effects on the glycosylation profile could not be 
determined.  
3. The proposed control strategy for the CQAs was not appropriate. 
Another challenge for pharmaceutical industries is the high failure rates of mAb candidates in 
the clinical trials coupled together with the high development costs. DiMasi et al. (2016) state 
that the failure rates of all mAb candidates in the clinical phases I, II and III were around 46%, 
43% and 10%, respectively, as illustrated in Figure 1.3. An estimation of total investment 
needed for a mAb to reach the market was calculated to be around $2.558 billion which includes 
purchase of necessary equipment and facilities. Of this, $1.098 billion was expected to be 
invested in the pre-clinical phase and includes discovery and testing of several candidates. The 
remaining $1.460 billion is invested in the process development and clinical trials (Figure 1.3). 
This means that the revenue of successful mAb candidates is used to drive the development of 
other potential candidates making the approved mAbs usually very expensive for the consumer. 
There is therefore a growing need for additional tools to aid in both clinical assessment and 
process development of mAbs in order to bring development costs and times down.  
1.2.3 Current Focus and Improvements in Process Development  
To address the challenges presented in Section 1.2.2, many different approaches and advances 
have been developed as briefly discussed in the following sections. 
Cell-line and media considerations: 
Grainger and James (2013) argued that a cell line selection should include product quality such 
as the glycosylation and not focus only on cell growth and product yield. They illustrated the 
possibility of choosing cell line and customising the media to achieve high product quality. 
However, as the glycosylation is cell line specific, no one media composition fits all, but needs 
to be characterised for each cell line which requires a significant number of experiments. 
Bruhlmann et al. (2015), who investigated the effects of media supplements on QAs of mAbs 
(i.e: post-translational modifications such as glycosylation, glycation, deamidation, 
isomerisation, oxidation, aggregation, LMW species, C- and N-terminal modifications) argued, 
that media development could greatly increase the quality of the product without the need for 
extensive cell line engineering. However, the number of media components that need to be 
characterised requires extensive experimentation to understand the impact of the components 
on the CQAs. In the case of Genentech & Roche, not carrying out exhaustive studies or risk 
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assessment analysis to identify CQAs and CPPs had a negative impact on the process 
understanding of how the CPPs affected the CQAs, e.g. the effect of the glycosylation profile. 
Due to these reasons the highest level of PAT and QbD in the form of product and process 
understanding for complex pharmaceuticals has not been reached yet (Mercier et al., 2014). 
High-throughput approaches: 
Sustained effort has gone into the development of more efficient high-throughput screening 
methods for both upstream and downstream processing to reduce use of resources, costs and to 
speed up process development (Bhambure et al., 2011). This includes high-throughput 
screening of cell lines across different fed-batch scales (Rouiller et al., 2016), high-throughput 
media development for increased cell growth, viability and product yield for both basal and 
feed media (Rouiller et al., 2013), high-throughput screening of basal media and feed 
component effects on post-translational modifications (Rouiller et al., 2014), high-throughput 
process development in upstream by using parallel small scale reactor systems (Tai et al., 2015), 
model-based high-throughput screening to find optimal ion exchange chromatography columns 
by using both mechanistic models and experimental designs to bring down the amount of 
experiments (Khalaf et al., 2016) or high-throughput screening of an ion chromatography step 
for process characterisation (Bhambure and Rathore, 2013). 
DSP platform orientation and streamlining: 
Over the last decade, the mAb DSP have become more platform oriented and also shifted 
towards continuous processing in order to reduces bottlenecks in production. Several 
purification strategies used by large pharmaceutical companies, such as Amgen (Shukla et al., 
2007), Genentech (Trexler-Schmidt et al., 2009), Biogen (Ghose et al., 2013) and KBI 
Biopharma (Shukla et al., 2017), indicate a general layout of the DSP platforms for mAbs that 
are very similar, as illustrated in Figure 1.4. 
 
 
Figure 1.4. General overview of platform-oriented purification of mAbs. The black boxes represent 
chromatographic columns and steps that are always included, whereas the red boxes represent chromatographic 
polishing steps that change depending on the behaviour and quality requirements of the mAb. The order of the 
second polishing step and the viral filtration can be switched (adapted from Shukla et al. (2017)) . 
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As illustrated in Figure 1.4, Protein A chromatography is used almost exclusively as the first 
step in the DSP due to its high specific binding to IgG1, IgG2 and IgG4 mAbs where the protein 
A ligand binds primarily to the region between the CH2 and CH3 domains in the Fc part of the 
antibody (see section 3.1 for more information on the antibody structure). Due to its high 
binding specificity towards mAbs, protein A chromatography is able to remove the majority of 
impurities such as HCPs, DNA and viruses from the cell culture supernatant. A monomeric 
mAb purity between 90-95% can thus be expected in many cases where protein A 
chromatography has been used (Shukla et al., 2007). Elution of the mAbs from the protein A 
column is performed by lowering the pH (to 2.5 - 4.0), thereby disrupting the binding between 
the protein A ligands and the mAbs.  
A natural step after the protein A chromatography is the viral inactivation step, as illustrated in 
Figure 1.4, due to the low pH which effectively inactivates enveloped virus particles. An 
important factor in this step is the hold time which is usually around two hours in order to 
inactivate the majority of the retained virus particles (Mattila et al., 2016). However, it has been 
shown that low pH can promote aggregation of mAbs and it is therefore important to thoroughly 
characterise both the protein A chromatography step and the viral inactivation step in order to 
minimise the loss of mAb product (Mazzer et al., 2015).  
Additional chromatographic steps, also known as polishing steps, are used after the viral 
inactivation for further removal of contaminants and undesired mAb variants. However, 
selection of chromatographic columns for polishing is very dependent on the characteristics of 
the desired mAb product and remaining contaminants in order to maximise retention of the final 
drug product. Commonly used columns are cation exchange chromatography (CIEX) and anion 
exchange chromatography (AIEX) which can separate mAb variants  according to charge and 
weight as well as facilitate the additional removal of HCPs, DNA and viruses (Liu et al., 2010). 
More specifically, the CIEX column contains ligands that are negatively charged and bind more 
efficiently to positively charged proteins, whereas the AIEX column contains positively 
charged ligands which bind more efficiently to negatively charged proteins. Therefore, 
depending on the charge of the mAb, the column can be selected to promote binding. Another 
commonly used polishing step is a hydrophobic interaction chromatography (HIC) which can 
be used to reduce high molecular weight species and host cell proteins. The HIC column 
contains hydrophobic ligands that bind to hydrophobic patches on the surface of the protein. 
The binding is promoted further by adding salts, such as ammonium sulphate, that lower the 
protein stability and allow for hydrophobic residues to surface (Gagnon, 1996a).  
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The viral filtration step illustrated in Figure 1.4 is performed to remove the majority of the 
remaining viral particles from the product in order to reduce the risk of viral infection in patients 
(ICH Harmonised Tripartite Guideline, 1997b). This step is placed towards the end of 
purification in order to avoid fouling of the filtration membrane as the majority of larger 
particles, such as aggregates and DNA, have been removed in earlier steps. This allows for the 
desired mAb product to pass through the membrane while larger virus particles are retained in 
the membrane pores or on the retention side of the membrane (Kern and Krishnan, 2006). In 
the final step, ultrafiltration/diafiltration (UF/DF), as illustrated in Figure 1.4 is applied in order 
to concentrate the final mAb as well as to exchange the buffer for increased stability and shelf 
life time (Liu et al., 2010). 
Modelling based approaches: 
The use of MVDA methods for process development and monitoring of QAs increased 
significantly during the last years. This gives increased insight into correlation between PPs and 
QAs that might otherwise go undetected.  Mercier et al. (2013) showed with PCA and PLS that 
the scalability had a significant effect on performance which was not considered before. 
Ivarsson et al. (2015) showed how the metabolic flux inside of the cells shifted with different 
pH and how it affected growth and production rate by using Flux Metabolic Analysis (FMA) 
which is especially important in scale-up where compartmentalisation of the reactor is likely to 
happen. Sokolov et al. (2016) illustrated how process characterisation could be performed for 
biosimilars with the use of PCA and Decision Trees (DT) on characterisation data to find 
optimal set points in order to get as close as possible to quality specifics of the originator. 
Rathore et al. (2015) used PCA and PLS to link PPs and amino acids concentrations in the 
media to their impact on the glycosylation in batch, fed-batch and fed-batch with microaeration. 
In a similar study by Green and Glassey (2015), the authors illustrated how the amino acid 
concentrations in the growth media as well as process parameters could be used to predict the 
glycosylation forms of mAbs with PLS. Another approach is to use knowledge-based 
modelling, such as presented by Khalaf et al. (2016) where the authors used mechanistic model 
whose parameters were estimated from experimental data to create a high-throughput screening 
of ion exchange columns. This is similar to hybrid modelling in process monitoring and control 
that is based on mechanistic models but whose parameters are estimated from a DoE data set 
(Glassey and Von Stosch, 2018). The advantage is that compared to other mechanistic models 
with static parameters, the hybrid models can dynamically adjust the parameters from the DoE 
data set (von Stosch et al., 2014). The cause for the slow integration of other MVDA methods 
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into industries can be speculated, but one of the main reasons is the broadly formulated 
framework of QbD and the lack of a clear implementation path to follow. 
Product understanding: 
The fundamental principle of the QbD framework is to increase process understanding in terms 
of the effect that PPs have on product quality. Zurdo (2013) suggested that the QbD framework 
needed to be extended to incorporate product understanding in terms of the developability of 
the pharmaceutical which would include manufacturability, safety, pharmacology and 
biological activity. The author argued that by using in silico risk assessment tools based on 
structural features of the mAbs and historic development data, predictions concerning 
manufacturability of an mAb could be made. In a later publication two case studies were 
presented where structural properties of mAbs were successfully linked to CQAs related to 
aggregation and half-life (Zurdo et al., 2015). Such tools can add great value to early process 
development of mAbs when implementing the QbD framework where very little is known about 
both the process and product. Thus, a more in-depth investigation of Quantitative Structure-
Activity Relationship (QSAR) framework and its potential benefits for QbD integration is 
explored here. 
1.3 Quantitative Structure-Activity Relationship  
The QSAR framework relates structural properties and features (also known as descriptors) of 
a compound to biological or physicochemical activity (Dehmer et al., 2012, Dudek et al., 2006). 
This methodology was first introduced by Hammet in the 1930s and was later refined by Hansch 
and Fujita and has become a standard tool for small drug discovery (Du et al., 2008). A method 
derived from QSAR, referred to as Quantitative Sequence-Activity Modelling (QSAM), has 
been introduced in recent years and focuses on relating structural descriptors of proteins, 
peptides and nucleic acids to activity (Zhou et al., 2010). The only difference between QSAR 
and QSAM is the development of descriptors whereas the guidelines for the predictive model 
development remain the same. Given the proteinaceous character of the mAbs, the QSAM 
methodology for descriptor generation will be of more relevance and the workflow described 
below will therefore focus more on protein based rather than small molecule based QSAR.  
1.3.1 Descriptor generation 
One of the most important steps in QSAR is how the structures of the pharmaceuticals in 
question can be described numerically in order to use them in correlation studies with prediction 
outputs of interest. For proteins, such as mAbs, two approaches to generate descriptors are 
discussed here: 1) descriptors generated from the amino acid primary sequence and 2) 
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descriptors generated from three-dimensional models of the mAbs. It has been shown that a 
combination of both physicochemical and 3D structure descriptors works best and also ensures 
that the model is not overly reliant on a single type of a descriptor (Hechinger et al., 2012). 
Amino acid composition-based descriptor generation: 
Extensive research has been carried out to develop new informative descriptors for peptides 
and proteins generated from their primary sequence (Zhou et al., 2008). This was first 
introduced by Sneath (1966) who derived amino acid descriptors for the 20 naturally occurring 
amino acids from qualitative data. Later on, Kidera et al. (1985) used 188 properties of the 20 
naturally occurring amino acids, which were converted into ten orthogonal new descriptors to 
describe the amino acids. Later the Z-scale, which consists of 3 new amino acid descriptors 
derived by applying PCA to 29 physiochemical properties (Hellberg et al., 1986, Hellberg et 
al., 1987a), was introduced. Other amino acid scales, which were also derived through PCA, 
include the extended Z-scale and T-scale (Sandberg et al., 1998, Tian et al., 2007). Other 
descriptors include the so called isotropic surface area (ISA) and the electronic charge index 
(ECI), which are derived from the 3D structures of the amino acids (Collantes and Dunn, 1995). 
All these descriptors were tested and performed well in respective studies on small peptides.  In 
a two-part review by van Westen et al (2013a, 2013b) many of the existing amino acid scales 
were benchmarked and compared. The authors demonstrated that the different scales described 
different physiochemical and topological properties which is useful when deciding on which 
scales to use (van Westen et al., 2013a, van Westen et al., 2013b). Doytchinova et al. (2005) 
applied the Z-scales descriptors to successfully predict ligand binding of peptides and 
Obrezanova et al. (2015) used several such amino acid scale to predict mAb aggregation 
propensity based on the primary sequence. However, even though amino acid descriptors 
explain the differences in the primary sequence, they do not take into consideration potential 
interaction between the amino acids in or between primary chains. It has been argued that this 
simplification can lead to a loss of information concerning properties of secondary and tertiary 
structure in larger proteins (Zhou et al., 2008).  
Descriptors can also be generated by using empirical equations on the entire primary sequence 
to infer protein properties such as the isoelectric point, hydrophobicity, molecular weight, 
physico-chemical properties and secondary structure content, to name a few. Many such tools 
and applications are available on bioinformatics sites, such as ExPASy (Gasteiger et al., 2005) 
and EMBL-EBI (Li et al., 2015). 
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Homology modelling and molecular dynamics for descriptor generation: 
Descriptors capturing structural and surfaces properties can be generated by using existing 
crystal or NMR structures or by building models using homology modelling. The latter is 
performed by finding proteins with existing 3D structures that have a high level of similarity to 
the primary sequence of the protein of interest. These proteins are then used as templates to 
predict the likely structure of the queried protein (Liao et al., 2011). This has been successfully 
used in many publications where information such as surface areas, angles and surface 
properties were extracted (Sharma et al., 2014, Sydow et al., 2014, Buyel et al., 2013). The 
method is especially useful when no crystal structure exists. Caution needs to be exercised, 
however, as the homology models are only predicted structures. Breneman et al. (1995) 
introduced a methodology for generating 2D surface descriptors, also called transferable atom 
equivalent (TAE) descriptors, by reconstructing the electronic surface properties of the 
molecular structures from a library of atomic charge density components. This has the 
advantage of representing surface variations such as hydrophobicity and charge distributions 
numerically, which is of great importance when studying for example protein binding to an 
anion exchange chromatographic column packing using different salts (Tugcu et al., 2003). 
Breneman et al. (2003) later introduced the Property-Encoded Surface Translator (PEST) 
algorithm which is a further development to better describe the surfaces of the proteins when 
applying the TAE molecular surface descriptors. However, it is important to note that the PEST 
algorithm need 3D models in order to generate the descriptors of interest. PEST, together with 
TAE descriptor, has been successfully applied in a QSAR study where the generated model was 
able to accurately predict protein separation from HCPs (Buyel et al., 2013). Robinson et al. 
(2017) used the TAE descriptors to relate the structural differences between several Fab 
fragments to predict column performance between different chromatographic systems. It has 
been argued, however, that caution needs to be exercised when using library-based descriptors 
as these are usually directly related to a specific state of a compound that was measured in a 
unique environment. This means that these descriptors should only be applied if experiments 
were carried out in an identical or similar environment. Otherwise, this might cause the 
descriptors to be biased  (Hechinger et al., 2012). Other structural properties, such as molecular 
angles and solvent accessible surface areas extracted from homology models, were used by 
Sydow et al. (2014) to determine the risk of degradation of asparagine and aspartate in mAbs 
as PTMs. Similarly, Sharma et al. (2014) investigated the risk of oxidation of surface accessible 
tryptophans.  
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Due to the flexibility and size of the mAbs it is very difficult to produce good 3D structures 
based on X-ray crystallography and NMR. Instead, homology modelling has proven to be a 
good alternative to circumvent this problem. However, due to the size and the many flexible 
parts, such as loops, in the mAbs, pure homology models might not give a sufficiently accurate 
representation of the reality. Molecular dynamics (MD) is a useful tool that can be used to 
minimise the energy of the entire protein and to simulate the dynamics of the protein of interest 
in different environments (Brandt et al., 2010). MD simulations have also shown very high 
similarities in the internal dynamics of mAbs when comparing the simulated results to those 
observed in reality (Kortkhonjia et al., 2013). It can therefore be argued that MD simulation 
should be applied to all homology models before descriptors are generated to mimic the 
environment of the samples that are used in QSAR studies. 
1.3.2 QSAR for protein behaviour prediction 
The QSAR framework has been applied to a diverse range of challenges where structural 
properties of pharmaceuticals have been used directly for the prediction of different process 
related aspects such as the prediction of isotherm parameters in ion-exchange chromatography 
(Ladiwala et al., 2005), ligand-binding in ion-exchange chromatography under high salt 
concentrations (Yang et al., 2007a), binding of proteins in ion-exchange chromatography under 
different pH conditions (Yang et al., 2007b), protein surface patch analysis for the choice of 
purification methods (Insaidoo et al., 2015), chromatographic separation of target proteins from 
HCPs (Buyel et al., 2013), viscosity, clearance and stability prediction for mAbs (Sharma et al., 
2014) and degradation prediction of asparagine and aspartate in mAbs (Sydow et al., 2014) to 
mention a few. This also showcases one of the main strengths of the QSAR/QSAM framework 
with its ability to link structural features to many different forms of prediction outputs. It is 
important to note, however, that identical experiments must have been performed on different 
pharmaceuticals in order to compare the differences in structure and their effect on the output. 
Equally important is that sufficient excitation is present in the output data in order for the effects 
to be linked to the corresponding structural feature (Bishop, 2006). 
1.4 Towards mAb process development by bridging QbD and QSAR 
There have been significant advances in computational prediction methods and they are starting 
to become more common in process development (Jiang et al., 2011). As mentioned by Zurdo 
et al (2015), the ability to predict product related characteristics that strongly relate to the QTPP 
and/or CQAs can greatly simplify process development, especially in the early stages when the 
product or process knowledge is limited. The implementation of QSAR in process related areas, 
such as protein purification, has been researched extensively (Chen et al., 2008, Yang et al., 
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2007a, Yang et al., 2007b, Ladiwala et al., 2005, Woo et al., 2015a, Hou et al., 2011, Robinson 
et al., 2017). Though not all the mentioned examples concern mAbs specifically, the outlined 
methodology used in the different research articles is still applicable. Given the significant 
proportion of mAb development cost that is incurred during downstream processing, 
considerable advantages can be gained by being able to predict the performance of 
chromatographic columns and their effect on product quality early in the process development. 
In the case of mAbs much of the cost is incurred during the purification due to the strict 
regulations surrounding clinical safety of the end product (Hammerschmidt et al., 2014, Farid, 
2007). Examples of regulations for mAbs include removal of harmful structural variants, such 
as those presented in Table 1.1, while retaining the desired structure based on evidence from 
clinical trials. The removal of contaminants, such as HCPs, DNA and viruses, is also necessary 
in order to avoid undesired immune responses in patients. Thus, for therapeutic use, a mAb 
purity of >99% is required in the final formulation (European Medicines Agency, 2016). 
Therefore, the integration of QSAR into QbD  is proposed based on the valuable insight that 
QSAR can provide in early process development and is illustrated in Figure 1.5 which also 
shows how the QbD framework can add to and improve the QSAR modelling with addition of 
new data.  
Two main approaches of integrating the QSAR framework into the QbD paradigm can be 
considered. The first approach is by only using generated structural descriptors for development 
of models able to predict protein behaviours. An example of this was published by Obrezanova 
et al. (2015) where the authors developed a model with the adaBoost algorithm based on 
decision trees that was able to predict the probability of mAb aggregation based on the structure 
of the primary sequence. The method is however more constrained as it requires data generated 
from identical experimental setups, and therefore identical PP settings in order to assume that 
the observed effect is caused only by the differences in structure between the proteins. 
Therefore, models developed this way are better for assessing the manufacturing feasibility 
and/or potential CQAs before starting the process development. The second approach is to use 
the PPs of interest, taken from previous mAb processes to use directly in the model development 
by either 1) adding the PPs together with the generated structural descriptors as inputs 
(Rodrigues de Azevedo et al., 2017) or 2) structural descriptors are calculated to be dependent 
on the PPs, meaning that the values of the descriptors will change with changing values of the 
PPs (Yang et al., 2007b). The latter is easiest done by generating descriptor from MD 
simulations where changes in the soluble environment can be implemented. This however 
requires that data is gathered from similar experimental setups where only the PPs of interest 
have been varied. This would usually not be a problem when gathering historic data generated 
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from the QbD paradigm as it will often conform to experimental designs based on DoEs where 
the experimental environment is strictly controlled. The added benefit of this approach is that 
the developed model will be able to account for both the structural differences as well as the 
impact from the studied PPs when predicting protein behaviour. This can potentially have great 
value in process development of new mAbs as PP ranges can be assessed in silico and therefore 
greatly aid in reducing the number of needed experiments, seen as grey arrows in Figure 1.5. 
The methods described above provide a reference for further risk assessment and 
characterisation to be performed in the QbD framework, as they provide information, such as 
the behaviour of the product in different scenarios and increase the product understanding. As 
additional information from new mAb processes becomes available, models can be improved 
by expanding the data sets used in the model development. This in turn will aid in providing 
more accurate predictions due to lowering the sparsity by incorporating more protein structures. 
Available characterisation research studies can also be used as additional sources of data in 
order to improve the models by expanding the data set for model development. 
 
Figure 1.5. Proposed integration of QSAR into QbD where the upper half illustrates the simplified framework of 
QbD (blue) and the lower half illustrates a simplified version of the QSAR framework (black). Transfer of 
characterisation data from previous mAb processes can be used directly for model development using QSAR. 
Depending on the purpose of the developed QSAR model, it can be used to directly aid in assessing CQAs or 
provide insight into PPs and ranges. 
1.5 Scope of this study 
This study focused on developing a QSAR framework that could aid in early stage process 
development of monoclonal antibody therapeutics to facilitate rapid developability. The 
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application of QSAR for proteins other than mAbs is not new and has been reported extensively 
in the past. An example of this is prediction of chromatographic performance of CIEX columns 
(Ladiwala et al., 2003, Malmquist et al., 2006), AIEX columns (Song et al., 2002, Tugcu et al., 
2003), HIC columns (Ladiwala et al., 2006, Chen et al., 2007, Chen et al., 2008) and multimodal 
columns (Chung et al., 2010, Woo et al., 2015a, Woo et al., 2015b). In the listed examples, the 
proteins used in the studies were all of unique sizes, structures and functions. However, the 
implementation of QSAR for the prediction of mAb behaviour in process related settings is still 
relatively new where areas such as aggregation propensity (Lauer et al., 2012, Obrezanova et 
al., 2015), chromatography performance of HIC (Robinson et al., 2017), chromatography 
performance of CIEX (Kittelmann et al., 2017) and degradation of solvent accessible asparagine 
and aspartate in the variable regions of the mAb structure (Sydow et al., 2014) have been 
explored recently.  
It is important to note that descriptor generation of mAb focused research have adhered to 
workflows used for QSAR models developed for the prediction of general protein behaviour 
where proteins were of different sizes, properties and functions such as those examples 
mentioned in the beginning of this section. However, due to the high sequence and structure 
similarities between mAbs, such descriptors might not necessarily capture the more subtle 
differences between mAbs that might be needed for accurate prediction with QSAR. For this 
reason, descriptors in this research were developed based on structural features and properties 
inherent to all mAbs as presented in Chapter 3 and Chapter 6 for primary sequence-based 
descriptors and 3D structure descriptors, respectively. Also, to date, no exploration of structural 
variations originating from different mAb isotypes and species origins has been performed. 
These structural variations were therefore explored in order to characterise their effect on 
generated descriptors (Chapter 4) and their potential impact on model performance in terms of 
a response of interest (Chapter 5 and Chapter 7). 
Another concern with previously published research is the lack of mAb samples used for model 
development, which was in many cases below 40 samples (Robinson et al., 2017, Kittelmann 
et al., 2017). Due to the large structural variability of mAbs, a smaller dataset will be limiting 
and might not necessarily contain the structural variability needed for accurate model 
prediction. In this study, a larger dataset published by Jain et al. (2017) was used, consisting of 
137 unique mAbs with 12 experimental assays performed for each mAb. This allowed for 
greater structural variation between mAbs to be included in the model development compared 
to previously published research. Out of the 12 experimental assays provided by Jain et al. 
(2017), HIC retention time and mAb yield were selected as responses to be used in model 
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development due to representing important factors of the DSP and USP, respectively, in 
industrial process development of mAbs. As mentioned previously in Section 1.2.3, HIC is a 
common polishing step in mAb purification but also allows for the investigation of their 
stability based on retention times as more hydrophobic mAb would elute later (Haverick et al., 
2014). As for the mAb yield, this parameter is important in order to ensure that enough product 
can be extracted cost effectively, given of course that the majority of the expressed mAb 
structures fulfils the QTPP and CQA requirements for the intended drug. 
The potential impact of successful prediction of mAb behaviour based on their structure is 
invaluable in biopharmaceutical industry as it can provide critical information pertaining to 
their stability (Obrezanova et al., 2015), behaviour in operational units (Robinson et al., 2017) 
and potential structural variants (Sydow et al., 2014), to mention a few. This can aid in early 
process development of new mAb candidates and in turn in a more informed risk assessment 
and process route selection, thereby reducing the number of required experiments to 
characterise the process, resulting in lower development costs and lead times.  
1.6 Summary 
Due to the high efficacy and safety of the mAbs, their market has grown considerably during 
the last three decades. This has led to an increased focus on improvement and optimisation of 
the process development in order to manufacture mAbs cheaper and faster.  
The QbD framework was reviewed as a means to increases the process understanding through 
characterisation of PPs and their effect on the product quality. However, due to the numerous 
PPs that need to be characterised, the QbD framework still faces challenges in implementation. 
Much research has been performed in areas such as high-throughput platforms and process 
optimisation to reduce attrition in the process development. More importantly, one of the 
biggest problems with QbD is the lack of knowledge about both the process and product in 
early process development where the manufacturability of an mAb might not be possible. 
The use of in silico methods for prediction of protein and mAb behaviour in different unit 
oprations has proven to be efficient to increase product knowledge. Based on the QSAR 
framework, historic process data from established and failed mAb processes can be used and 
linked with structural properties of the mAbs in order to investigate potential behaviour during 
processing. Different strategies for generating structural properties or descriptors of an mAb 
have been suggested and reviewed based on the amino acid composition, homology modelling 
and MD simulation.  
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The integration of QSAR and QbD frameworks is therefore proposed here to increase product 






Chapter 2  
 
Modelling Development and Assessment 
In this Chapter, an overview of some of the current and more traditional techniques used for 
data exploration, classification and regression is presented. The theory of each method is 
explained with references to further detailed literature and some examples of applicability are 
highlighted. Model training and validation with cross-validation in particular are reviewed and 
their importance in model training and validation is critically discussed. The material in this 
chapter acts as a foundation for all model development performed in this thesis and it also 
provides a useful overview of the tools for tackling a wide variety of different modelling 
problems in other disciplines and industrial sectors. 
2.1 Matrix, vector and index notations 
For consistency and to avoid confusion, specific naming conventions is used throughout for the 
independent and dependent variables in this chapter to describe the structure of vectors and 
matrices used in the different multivariate techniques explained below. Additional matrix, 
vector or index notations specific to individual methods are specified and explained in 
connection with the method in question. 
2.1.1 Independent data 
The independent data will be referred to as 𝑿 shown in eq.(2.1) where the rows correspond to 
individual samples and the columns to individual independent variables. The term structural 
descriptors defined in QSAR modelling is equivalent to that of the independent variables 
  











Index notation for samples in this thesis will use 𝑖, 𝑗 = 1, … , 𝑁 where 𝑖 and 𝑗 are individual 
arbitrary samples and 𝑁 is the total number of samples in the data set. Index notation for 
variables/descriptors will use 𝑘, 𝑙 = 1,… ,𝑀 where 𝑘 and 𝑙 are individual arbitrary 
variables/descriptors and 𝑀 is the total number of variables/descriptors in 𝑿. Small letter 𝒙 in 
bold in this chapter indicates either a column vector for a single variable eq.(2.2) or a row vector 
for a single sample eq.(2.3) and can be identified based on the index notation belonging to either 
the variables or the samples.  
  






 𝒙𝑖 = [𝑥𝑖1 𝑥𝑖2 ⋯ 𝑥𝑖𝑀] (2.3) 
 
2.1.2 Dependent data 
The dependent variables or response variables will be referred to as 𝒀 shown in eq.(2.4) where 
the rows correspond to individual samples and the columns to the individual response variables.  
 







𝑦𝑁1 𝑦𝑁2 ⋯ 𝑦𝑁𝐷
] (2.4) 
 
Index notation for response variables will use 𝑓, 𝑔, ℎ = 1,… , 𝐷 where 𝑓, 𝑔 and ℎ are individual 
arbitrary responses and 𝐷 is the total number of response variables in 𝒀. Small letter 𝒚 in bold 
in this chapter indicates either a column vector for a single response eq.(2.5) or a row vector 
for a single sample eq.(2.6) and can be identified based on the index notation belonging to either 
the variables or the samples. 
 






 𝒚𝑖 = [𝑦𝑖1 𝑦𝑖2 ⋯ 𝑦𝑖𝐷] (2.6) 
 
31 
2.2 Exploratory Data Analysis 
Exploratory data analysis (EDA) is applied to better understand the main characteristics of a 
data set and can therefore provide an overview of the variables and samples in a study used to 
identify similarities/dissimilarities, systematic trends and outlies (Biancolillo and Marini, 
2018). EDA is therefore a crucial step prior to any predictive modelling in order to identify 
sources of variation that can potential impact on model performance. In this research, Principal 
Component Analysis (PCA) has been reviewed due to being one of the most commonly used 
techniques EDA. 
2.2.1 Principal Component Analysis 
PCA is one of the oldest and most widely used data exploration tools in fields of statistics, 
biology and chemometrics. The idea behind PCA was first introduced by Pearson in 1901 who 
proposed the that lines could be placed in a high dimensional variable space that had a best fit 
to a set of sample points. The direction of the lines in the original variable space were placed in 
such a way that the correlations between the lines and the original variables were maximised, 
thus ensuring that most of the variation in the data was captured (Pearson, 1901). The method 
was later improved upon by Hotelling in 1933 who instead of using lines, used linear 
transformations to transform the data to a new coordinate system where the new axes were 
linear combinations on the original variables (Hotelling, 1933).  
2.2.1.1 Theory 
Given a data matrix, e.g. 𝑿, a new set of variables called Principal Components (PCs) are 
calculated which describe the variation of the original variables according to: 
 
 
𝑿 = 𝑻𝑷𝑇 + 𝑬 = 𝒕1𝒑1
𝑇 + 𝒕2𝒑2
𝑇 + ⋯+ 𝒕𝑅𝒑𝑅
𝑇 + 𝑬,
𝑟 = 1, … , 𝑅 
(2.7) 
 
where 𝑻 = [𝒕1 … 𝒕𝑅] (N x R) is the sample score matrix and R is the number of components, 
𝒕𝑟 (N x 1) is the score vector of component 𝑟, 𝑷 = [𝒑1 … 𝒑𝑅] (M x R) is the loadings matrix, 
𝒑𝑟 (M x 1) is the loading vector of component 𝑟 and 𝑬 (N x M) is the residual error matrix not 
explained by the PCs. 
The loading vectors are linear combinations of the original variables are pair-wise orthogonal. 
When stronger correlations between the original variables are present, fewer PCs are required 
to explain the majority of the variation in 𝑿. Also, due to the orthogonality, each PC has an 
32 
individual contribution to the explained variation according to eq.(2.8). Thus, increasing the 













= ‖𝑿‖𝟐 − ‖𝑬‖𝟐 
(2.8) 
 
PCA relies on the calculation of the covariance matrix, 𝚺, as it describes the covariance between 










𝑘, 𝑙 = 1,… ,𝑀 
(2.9) 
 
The full covariance matrix, 𝚺, is defined in eq.(2.10) where the diagonal elements become the 
variances for the individual variables, cov(𝒙𝑘, 𝒙𝑘) = 𝜎𝑘
2. Eq.(2.10) can be simplified as 

























𝑇 𝑿𝐶𝑒𝑛𝑡 (2.11) 
 
In order to find the directions and importance of the PCs, the eigenvalues, 𝜆𝑘, and eigenvectors, 
𝒗𝑘 (M x 1), are calculated from 𝚺. For details on calculation and properties of eigenvalues and 
eigenvectors, refer to Appendix D.1. The eigenvectors calculated from covariance matrix play 
a central role in the calculation of the PCs as they are pair-wise orthogonal and represent the 
directions in the original variable space in which the data variations are the highest.  
The eigenvalues on the other hand determines the importance of their corresponding 
eigenvector where a higher eigenvalue indicates a larger data variation in the direction of the 
eigenvector. The covariance matrix, 𝚺, can then be decomposed using the eigenvectors and 
eigenvalues which is known as eigen-decomposition according to: 
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 𝚺 = 𝑽𝚲𝑽
𝑇 (2.12) 
 
where 𝑽 = [𝒗1 𝒗2 … 𝒗𝑀] is the eigenvector matrix and 𝚲 = diag(𝜆1, 𝜆2, … , 𝜆𝑀) is a 
diagonal matrix consisting of the eigenvalues where 𝜆1 ≥ 𝜆2 ≥ ⋯ ≥ 𝜆𝑀. Based on the 
definition of PCA stated in eq.(2.7), the PC loadings are equal to the eigenvector matrix due to 
their orthogonality according to  eq.(2.13). An example of the placement of two eigenvectors 
is illustrated in Figure 2.1c. The PC scores are then calculated as the product of the mean centred 
𝑿 matrix and the loadings, 𝑷, according to eq.(2.14). Figure 2.1d illustrates the new placement 
of samples on two PCs where the red and blue dashed lines represents the scores on the first PC 
and second PC for sample 𝑖. The representation is also known as a score plot. 
 
 𝑷 = 𝑽 (2.13) 
 𝑻 = 𝑿𝐶𝑒𝑛𝑡𝑽 = 𝑿𝐶𝑒𝑛𝑡𝑷 (2.14) 
 
Alternatively, the principal components can be calculated using Singular Value Decomposition 
(SVD) which is present in Appendix D.2. 
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Figure 2.1. Overview and critical steps of data decomposition with PCA in two dimensions. (a) The raw data is 
first (b) pre-treated by mean centring the samples around the origin. (c) Linear combinations of the original 
variables, 𝑥1 and 𝑥2, known as eigenvectors are then calculated where the first eigenvector, 𝒗1 (red), lies in the 
direction of the greatest data variation and the second eigenvector, 𝒗2 (blue), in the direction of the second greatest 
data variation. (d) Final transformation of samples to the PC1 (red line) and PC2 (blue line) axes where each sample 
is represented by its individual scores (adapted from O'Malley (2008)) 
2.2.1.2 Applicability of PCA in this research 
PCA is a very useful tool for visualisation and exploration of high dimensional data set due to 
its ability to reduce the variable dimensionality and to capture strong correlations between 
variables which might otherwise be difficult to explore. PCA also has powerful diagnostic 
capabilities for detection of outliers based on residual values and the calculation of Hotelling 
T2 (Hotelling, 1933). This provides evidence for characterisation of not only ill-fitted samples 
with high residual values, but can be used to identify extreme samples that are forcing the 
direction of the PCs. Thus, PCA aids in the identification of samples which require further 
investigation due to different behaviour compared to the other samples in the data set (Bro and 
Smilde, 2014). 
PCA has been extensively used over the years within bio-related research for applications 
ranging from the effects of raw material variations in media composition (O’Kennedy, 2016), 
characterisation of fermentation process (Sokolov et al., 2016, Rathore et al., 2015), fault 
detection in fermentation (Gunther et al., 2006) and effects of scalability on bioprocesses 
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(Mercier et al., 2013) to mention a few. In all applications, PCA was shown to be an effective 
method used to identify sources of variation that impacted upon the individual problem 
statements. The authors also highlighted the importance of selecting the right number of 
components in order to filter out noise and keep application related variation. 
The selection of the number of PCs to use when decomposing 𝑿 depends mainly on the problem 
statement as well as the data. In the visualisation of the scores, class information can be 
incorporated by colouring samples according to the available classes which might aid in 
determining the number of PCs needed to find a good separation class separation (Biancolillo 
and Marini, 2018, Bro and Smilde, 2014). However, due to being unsupervised and depending 
only on the data variation in 𝑿, PCA will not necessarily lead to a good separation of classes if 
the data variation is not directly correlated to the class information. Alternatively, a scree test 
can be performed where the eigenvalues or the captured variation are plotted against their 
corresponding PCs. The number of PCs are chosen based on when the decrease in eigenvalues 
becomes linear, indicating that the model is starting to capture noise (D'Agostino Sr and 
Russell, 2005). Another method is the Broken stick method where a line based on the broken 
stick distribution is added to the scree plot (MacArthur, 1957). The line mimics the behaviour 
of eigenvalues calculated from a completely randomised data set, thus effectively representing 
noise. If eigenvalues in the PCA model lies above the line this is an indication that the PC 
capture structured variation. The last reviewed approach is to define a limit for the minimum 
total explained variance which must be captured by the PCA model (Bro and Smilde, 2014).  
In this research, a limit for the minimum total explained variance was used due to two reasons: 
1) The components in PCA are additive, meaning that even if extra components are added to 
the model, the structure of the initial components will remain unchanged. 2) PCA was only used 
for exploration and therefore a strict number of components does not need to be defined. Bro 
and Smilde (2014) argued that this allows for greater exploration of the behaviour in the 
individual components. However, it is mportant to remember that it also inadvertently increases 
the chances of including components that only capture noise.  
It is important to note that PCA will only perform well if the relationship between correlated 
variables is linear, meaning for non-linear correlations PCA will not be able to capture the 
correlation between variables. 
2.3 Classification 
When distinct classes exist in the data set and clear discrimination is needed, dedicated 
classification methods may be more appropriate for the task and can be used to investigate 
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potential correlation between variables in 𝑿 and the sample classes. The theory of the popular 
classification methods PLS-DA and SVC has been covered in this research and their 
applicability assessed.   
2.3.1 Partial Least Square – Discriminant Analysis 
PLS-DA like the name implies, is a combination of Partial Least Squares (PLS) and Linear 
Discriminant Analysis (LDA). However, only LDA will be covered in this section due to being 
the classifier whereas PLS is strictly a regression method (see section Section 2.4.1). As for the 
LDA algorithm, Bayes decision rule was used in this research due to being better suited to the 
problem statement (see Section 2.3.1.2). The method theory has been covered below 
2.3.1.1 Theory 
Before describing the theory of the Bayes´ method, it is important to understand the structure 
of the input data into the DA algorithm. Prior to the classification, a PLS regression model will 
be trained with 𝑿 and 𝒀. The matrix 𝒀 (N x C) contains the class memberships of the samples 
and is represented in the form of dummy variables. An example of 𝒀 in a binary classification 
problem (𝐷 = 2) with classes 𝐶1 and 𝐶2 is presented in Figure 2.2a. Two dummy variables have 
been generated as column vectors representing each class where the class membership of each 
sample, 𝒙𝑖, is assigned with values of either one and zero. A value of one indicates membership 
to the class represented in the dummy variable while a value of zero indicates membership to 
another class, e.g. if 𝑦𝑖1 = 1 then the sample 𝒙𝑖 ∈ 𝐶1. 
However, the predictions from the PLS model, ?̂?, will not be predicted perfectly as ones and 
zeros but will instead have predictions close to the original values of 𝒀. An example of PLS 
predictions is presented in Figure 2.2b. 
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Figure 2.2. The structure of the response vector 𝒀 in a binary classification problem used in PLS-DA. (a) Dummy 
variables are used to construct 𝒀 and assign class memberships of samples to either 𝐶1 (blue) and 𝐶2 (red). (b) 
Example predictions from the PLS regression. 
A binary classification problem however will not need two dummy variables in order to 
represent the classes due to all samples being listed as either ones or zeros in each column. The 
PLS-DA algorithm will build two classifiers based on each dummy variable. The solutions of 
these classifiers however will be identical due to the class membership of the samples being 
retained regardless of which column in ?̂? is used as well as the individual class means and 
variances of 𝐶1 and 𝐶2 being identical in both columns (Brereton and Lloyd, 2014). Therefore, 
in order to avoid confusion, Bayes method will be explained in relation to the second column 
in ?̂? which, for convenience, will be referred to as ?̂? = (?̂?1, ?̂?2, … , ?̂?𝑁).  





 ∝ 𝑃(?̂?𝑖|𝐶𝑐)𝑃(𝐶𝑐) (2.15) 
 
𝑃(∁𝑐|?̂?𝑖) is the posterior probability of a sample 𝑖 belonging to class 𝐶𝑐 given a particular value 
of ?̂?𝑖 where 𝑐 = 1,2. The 𝑃(?̂?𝑖|∁𝑐) term is the likelihood or the probability of observing ?̂?𝑖 
given 𝐶𝑐. The 𝑃(𝐶𝑐) term is the prior probability of class 𝐶𝑐, or more specifically, the 
probability of observing class 𝐶𝑐. 𝑃(?̂?𝑖) is the probability of observing ?̂?𝑖. The posterior 
probability is directly proportional to the numerator in eq.(2.15) due to that 𝑃(?̂?𝑖) will not 
change regardless of the class defined in the posterior. 













where 𝜎𝑐 is the standard deviations of samples belonging to class 𝐶𝑐 and ?̅?𝑐 is the sample mean 
of class 𝐶𝑐. An example of the likelihood functions is illustrated in Figure 2.3a for class 𝐶1 (blue 
line) and 𝐶2 (red line) where the predicted values are centred around zero and one, respectively. 
The prior class probabilities are calculated as the ratio of samples belonging to a specific class 





= 1, 𝑃(∁𝑐) =
𝑁𝑐
𝑁
  (2.17) 
 
where 𝑁𝑐 is the number of samples belonging to class 𝐶𝑐. The sum of all priors needs to be 
equal to one. The probability of observing ?̂?𝑖 is the sum of the likelihoods weighted by their 
corresponding class priors according to: 
 





An example of the distribution of 𝑃(?̂?𝑖) is illustrated in Figure 2.3a as the grey dashed line and 
it can be observed that the peaks of the likelihoods are preserved in the distribution which was 
weighted with 𝑃(𝐶1) = 𝑃(𝐶2) = 0.5 in order for the distribution area to become equal to one. 
The posterior probabilities for class 𝐶1 and 𝐶2  are illustrated in Figure 2.3b as the blue and red 
line, respectively. It can be observed that samples around zero on the ?̂? axis will be classified 
as 𝐶1 while samples around one be classified as 𝐶2. A point of interest is where 𝑃(𝐶1|?̂?) =




Figure 2.3. Probability distributions used in Bayes theorem. (a) Examples of the likelihood distributions of ŷ 
belonging to class C1 (blue line) and C2 (red line) centred around zero and one, respectively. The distribution of ŷ 
(dashed grey line) with equal samples sizes, P(C1) = P(C2) = 0.5. (b) The posterior probabilities of a sample 
belonging to either to class C1 (blue line) or C2 (red line) based on ŷ with the decision boundary, d (dashed black 
line) (adapted from Pérez et al. (2009)). 
Two options exist for classification of samples once the posterior probability functions have 
been calculated: 1) the decision boundary can used directly to determine the class of a sample 
𝑖 based on ?̂?𝑖 from the PLS model, or 2) the probabilities of a sample 𝑖 is calculated using the 
posterior probability function according to eq.(2.15) and the class with the highest probability 
is assigned to the sample. In this research, the latter option has been used. 
2.3.1.2 Applicability of PLS-DA in this research 
If the goal is to investigate discrimination between sample classes, PLS-DA will be much more 
useful compared to PCA due to the maximisation of covariance between 𝑿 and 𝒀 (Ballabio and 
Consonni, 2013).Numerous PLS-DA algorithms with different decision boundary rules and 
their application in the PLS algorithm have been developed in the past (Povey et al., 2014, Chen 
et al., 2018). It is therefore important to consider the different aspects and choices available for 
PLS-DA with regards to the problem statement in order to develop meaningful models. Several 
decision rules exist which can be used in PLS-DA to generate the decision boundary where the 
two most common ones are: 1) Fisher’s LDA which minimises the variance in the individual 
classes while maximising the distance between the class means and assumes Gaussian 
distribution and equal variance between classes (Barker and Rayens, 2003). 2) Bayes decision 
rule which allows for prior class probabilities to be used. Bayes rule applies Gaussian 
distribution fit to the individual classes, but does not assume the class variances to be equal 
(Indahl et al., 2007, Pérez et al., 2009). For LDA, class imbalances have a negative impact on 
the model due to that the decision boundary will be moved closer to the class containing the 
most samples which consequently can cause a higher misclassification rate if the class variance 
is large (Brereton and Lloyd, 2014). This is however not a problem with Bayes rule due to 
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assignment of class weights based on the prior probabilities of the class occurrence within the 
data set as seen in eq. (2.15). As a result, Bayes decision rule will modify and place the decision 
boundary in the centre between the two classes (Indahl et al., 2007).  For this reason, Bayes 
decision rule was therefore chosen in this research as the data set available from Jain et al. 
(2017) demonstrated uneven class representation. 
Kjeldahl and Bro (2010) as well as Gromski et al. (2015) reported on a common misconception 
about PLS-DA where many publications report model performance based on 𝑅2 and 𝑄2 (see 
Section 2.6.1). This is often misleading as these describes the model fit with regards to 
regression and give no information pertaining to correct classification and misclassification of 
a sample. In this research, performance metrics conforming to classification problem statements 
are strictly used (see Section 2.6.2). 
Another important aspect to consider is the contribution of random chance-correlation between 
𝑿 and 𝒀 in PLS-DA. Perez and Narasimhan (2018) showed that the accuracy of PLS-DA fitted 
on randomly generated variables increased when the number of variables became much greater 
than the number of samples in the data set (𝑀 ≫ 𝑁). This is caused by random chance-
correlation between 𝑿 and 𝒀, thus making it appear as if PLS-DA resulted in a clear 
discrimination of classes but where in reality, none should exist. Perez and Narasimhan (2018) 
as well as Westerhuis et al. (2008) highlighted the importance of rigorous cross-validation (see 
Section 2.5) in order to ensure that PLS-DA captures the true underlying pattern in the data. 
In reviews by Gromski et al. (2015) and Brereton and Lloyd (2014), the authors stated that PLS-
DA is often outperformed by other classification methods such as Support Vector Machines for 
classification (SVC). PLS-DA might therefore not be the optimal choice of classifier to apply 
in many problem statements. However, PLS-DA has unparalleled diagnostic capabilities 
compared to other methods due to the PLS component in the algorithm which can assess sample 
and variable contributions to the predictions (see Section 2.4.1 for more information). 
Therefore, PLS-DA should be seen as an intermediate step in classification model development 
to be used for outlier detection and investigation of highly contributing variables prior to model 
development with an alternative classifier (Brereton and Lloyd, 2014, Gromski et al., 2015). 
2.3.2 Support Vector Machines for Classification 
Support Vector Machines (SVM) for classification (SVC) were first introduced by Boser et al. 
(1992) as a linear or non-linear classification method that maximises the separation of classes 
through calculation of optimal placement of the decision boundary. The method is based on the 
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original work of Vapnik who first introduced the method in 1963 as the “generalised portrait 
algorithm” (Vapnik and Lerner, 1963). 
The aspect that the SVC algorithm addresses, that many classification techniques do not, is that 
of over-fitting. As previously discussed, when training a classifier to maximise correct 
classification it is possible to fit the classifier over-fit to the training set. This has the effect of 
degrading the performance of the classifier when presented with unseen data. In a binary 
classification problem, the SVC algorithm trains a decision function that maximises the 
generalisation between the classes. In doing so, this makes the algorithm more robust.  
In literature, the abbreviations of SVM and SVC are used interchangeably so in order to avoid 
confusion, this research uses SVC to distinguish SVM for classification from that of SVM for 
regression (SVR) which has also been applied in this research (see Section 2.4.2). 
2.3.2.1 Theory 
In a binary classification problem that is linearly separable, for any given data set, e.g. 𝑿, where 
each sample is assigned a class according to 𝑦𝑖 ∈ {−1,1}, the SVC algorithm will always find 
the largest margin or the “widest street” that separates the two classes. The separation is 
illustrated in Figure 2.4a of positive samples (red dots) and negative samples (blue dots) 
according to a defined hyperplane shown as the black line.  
 
 
Figure 2.4. SVC placement of the decision boundary (black line) generated from selected samples that act as 
support vectors (black circles) which maximises class discrimination in a problem that is (a) linearly separable and 
(b) not linearly separable. The SVC constraints for separating positive and negative class samples are shown as 
the red dashed line and blue dashed line, respectively (adapted from Boser et al. (1992)) 
The SVC algorithm defines the boundaries for each class according to: 
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 𝝎 ∙ 𝒙𝑖
+ + 𝑏 ≥ 1 (2.19) 
 𝝎 ∙ 𝒙𝑖
− + 𝑏 ≤ −1 (2.20) 
 
where 𝝎 = (𝜔1, 𝜔2, … , 𝜔𝑀) (M x 1) is the normal vector of the desired hyperplane, 𝑏 is the 
distance from the origin to the hyperplane and is parallel to 𝝎, 𝒙𝑖
+ are samples for which 𝑦𝑖 = 1 
and 𝒙𝑖
− are samples for which 𝑦𝑖 = −1. For simplicity, eq.(2.19) and eq.(2.20) can be rewritten 
as a single expression through multiplication of 𝑦𝑖 according to: 
 
 𝑦𝑖(𝝎 ∙ 𝒙𝑖 + 𝑏) − 1 ≥ 0 (2.21) 
 
The orientation and placement of the hyper plane in the variable space is defined by a subset of 
samples, positive and negative, called support vectors (SVs) that defines the boundaries 
according to: 
 
 𝑦𝑆𝑉(𝝎 ∙ 𝒙𝑆𝑉 + 𝑏) − 1 = 0 (2.22) 
 
The maximal width of the margin is defined by the SVs and will always be equal to 2 ‖𝝎‖2⁄  
where ‖𝝎‖2 is the magnitude of 𝝎. Therefore, in order to maximise the separation of samples, 
‖𝝎‖2 needs to be minimised. Based on the defined width of the margin and the decision 

















2 is the objective function for which 𝝎 and 𝑏 are the variables that needs to be 
optimised and eq.(2.21) has been added as linear constraints. As can be observed, the original 
minimisation of ‖𝝎‖2 has been slightly modified to ‖𝝎‖2
2 instead which transforms the 
optimization into a quadratic programming (QP) problem, meaning that the solution space 
becomes convex and a global solution can always be produced. The primal can be solved 
directly using QP designed solvers to find the minimum value in the objective function. 
However, solving the primal can be computationally cumbersome if 𝑀 is large which is usually 
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the case where data sets today can consist of thousands of variables. The QP problem in 























where 𝑊(𝜶) is the new optimisation function called Wolf’s dual and 𝜶 = (𝛼1, 𝛼2, … , 𝛼𝑁) (N 
x 1) are multipliers for the constraints in expression eq.(2.23). For detailed formulation of the 
dual with Lagrange Multipliers (see Appendix D.3). It can be observed in expression eq.(2.24) 
that the dual is only dependent on the samples in the data set to form of the inner product 
between pairs of samples. This is an especially beneficial quality of the dual formulation due 
to 𝑁 ≪ 𝑀 in many data sets today. For support vectors, the values of 𝛼𝑖 will be non-zero and 
𝒙𝑖 ∈ 𝒙𝑆𝑉 while samples laying further away from the boundaries will have 𝛼𝑖 equal to zero. 
The optimal solution for 𝜶 is obtained by using the Sequential Minimal Optimisation (SMO) 
algorithm which is specially designed to handle QP problems in SVC for both classification 
and regression (Platt, 1998, Shevade et al., 2000). The variables 𝝎 and 𝑏 can then be solved 
using the identified support vectors.  
Class prediction of an unknown sample, 𝒙𝑢, can then be performed according to: 
 
 
𝐷(𝒙) = sign(𝝎 ∙ 𝒙 + 𝑏) = sign (∑𝛼𝑖𝑦𝑖𝒙𝑖
𝑁
𝑖=1
⋅ 𝒙𝑢 + 𝑏) (2.25) 
 
where 𝐷(𝒙) is the decision function for a sample 𝒙. Substitution of 𝝎 has been performed with 
eq.(D.13) in the last equality of eq.(2.25). This also shows that the solution of the hyper plane 
is dependent only on the samples.  
2.3.2.2 Soft Margin 
So far only cases that are linearly separable have been discussed. For non-separable 
classification problems such as the example illustrated in Figure 2.4b where a positive sample 
(red) is mixed in with the negative samples (blue) the QP problem in eq.(2.23) will fail. Cortes 
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and Vapnik adjusted for this by introducing slack variables, 𝜉𝑖, to allow for some 
misclassification and is known as soft margin classifier (Cortes and Vapnik, 1995). The QP 













subject to = 𝑦𝑖(𝝎 ∙ 𝒙𝑖 + 𝑏) ≥ 1 − 𝜉𝑖  
= 𝜉𝑖 ≥ 0 
(2.26) 
 
where 𝐶 is the cost parameter which is a regularisation term used to penalise the QP problem 
and must be greater than zero. The second term in the objective function of eq.(2.26) is known 
as the loss function and controls the misclassification of samples. It can be observed from the 
constraints in eq.(2.26) that samples now are allowed to fall inside of the margin, 𝜉𝑖 < 1, as 
well as to be misclassified, 𝜉𝑖 > 1. The cost parameter, 𝐶, controls the flexibility where a small 
value introduces more slack, meaning more samples will have 𝜉𝑖 > 0 and therefore allows for 
more misclassification. A large value of 𝐶 on the other hand forces the slack variables to 
become closer to zero and classification becomes stricter. If 𝐶 is set to infinity the QP problem 
in eq.(2.26) becomes equivalent to eq.(2.23) which appropriately is known as a hard margin 
classifier. 






















where can be observed that only the constraints for 𝛼𝑖 has changed and now has an upper limit 
of 𝐶 when compared to the dual of the hard margin QP problem in eq.(2.23). The solution of 𝜶 
is obtained using the SMO algorithm.  
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2.3.2.3 Kernel Trick for non-linearity 
For non-linear application of SVC, the so-called Kernel trick can be used to transform the 
samples from the original variable space to a higher dimensional feature space with the use of 
a Kernel function, Κ, according to:  
 
 Κ(𝒙𝑖, 𝒙𝑗) = 𝜑(𝒙𝑖) ∙ 𝜑(𝒙𝑗) (2.28) 
 
where 𝜑(𝒙𝑖) = (𝜑1(𝒙𝑖), 𝜑2(𝒙𝑖),… , 𝜑𝐿(𝒙𝑖)) is called the feature map of 𝒙𝑖 and 𝐿 is the number 
of features for which 𝐿 > 𝑀. An example of a non-linear mapping from a two-dimensional to 
a three-dimensional feature space is illustrated in Figure 2.5 where the classification problem 
becomes linearly separable. 
 
 
Figure 2.5. Transformation with a non-linear mapping function, 𝜑(𝒙), from a two-dimensional variable space to 
a three-dimensional feature space where the positive samples (red) become linearly separable from the negative 
samples (blue). 
A requirement of the Kernel function is that the corresponding gram matrix, 𝚪, shown in  
eq.(2.29) must be symmetric, e.g. Κ(𝒙1, 𝒙2) = Κ(𝒙2, 𝒙1), and positive semi-definite (Shawe-
Taylor and Cristianini, 2004). 
 
 𝚪 = [
Κ(𝒙1, 𝒙1) Κ(𝒙1, 𝒙2)





Κ(𝒙𝑁, 𝒙1) Κ(𝒙𝑁, 𝒙2) ⋯ Κ(𝒙𝑁 , 𝒙𝑁)
] (2.29) 
 
Two popular kernels often used in research are the polynomial kernel in eq.(2.30) where 𝑑 is 
the polynomial degree and the radial basis function (RBF) kernel in eq.(2.31) where 𝜎 is the 

























Cortes and Vapnik showed in 1995 that the dot products in the dual formulations of the hard 
margin in eq.(2.24) and the soft margin in eq.(2.27) classifiers could effectively be replaced 
with a kernel function, Κ, in order to train the SVC algorithm (Cortes and Vapnik, 1995). The 
decision boundary function in eq.(2.25) can then be reformulated to include the non-linear 
hyper plane for classification of the samples according to: 
 
 𝐷(𝒙) = sign(∑𝛼𝑖𝑦𝑖
𝑁
𝑖=1
Κ(𝒙𝑖, 𝒙) + 𝑏) (2.32) 
 
2.3.2.4 Applicability of SVC in this research 
The main strength of SVC is that the method is robust in high-dimensional problems where the 
placement of the decision boundary is decided by a small subset of samples (support vectors). 
This results in better generalisation performance compared to that of PLS-DA (Gromski et al., 
2015). However, a disadvantage of SVC is that the interpretation of important variables is 
difficult due to lack of supporting statistics of variable contribution to the response and can only 
be assessed based on the magnitude of the weights, 𝝎. This becomes even more difficult if a 
non-linear kernel is applied due to the generation of extra variables and the non-linear nature 
of the decision boundary (Maldonado and Weber, 2009). 
Multiple toolboxes exist for implementation of SVM. In a study by Steinwart and Thomann 
(2017), the authors compared to execution times and performances of several popular SVM 
toolboxes that are available for free. In this research, the LibSVM toolbox was applied, though 
not being the fastest, is has been extensively documented and continuously updated in order to 
provide more robust solutions (Chang and Lin, 2011). 
Similar to that of PLS-DA, class imbalances present in the data set of interest need to be 
considered when using soft-margin SVC. Several strategies exist to approach this where 
separate cost values, 𝐶, for each class can be applied, similar to that of prior probabilities in 
PLS-DA discussed in Section 2.3.1.2 (Akbani et al., 2004). Alternatively, a higher loss penalties 
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can be assigned to the minority class samples, thus effectively changing the optimal solution to 
the QP problem to accept less misclassification of the minority class (Hsu et al., 2003). In this 
research, the former approach was used due to being similar to that of Bayes rule used in PLS-
DA, thus allowing for a fairer comparison between the classification methods. 
Another important consideration is the selection of the cost parameter 𝐶 and potential kernel 
parameters which greatly affects the performance of the model. Several alternatives for 
optimisation of are available but where the grid search method (Hsu et al., 2003) and Bayesian 
optimisation (Cawley and Talbot, 2007, Czarnecki et al., 2015) are most commonly used. In 
the grid search approach, ranges containing several values for each of the parameters are 
defined to form a grid of different parameter permutations which are validated via cross-
validation in order to identify the best parameters (see Section 2.5). The Bayesian optimisation 
on the other hand uses the information available from previous parameter evaluations as well 
as local gradient approximations which allows the algorithm to find a parameter solution with 
relatively few evaluations and thus resulting in being faster than the grid search approach 
(Snoek et al., 2012). However, due to the fact that the solution space of the parameters is often 
non-convex, the Bayesian optimisation approach is at risk of selecting a local solution. The grid 
search approach was therefore used in this research due to being more robust and extensive in 
evaluation of parameter permutations (Hsu et al., 2003). 
2.3.3 Multiclass Classification Problems 
Many classification problems usually consist of more than two classes which need to be 
separated. However, many classification techniques, including SVC, will only work for binary 
classification problems. To circumvent this problem, two approaches referred to as “One versus 
Rest” (OvR) and “One versus One” (OvO) are often applied in research (Statnikov et al., 2004, 
Galar et al., 2011).  
In the OvO strategy, illustrated in Figure 2.6a, an individual classification model is developed 
for each unique class-pair. This results in a total of 
1
2
𝑐(𝑐 − 1) models where 𝑐 is the number of 
classes in the data set. Class assignment of samples is decided by the number of times a class 
has been chosen in the developed models. This method tends to work best with an odd number 
of classes due to a lower risk of a sample being unassigned if the sample proves difficult to 
classify. 
In the OvR strategy, illustrated in Figure 2.6b, an individual model is developed for each class 
with the remaining classes pooled together which results in a total of 𝑐 models being developed. 
Class assignment can be performed using the intrinsic properties of the used classification 
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method. For PLS-DA, class assignment can be performed using the generated posterior 
probabilities which will be closer to one in the model representing the class of interest while 
being closer to zero in the remaining models. In SVC, class assignment can be performed using 
the generated decision values which will be positive in the model representing the class of 
interest while having negative values in the remaining models. 
In a study performed by Hsu and Lin (2002), both OvR and OvO were extensively tested on 
several different data set with SVC. It was observed that both strategies had comparable 
performance thus making it difficult to identify the superior strategy. In this research, the OvR 
strategy was selected due to two reasons: 1) Each class is represented by an individual model, 
thus making the evaluation of the individual classes simpler due to that none of the samples 
will be unassigned a class. 2) There is less risk of over-fitting of the model due to lack of 
samples (see Section 2.5). 
 
Figure 2.6. Classification strategies for multiclass problems with (a) One versus One and (b) One versus Rest. 
Decision boundaries are shown as dashed black lines (adapted from Statnikov et al. (2004)). 
2.4 Regression 
QSAR model development linking the measurements of the selected response data to the 
structural descriptors of mAbs was performed with dedicated regression methods. In this 
research, the theory of PLS and SVR have been covered and their applicability to QSAR 
modelling have been reviewed. 
2.4.1 Partial Least Square Regression 
PLS is one of the most widely used regression tools in the field of chemometrics due to its 
simplicity and strong diagnostic capabilities. PLS was first introduced by Wold as a method to 
model the relationship between 𝑿 and 𝒀 through matrix decomposition similar to that of PCA 
(Wold et al., 1984). Unlike Multiple Linear Regression (MLR), PLS will still work even if the 
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variables are more numerous than the samples (N > M), the variables are correlated and noisy. 
The PLS algorithm is also able to model several response (dependent) variables in 𝒀 (D > 1) 
simultaneously (Wold et al., 2001). Two common algorithms used to perform PLS modelling 
are NIPALS (Geladi and Kowalski, 1986) and SIMPLS (De Jong, 1993). In this section, PLS 
implementation will be explained according to the NIPALS algorithm. 
2.4.1.1 Theory 
Like PCA, PLS will find a set of new variables which are linear combinations of the original 
variables in 𝑿 and the response variables in 𝒀 according to eq.(2.33) and eq.(2.34), respectively. 
These new variables are called Latent Variables (LVs) but will be referred to as components 
throughout this section.  
 
 𝑿 = 𝑻𝑷




+ 𝑬 (2.33) 
 𝒀 = 𝑼𝑸




+ 𝑯 (2.34) 
 
where 𝑻 (N x R) and 𝑼 (N x R) are the score matrices of 𝑿 and 𝒀, respectively, and where 𝒕𝑟 
(N x 1) and 𝒖𝑟 (N x 1) are the individual scores for component 𝑟, 𝑷 (M x R) and 𝑸 (D x R) are 
the loading matrices of 𝑿 and 𝒀, respectively, where 𝒑𝑟 (M x 1) and 𝒒𝑟 (D x 1) are the individual 
loadings for component 𝑟. 𝑬 (N x M) and 𝑯 (N x D) are the residual matrices of 𝑿 and 𝒀, 
respectively. In order to have good prediction of 𝒀, the corresponding components in the score 
matrices, 𝑻 and 𝑼, needs to be calculated in such a way so that the relationship between them 




Figure 2.7. Correlation of scores of the first component from the decomposed 𝑿 and 𝒀 blocks with PLS. 
Eq.(2.34) can then be reformulated according to: 
 
 𝒀 = 𝑻𝑸




+ 𝑭 (2.35) 
 𝑻 ≠ 𝑿𝑷  (2.36) 
 
where 𝑭 (N x D) is the new residual matrix of 𝒀. This means that the X-loadings, 𝒑𝑟 and the 
Y-loadings, 𝒒𝑟, of a component 𝑟 needs to be calculated so that the captured variation in 𝑿 is 
correlated to the captured variation in 𝒀. Thus,  𝑻 cannot be calculated in the same was as in 
PCA eq.(2.36). Instead, PLS introduces a new variable, 𝑾 (M x R), which are known as weights 
that describes the relationship between 𝑿 and 𝒀. The weights of the first component, 𝒘1, are 
calculated as the first eigenvector, 𝒗1, from 𝑿
𝑇𝒀𝒀𝑇𝑿 which is proportional to the product of 






𝑿𝑇𝒀𝒀𝑇𝑿 ∝ 𝑿𝑇𝒀𝒀𝑇𝑿 (2.37) 
 
Eq.(2.37) is only valid if both 𝑿 and 𝒀 have been centred prior to the calculation (see Section 
2.7). For more information on eigenvectors, refer to Appendix D.1. It can be shown that the 








where 𝒀𝑓 is the response variable with the largest magnitude when D > 1. If only one response 
variable is available (D = 1), then 𝒀𝑓 = 𝒀. The X-scores, 𝒕1, can be calculated once 𝒘1 
according to eq.(2.39). The X-loadings can then be acquired by projecting 𝑿 onto 𝒕1 according 
to (2.40). 
 







Trough substitution of eq.(2.39) into eq.(2.35), the Y-loadings and Y-scores can be calculated 













𝑿 and 𝒀 are then deflated in order to calculate following components according to eq.(2.43) 
and eq.(2.44), respectively. 
 
 𝑬1 = 𝑿 − 𝒕1𝒑1
𝑇 (2.43) 
 𝑭1 = 𝒀 − 𝒖1𝒒1
𝑇 (2.44) 
 
Where 𝑬1 and 𝑭1 are the residual matrices of 𝑿 and 𝒀, respectively after deflation with the first 
component. The weights for the second component are then calculated according to eq.(2.45) 
where 𝒕2, 𝒑2, 𝒒2 and 𝒄2 are calculated as previously shown with regards to 𝑬1 and 𝑭1 instead 










However, due to the deflation of 𝑿, the individual component weights, 𝒘𝑟, will not be directly 
related to 𝑿 but instead related to the corresponding residual matrix from the previous 




∗ = 𝑾(𝑷𝑇𝑾)−1 (2.46) 
 
where 𝑾∗ (M x R) is directly related to 𝑿. The X-scores in expression (2.39) can then be 
reformulated to: 
 
 𝑻 = 𝑿𝑾
∗ = 𝑿𝑾(𝑷𝑇𝑾)−1 (2.47) 
 
The prediction of 𝒀 in eq.(2.35) can then be rewritten to the more formal expression: 
 
 𝒀 = 𝑿𝑩 + 𝑭 (2.48) 
 
where the regression coefficients, 𝑩, are estimated according to: 
 
 𝑩 = 𝑾(𝑷
𝑇𝑾)−1𝑸𝑇 (2.49) 
 
2.4.1.2 Applicability of PLS in this research 
The main strength of PLS is its simplicity and diagnostic capabilities. Due to being a 
decomposition method, the diagnostic capabilities that are inherent in the PCA are also a feature 
of PLS (Bro and Smilde, 2014). This greatly aids in identification of outliers and samples that 
need to be further investigated. Contribution of variables to the prediction can be directly 
assessed in the PLS model with Variable Importance in Projection (VIP) and Selective Ratio 
(SR) (Farres et al., 2015). It is, however important to remember that both VIP and SR are linked 
to the performance of the model and therefore if low, the resulting VIP and SR values will be 
meaningless (Andersen and Bro, 2010). Alternatively, the contributions from individual 
components can be explored based on the corrected weights, 𝑾∗, as they represent the linear 
combinations of variables related to the scores, 𝑻. 
A common problem when PLS is used in QSAR applications is the sheer number of 
independent variables that are used as input. This can be potentially detrimental and PLS 
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models can become over-fitted due to chance-correlation between redundant or noisy 
descriptors in 𝑿 and the response, 𝒀 (Faber and Rajko, 2007). Therefore, in many QSAR 
instances, variable selection strategies become necessary in order to reduce the number of 
redundant or noisy variables (see Section 2.9). Bauer et al. (2017)applied PLS for prediction of 
protein diffusion coefficients used to understand protein-protein interactions based on 
independent variables generated from protein crystal structures. The authors used the VIP 
Scores to select highly contributing descriptors in order to increase model performance to a 𝑅2 
value of 0.9, thus indicating high correlation between 𝑿 and 𝒀 (refer to Section 2.6.1 for more 
information on 𝑅2). In another study, Mazza et al. (2001) applied PLS for prediction of retention 
times in ion-exchange chromatography based on independent variables generated from protein 
crystal structures (Mazza et al., 2001). The authors applied Genetic Algorithm to reduce the 
number of noisy independent variables which resulted in a model performance of 𝑅2 value 
around 0.94. Application of PLS in this research was therefore performed with variable 
reduction (see Section 2.8) and variable selection (see Section 2.9) in order to reduce noise and 
redundancy able to affect model performance. 
2.4.2 Support Vector Machines for Regression 
SVM for regression (SVR) is an extension of SVC which was first introduced by Drucker et al. 
(1997). This method applies the same fundamental principles that were used in SVC and does 
not depend on the variable dimensionality but only on the samples that are presented to the 
algorithm. 
2.4.2.1 Theory 
The theory for SVR is very similar to that of SVC (see Section 2.3.2.1). The main difference is 
that instead of defining the largest margin used to separate the samples, SVR will define a tube 
in which the majority of the samples will be located. The tube is defined by the two constraints 
shown in eq.(2.50) and eq.(2.51) and illustrated in Figure 2.8 as the dashed blue line and the 
dashed red line, respectively. 
 
 𝑦𝑖 − 𝝎
𝑇𝒙𝑖 − 𝑏 ≤ 𝜖 (2.50) 
 𝝎
𝑇𝒙𝑖 + 𝑏 − 𝑦𝑖 ≤ 𝜖 (2.51) 
 
𝜖 is called the insensitive loss where 𝜖 > 0 and is set be the user. As can be observed in Figure 
2.8, the width of the tube is defined by the insensitive loss and will be equal to 2𝜖. In SVR, 
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slack variables (𝜉𝑖
∗ and 𝜉𝑖) are commonly introduced due to noise normally being present in 
both 𝑿 and 𝒀 which can be difficult for a hard margin regressor to fit.  
 
 
Figure 2.8. Placement of regression tube in SVR defined by two constraints (red and blue dashed lines) that 
encompasses the majority of the samples and where samples falling outside of the tube are penalised by the slack 
variables 𝜉𝑖
∗ and 𝜉𝑖. Support vectors are indicated as the filled black circles and the green vector perpendicular to 
the black regression line represents the support vector weights, 𝝎 (adapted from Drucker et al. (1997)). 
A QP problem can then be formulated according to eq.(2.52) which is very similar to the QP 
problem stated in eq.(2.26) for SVC. The only difference is the addition of an extra constraint 














subject to = 𝝎𝑇𝒙𝑖 + 𝑏 − 𝑦𝑖 ≤ 𝜖 + 𝜉𝑖  
= 𝑦𝑖 − 𝝎
𝑇𝒙𝑖 − 𝑏 ≤ 𝜖 + 𝜉𝑖
∗ 
= 𝜉𝑖 , 𝜉𝑖
∗ ≥ 0 
(2.52) 
 
For samples that are placed above or below the tube the slack variables 𝜉𝑖 and 𝜉𝑖
∗ respectively, 
will become non-zero. For samples placed inside of the tube, 𝜉𝑖 and 𝜉𝑖
∗ will equal zero and thus 
not affect the loss and is known as hinge or 𝑙1-loss (Rosasco et al., 2004). The Lagrange dual 

























subject to = 0 ≤ 𝛼𝑖 , 𝛼𝑖











where 𝛼𝑖 and 𝛼𝑖
∗ are the Lagrange multipliers to the constraints in eq.(2.50) and eq.(2.51), 
respectively, and will both consist of N elements. For more information on Lagrange 
Multipliers, refer to Appendix D.3. The SMO algorithm is commonly used to solve for 𝜶 and 
𝜶∗ due to being a QP problem (Platt, 1998). Similar to SVC, samples with non-zero values in 
𝛼𝑖 or 𝛼𝑖
∗ in the solution will be support vectors and used to define 𝝎 and 𝑏. Prediction of an 
unknown sample, 𝒙𝑢, can then be performed according to eq.(2.54) for linear regression. 
 
 𝑓(𝒙𝑢) = 𝝎




⋅ 𝒙𝑢 + 𝑏 (2.54) 
 
Or according to (2.55) for non-linear regression with a Kernel (see Section 2.3.2.3).  
 
 𝑓(𝒙𝑢) = 𝝎




Κ(𝒙𝑖, 𝒙𝑢) + 𝑏 (2.55) 
 
2.4.2.2 Applicability of SVR in this research 
Many of the listed strengths and caveats presented for SVC will apply to SVR. This means that 
SVR has a high generalisation performance due to the selection of a small subset of samples 
that act as support vectors which also makes the method robust in high-dimensional problems. 
This makes SVR a popular choice in QSAR applications and it has been used extensively for 
prediction of chromatographic column performance (Robinson et al., 2017, Ladiwala et al., 
2006, Chen et al., 2008, Woo et al., 2015a, Woo et al., 2015b, Chung et al., 2010). However, 
the authors highlighted that an initial variable selection step is necessary in order to reduce the 
number of non-correlated descriptors in order to increase performance. 
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Like the PLS method, the performance of SVR will suffer if too many redundant variables are 
present in data set, thus masking the independent variables that are correlated to the response. 
It has therefore been suggested to use variable selection techniques in order to reduce the 
number of redundant variables in high-dimensional data when using Support Vector Machine 
based methods (Zhang et al., 2016).  
Determination of model parameters (𝐶, 𝛾 and 𝜖) in SVR can be performed through grid search 
with predefined ranges just as described in Section 2.3.2.4 for SVC. However, defining the 
range for 𝜖 is more complex due to being related to the intrinsic variation in the data. This is 
easier understood when observing the width of the tube in Figure 2.8 where the majority of 
samples are placed within the tube. More intuitively, this requires knowledge about the 
distribution of the residual values, 𝜀𝑖, pertaining to any given prediction according to eq.(2.56) 
and should conform to 𝜀𝑖~𝑁(0, 𝜎𝜀).   
 
 𝑦𝑖 = ?̂?𝑖 + 𝜀𝑖 (2.56) 
 
Cherkassky and Ma (2004) proposed that a linear model could be fitted to the data prior to 
applying SVR in order to investigate the distribution of the residuals (Cherkassky and Ma, 
2004). 
2.5 Cross Validation 
Larson (1931) discovered that when training a model through “resubstitution” where all 
samples in a data set are used for both training and performance validation, the resulting model 
became heavily biased due to memorising the noise present in the data which led to extremely 
poor predictions of future samples. In order to circumvent this issue, cross-validation was 
introduced which provided a framework to train and validate models more robustly. Cross-
validation has two main goals to achieve (Raschka, 2018): 
1. Estimation of the generalisation error, i.e. the predictive performance of the model on 
future (unseen) data. 
2. Model selection or tuning of the model complexity to increase model performance. This 
refers to the number of components to use in PCA, PLS and PLS-DA as well as selection 
of 𝐶, 𝜖 and kernel parameters in SVC and SVR to achieve optimal model performance. 
In literature, model complexity is also commonly referred to as the model 
hyperparameters. However, throughout this thesis the term model complexity will be 
used.  
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The core philosophy of cross validation (CV) lies in the practise of splitting the available data 
in order to train and validate a model. The core concepts will therefore first be explained with 
regards to the generalisation error and then how CV can be used to select model complexity.  
2.5.1 Generalisation Error 
One of the simplest and most commonly used technique to estimate the generalisation error of 
a model is the hold-out method. The method effectively splits the available data set into two 
parts where one is used to train the model and the other is used for validation. These will be 
referred to as the calibration set and test set illustrated in Figure 2.9 and will contain 𝑁𝐶𝑎𝑙 and 
𝑁𝑇𝑒𝑠𝑡 samples, respectively.  
 
 
Figure 2.9. Splitting of all available samples in a data set into a calibration set for training (dark box) and a test set 
for model validation (red box) (adapted from Raschka (2018)). 
Generally, the generalisation error can be estimated as the mean squared error (MSE) for 












In eq.(2.57), ?̂?𝑖 = 𝑓(𝒙𝑖), and is the predicted value of 𝑦𝑖 based on a defined function such as 
one generated from PLS or SVR. For a classification problem, the generalisation error can be 
estimated based on the error rate presented in eq.(2.62) in Section 2.6.2 for methods such as 
PLS-DA and SVC. Similarly, the calibration error can be estimated by using the calibration 
samples instead and is shown as the black line in Figure 2.10a. As can be observed, the error of 
the test set will be large if the model complexity is to low which in turn also results in high 
calibration error. This usually occurs when the model fails to capture the correlation between 
𝑿 and 𝒀. Alternatively, the error of the test set will be high when the model is fitted to noise or 




Figure 2.10.  (a) Behaviour of the test or generalisation error (red line) compared to the fitted model error (black 
line) with regards to increasing model complexity. (b) Decomposition of the generalisation error (red line) into the 
two components model variance (green line) and model bias (blue line) (adapted from Hastie et al. (2009a)). 
Eq.(2.57) can be further decomposed into the irreducible error (𝜎𝑖𝑟𝑟
2 ), the variance of the error 
(Var𝜀) and the bias of the error (Bias𝜀) according to:   
 
 ErrorTest = 𝜎𝑖𝑟𝑟
2 + Var𝜀 + Bias𝜀
2 (2.58) 
 
The irreducible error is inherent to the available data and cannot be removed from the model 
whereas the variance and bias are dependent on the model complexity as is illustrated in Figure 
2.10b. More specifically, the bias is directly related to the fit of the model where a high bias 
means that the model fails to capture the relation between 𝑿 and 𝒀 and the model becomes 
under-fitted. The variance, on the other hand, gives an estimation of the error related to 
fluctuations in samples where a high variance means that the model has been fitted to random 
noise and is therefore over-fitted. When selecting the model complexity, both the variance and 
bias should be as low as possible which is usually indicated as the minimum value of the error 
versus the model complexity illustrated as the red line in Figure 2.10b. This is more specifically 
referred to as the variance-bias trade-off and implies that a model cannot be trained perfectly 
and will always include some bias and variance (Hastie et al., 2009a).  
It should be noted that the generalisation error is heavily dependent on the samples in the test 
as well as the sample sizes of the calibration and test sets. This is better understood when 
considering the resubstitution method investigated by Larson in 1931 where the model became 
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heavily biased due to being trained and validated with the same samples. If most of the samples 
are kept for model training, the test set might no longer be representative of the full sample 
population which might cause the model to become over-fitted. This is more commonly referred 
to as optimistic bias. Alternatively, if the majority of samples is placed in the test set for 
validation, then the model training might be negatively impacted due to lack of variability as 
the calibration set no longer represents the full sample population. This is more commonly 
referred to as pessimistic bias. The number of samples to use in the test and calibration set is 
widely discussed but a usual rule of thumb is to keep the majority of samples in the calibration 
set, thereby including most of the data variability for training. Usual calibration/test splits are 
70/30 and 80/20 (Raschka, 2018). 
In classification problems, it is important to consider the class distributions in the test and 
calibration sets which preferably should be conserved in the test and calibration sets when 
compared to the full sample set. This is known as sample stratification which ensures that class 
distributions are conserved in the test and calibration set. Not using sample stratification can 
have a negative impact on the model performance due to misrepresentation of available classes 
which becomes especially critical in unbalanced data sets where big difference in sample sizes 
can be present between specific classes. In the worst case, this might mean that a class is left 
out entirely from the test set and model validation based on the generalisation error becomes 
biased (Shahrokh and Dougherty, 2013).   
Several strategies exist for splitting the available samples into calibration and test sets (Martin 
et al., 2012). One of the most common methods is random splitting where samples for the 
calibration and test sets are selected at random and only the number of samples belonging to 
each set needs to be specified. For the purposes of this research, the structured splitting 
approach of the Kennard-Stone algorithm (CADEX) has been applied due to being better suited 
to QSAR modelling problems compared to random splitting (Kennard and Stone, 1969, Martin 
et al., 2012). The CADEX algorithm selects samples based on the Euclidean distance between 
pairs of samples over the variable space of 𝑿. Pair-wise samples with high distances are placed 
in the calibration set while pair-wise samples that have a short distance will have one sample 
placed in the test set and the other in calibration set. Thus, the CADEX algorithm ensures that 
most of the variability in the variable space is presented to the model during training as well as 
that selected test samples are represented by similar samples in the calibration set (Kennard and 
Stone, 1969).  
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2.5.2 Selection of Model Complexity 
As mentioned previously, the calibration set is used to train the model. This means that selected 
calibration samples are explicitly used to tune the model complexity. This has an added benefit 
of model tuning being separate from the estimation of the generalization error and thus having 
lower risk of generating a biased model. Similar to the splitting of the full data set into a 
calibration and test set, the calibration set is further divided into smaller subsets or splits which 
are used to train the model and is known as re-sampling. An example of re-sampling for model 
training based on the K-fold method is presented in Figure 2.11. As can be observed the 
available samples in the calibration set is split into K smaller subsets. A sub-model is generated 
on all subsets except one (shown in red in Figure 2.11) which instead is used to validate the 
sub-model in the same way as the test set is used to estimate the generalization error described 
previously. This is repeated until all subsets have been used for validation once, thus resulting 
in K sub-models and K error estimations. The described repletion of sub-model development 
and validation is usually referred to as the inner cross validation loop. An average is usually 
calculated from the sub-model errors and represents the model performance for a specific 
selection of model complexity. The estimated error will behave similarly to the generalisation 
error illustrated in Figure 2.10a and Figure 2.10b and can be decomposed in the same way as 
shown in eq.(2.58). This means that both the bias and variance can be controlled explicitly 
through choice of the model complexity where the optimal model parameter set will have the 
lowest error illustrated in Figure 2.10b as the red line. It is important to note, however, that the 
minimum of the test error and the minimum of the cross-validation error is not guaranteed to 
overlap with each other with regards to the model complexity. This is a complex problem which 
is very dependent on the splitting of samples into calibration and test sets as well as the re-




Figure 2.11. K-fold cross-validation resampling of the calibration samples for model training (adapted from 
Raschka (2018)). 
Several strategies for the inner cross validation loop exist where some of the most commonly 
used are Leave-One-Out (LOO), K-fold and repeated K-fold (Wong, 2015). 
2.6 Model Validation Metrics 
In order to accurately evaluate trained models, several metrics for both regression and 
classification have been presented below. 
2.6.1 Regression Metrics 
The root mean squared error (RMSE) represents the variation of the error observed between the 
measured and predicted responses and is shown in eq.(2.59). The RMSE is commonly used to 
assess the model complexity due to direct evaluation of the differences between measured and 
predicted values.  
 













The squared Pearson Correlation coefficient (𝑅2) provides a measure of the correlation between 
the measured and predicted responses and is presented in eq.(2.60). The 𝑅2 metric can take on 
values between zero and one where a value closer to zero represents low correlation and poor 
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The coefficient of determination (𝑄2) provides a measure of well the model is able to explain 
the variation in the response vector and has been presented in eq.(2.61). 𝑄2 can attain negative 
values which is an indication that the model performs worse than if all responses would have 
been predicted as the mean of the measured responses, in which case the 𝑄2 would attain a 
value of zero. A value closer to one indicates good model fit and that high correlation between 
𝑿 and 𝒀. 
 
 𝑄
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2.6.2 Classification Metrics 
Validation of classification models are fundamentally different from regression models where 
instead the performance is evaluated based on the number of correctly classified and 
misclassified samples. In a binary classification problem, the classes are usually referred to as 
positive and negative. The predictions can therefore be categorised according to four definition 
depending on the true class of the samples: True positives (TP) are the number of positive 
samples that were correctly classified, False positives (FP) are the number of negative samples 
incorrectly classified as positive, True negatives (TN) are the number of negative samples 
correctly classified as positive and False negatives (FN) are the number of positive samples 
incorrectly classified as negative. These four values lie at the core of all model evaluation for 
classification problem and is usually presented in the form of a confusion matrix. For evaluation 
of a multiple classification problems, the OvR strategy can be implemented in order to generate 
a confusion matrix for each class. An example of this is presented in Figure 2.12a in which the 
predictions of three classes have been presented in a confusion matrix. By defining Class 1 as 
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the positive class and the negative class as Class 2 and Class 3, a binary representation for the 
predictions of class 1 can be evaluated which is illustrated in Figure 2.12b. 
 
 
Figure 2.12. Representation of a confusion matrix as an overview of model performance for (a) multiple classes 
of (b) two classes (adapted from Fawcett (2006)). 
A common classification metric used in research is the Error rate (ER) which represents the 
proportion of samples which were incorrectly classified and can take a value between 0 (all 
samples misclassified) and 1 (all samples correctly classified). Calculation of ER was 
performed according to eq.(2.62). 
 
 ER =  
𝐹𝑃 + 𝐹𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁
 (2.62) 
 
The Sensitivity (Sen) represents the proportion of positive cases that were correctly identified 
and can take a value between 0 (all samples misclassified) and 1 (all samples correctly 







The Specificity (Spec) represents the proportion of negatives cases that were classified correctly 
and can take a value between one (all samples correctly classified) and zero (all samples 








The Matthews Correlation coefficient (MCC) considers all aspects of the confusion matrix (TP, 
TN, FP and FN) and is regarded as a balanced measure that can be used even if the sample sizes 
of the different classes are very different (Jurman et al., 2012, Gorodkin, 2004). MCC can take 
a value between -1 and 1 where a value of 1 means that all samples have been correctly 
classified and a value between -1 to 0 means that all samples have been misclassified. For a 
binary confusion matrix, the MCC was calculated according to eq.(2.65). 
 
 MCC =
𝑇𝑃 ∗ 𝑇𝑁 − 𝐹𝑃 ∗ 𝐹𝑁
√(𝑇𝑃 + 𝐹𝑃)(𝑇𝑃 + 𝐹𝑁)√(𝑇𝑁 + 𝐹𝑃)(𝑇𝑁 + 𝐹𝑁)
 (2.65) 
 
The MCC metric can be extended for use on multiple classes according to eq.(2.66). 
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Individual class performances were also evaluated with receiver operating characteristics 
(ROC) curves which explores the separation of the classes according to the predicted class 
distributions. More specifically, the “area under the curve” (AUC) can be used as a performs 
metric of the class separation where a value of one indicates perfect classification and a value 
of 0.5 which indicates that no separation of the classes have been observed (Fawcett, 2006). In 
PLS-DA, the class distributions can be defined based on the calculated posterior probabilities 
in eq.(2.18) while in SVC, the distributions can be defined according to the calculated decision 
values in eq.(2.25). The ROC curve is calculated by sliding a threshold boundary over the class 
distributions thus allowing for the TP, TN, FP and FP which results in differing values of the 
sensitivity and specificity depending on the threshold value. For classes that are well separated 
as illustrated in Figure 2.13a, the resulting ROC curve will take on a shape as illustrated Figure 
2.13b where the AUC value is close to one. In cases where class distributions are harder to 
separate as illustrated in Figure 2.13c, the resulting ROC curve will be closer the dashed black 




Figure 2.13. ROC curve development for two classes. The number of TP, TN, FP and FN changes depending on 
to the placement of the threshold which is less drastic in a problem with (a) well-separated class distributions 
compared to a problem with (b) overlapping class distributions. ROC curves from (b) well separated class 
distributions and (d) overlapping class distributions where the black dashed line represents the AUC value of 0.5 
(adapted from Marini (2017)). 
2.6.3 Y-Randomisation  
Due to the large number of descriptors often used in QSAR modelling, it is important to 
evaluate if the correlation between 𝑿 and 𝒀 captured by the model is related to the true 
underlying pattern or if it was caused by chance correlation of noisy descriptors. Y-
Randomisation is a tool used in validation of QSAR models which compares the performance 
of models trained with randomised response vectors to that of a model trained with an unaltered 
response vector (Rücker et al., 2007). A number of randomised models are usually developed 
and the performance metric of interest is then averaged. If the averaged performance metric 
shows good performance, the trained model was likely fitted to noisy and redundant descriptors 
and can therefore not be used. For regression the metrics 𝑄2 and 𝑅2 are often used while in 
classification the metrics ER of MCC can be used. In this research 50 models were developed 
on individually randomised response vectors where the metric of interest was then averaged.  
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2.7 Data Pre-treatment 
As previously mentioned in the theory of PCA and PLS, it is important to mean-centre 𝑿 and 
𝒀 prior to developing the model in order for these methods to work. More generally, an action 
that modifies the data prior to model development is called pre-treatment or pre-processing and 
is used to increase the interpretation of the data sets (van den Berg et al., 2006). This is more 
simply understood when considering the influence of the variables in model development. As 
an example, when evaluating untreated data set each individual variable will conform to some 
specific distribution (normal distribution was used in this example) where 𝒙𝑘~𝑁(𝜇𝑘, 𝜎𝑘
2) where 
𝜇1 ≠ 𝜇2 ≠ ⋯ ≠ 𝜇𝑀 and 𝜎1
2 ≠ 𝜎2
2 ≠ ⋯ ≠ 𝜎𝑀
2  which is illustrated in Figure 2.14a. For PCA and 
PLS, mean centring is a required step due to that the methods being dependent on the calculation 
of the covariance, which assumes that the data is centred around the origin. If models are 
developed on an uncentred data set with PCA or PLS, the first component will always be placed 
so it points from the origin to the centre of the data in the variable space in order to correct for 
the offset (Bro and Smilde, 2014). The effect will not be as pronounced for SVC or SVR which 
can adjust for uncentred data by correcting with the offset variable, 𝑏, of the hyperplane or the 
tube, respectively. An example of a set of the mean centred variables is illustrated in and Figure 




Figure 2.14. The effect of pre-treatment on variables on a data set. (a) Raw or untreated data set. (b) Mean centred 
data set. (c) Mean centred and scaled data set (adapted from van den Berg et al. (2006)). 
Another important factor is the scaling of the descriptors. Commonly in many data sets, the 
ranges in the variables will be very different when compared to each other. This gives variables 
with a larger variation a bigger chance to influence the model compared to variables with a 
much smaller variation (Bro and Smilde, 2014). Thus, all variables are commonly scaled to 
67 
have equal variation or range in order for them to equally impact the model structure. In this 
research, the autoscaling method was used for pre-treatment of all data except class labels. The 
method both mean centres all variables as well as scales them according to the standard 
deviation of each variable according to eq.(2.67). This means that all variables in the data set 




















 is an auto-scaled element in 𝑿, ?̅?𝑘 and 𝜎𝑘 are the mean and the standard 
deviation of variable 𝑘. An example of autoscaled variables is presented in Figure 2.14c. 
2.8 Variable Reduction 
Due to the large number of variables (descriptors) that are generated in QSAR modelling, it is 
often beneficial to use unsupervised methods to remove collinear variables prior to further 
variable selection or model development. The V-WSP algorithm was applied to the 𝑿 block in 
order to select a representative set of variables. This V-WSP algorithm works by replacing a 
group of variables with high multi-collinearity with a single variable from the group if the 
correlation between the variables is larger than a predefined threshold (Ballabio et al., 2014). 
The Procrustes index was used to evaluate the loss of information between the non-reduced and 
the reduced 𝑿 block. The Procrustes index takes on values between zero and one where a value 
of zero indicates that no information loss has occurred while a value closer to one indicates that 
the majority of information in 𝑿 has been lost (Peres-Neto and Jackson, 2001). 
2.9 Variable Selection 
Supervised variable selection methods were applied in this research to further reduce the 
number of variables in order to increase correlation between 𝑿 and 𝒀. Three different methods 
were applied for which short descriptions have been given below. 
2.9.1 Recursive Partial Least Squares 
The Recursive Partial Least Squares (rPLS) is a variable selection method which iteratively 
reweights the variables in 𝑿 through multiplication with a matrix 𝑨 in which the diagonal 
elements  𝑎𝑘𝑘 = |𝑏𝑘| from the regression coefficients vector 𝑩 generated from the PLS model. 
A new PLS model is developed on reweighted 𝑿 and this is repeated until a minimum in the 
cross-validation error has been reached. By iteratively updating 𝑩 and 𝑿 as described, the 
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regression coefficients of variables with small contributions to the predictions will be forced to 
zero whereas those for variables with high contribution become larger. The stopping criterion 
in rPLS is based on the calculated cross-validation error at each iteration which will be forced 
to stop once the error start rising (Rinnan et al., 2014).  
The method is however reliant on the model performance prior to variable selection. This means 
that if the model performance is poor prior to selection, the rPLS algorithm will not be able to 
select the correct variables. This is similar to that of variable evaluation with VIP and SR in 
PLS (Andersen and Bro, 2010). 
2.9.2 Genetic Algorithm 
The genetic algorithm (GA) is based on the evolutionary principle of “survival of the fittest” 
(Leardi, 2007). GA works by generating subsets of variables where each subset usually contains 
between 30-50% of all available variables in the data set. Such a subset can be seen as a logical 
vector consisting of 𝑀 elements, identical to that of the number of variables, where an element 
value of one or zero indicates inclusion or exclusion, respectively, of the variable in the subset. 
Each subset is often referred to as chromosome or individual and all the generated subsets is 
referred to as a population. An individual model is trained on each chromosome and evaluated 
according to the cross-validation error as an estimation of the fitness. A new population 
(generation) is then produced through crossover illustrated in Figure 2.15 where two 
chromosomes (parents) are used to generate two new chromosomes (children). Many methods 
for selecting the parent chromosomes exist but where the Roulette Wheel is one of the most 
commonly used. The parent chromosomes are selected at random but where chromosomes with 
a better fit have a higher chance of being selected (Pandey et al., 2014). The parent selection 
and crossover are repeated until the number of children equals that of the original population 
size. New models are trained on the children chromosomes and the full process is iterated. 
 
 
Figure 2.15. Crossover of variables between two parent chromosomes A and B resulting in two new variable 
permutations in the form of child C and D. The red line indicates the crossover site which is selected at random by 
the GA method (adapted from Pandey et al. (2014)). 
One of the main strengths of GA is the ability to test many different variable permutations and 
select variables highly correlated to the response. However, one of the biggest drawbacks with 
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the method is the low reproducibility of generated results due to many aspects of the algorithm 
is based on random selection. A common method to increase reproducibility is to repeat the GA 
for several iterations in order to find variables that are most commonly selected. It has also been 
suggested that no more than 200 variables should be used in GA due to potential over-fitting 
(Leardi, 2000). Another drawback with the method is defining the many parameters such as: 
population size, single or double crossover, mutation rate and number of variables to include in 
the initial chromosome to mention a few. 
The modelling method used in GA is commonly referred to as the fitness function which is not 
restricted to any particular method and can be either a classification or regression method. 
However, the fitness function should be sufficiently fast to train due to the numerous models 
that needs to be developed in order for GA to not become to computationally intensive (Niazi 
and Leardi, 2012). 
2.9.3 Sparse L1-SVR 
L1-SVR or more commonly referred to as LASSO-SVR is based on similar theory to that of 
SVR discussed in Section 2.4.2. The main difference is that the minimisation problem in 
eq.(2.52) uses the L1-norm, ‖𝝎‖1, instead of the squared L2-norm, ‖𝝎‖2
2. This, however, has 
a significant effect on the normal vector, 𝝎, which will become sparse. Meaning that many 
elements in 𝝎 will attain a value of zero. This is easier understood using Figure 2.16 for a 
regression problem with two variables. The red ellipses illustrated in the figure indicate the loss 
function or the error between the predicted and measured responses. First, considering the L2-
norm illustrated in Figure 2.16a, the possible solutions for 𝝎 will take the shape of a circle seen 
in green, the radius of which is determined by the constraints and the value of 𝐶. It can be 
observed that the optimal solution consists of non-zero values in 𝝎, meaning that both variables 
will contribute to the prediction. In the case of the L1-norm, the solutions for will take the shape 
of a diamond illustrated as the green area in Figure 2.16b. Because of this shape, the optimal 





Figure 2.16. Comparison of solutions for (a) L2-norm and (b) L1-norm. The red ellipses represent the error 
between the predicted and measured responses in the samples set while the green areas represent the allowed 
solutions for 𝝎 (adapted from Zhu et al. (2004)). 
It is important to remember when using LASSO that the so-called “irrepresentable condition” 
must hold true which indicates that correlation between redundant and important variables must 
be low (Zhao and Yu, 2006).  
2.10 Summary 
This chapter laid the foundation of the multivariate methods and techniques used in this thesis. 
From the literature review of the methods in this chapter, it is apparent that each method has 
associated advantages and limitations. However, considerations regarding their application, 
training and validation have been made in order to increase the chance for successful 
implementation.   
As discussed, the classification methods were selected to better handle uneven class balances 
that were present in the data set from Jain et al (2017). For this purpose, PLS-DA with Bayes 
decision rule and SVC with defined cost function values for each class were selected. The two 
methods are also complementary to each other, where PLS-DA can provide insight to potential 
outliers and have higher transparency in regards to variable contribution to the response 
whereas SVC usually have higher generalisation performance due to only using a subset of 
samples as support vectors. 
Similarly, all regression methods in this chapter were reviewed and evaluated in order to 
conform to QSAR modelling. The two methods, PLS and SVR were selected due to having 
been applied successfully in similar QSAR implementations as have been demonstrated in 
literature. The methods are also complementary to each other where PLS have higher 
transparency in regards to sample and variable contribution and SVR a higher generalisation 
performance.  
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Due to the large number of descriptors needed to capture the structural information of the mAb 
structures, it became clear that variable reduction and selection techniques had to be applied. 
The unsupervised reduction method V-WSP was reviewed and included model development 
process in order to reduce the number of highly correlated descriptors. In addition, three 
variable selection methods: rPLS, GA and LASSO were reviewed, and their strengths and 
weaknesses listed. These methods were selected due to being slightly different in how they 
select variables. The rPLS and LASSO algorithms are highly dependent on the number of 
redundant variables in the descriptor set which can greatly decrease their performance if to 
many redundant variables are present. The GA algorithm instead selects variables based on a 






Chapter 3  
 
Primary sequence-based descriptors 
In order to develop predictive models that can aid in mAb process development, structural 
descriptors need to be generated in order to compare the different mAbs. In this chapter the 
general structure of mAbs and common sources of structural variations that might impact the 
descriptors are highlighted and discussed. Four novel strategies have been developed for 
primary sequence preparation and descriptor calculation which are discussed in detail. 
3.1 The Antibody Structure 
There are five main heavy chain classes of antibodies: IgA, IgD, IgE, IgG and IgM where IgG 
have the highest occurrence in the human body with around ~75% of all antibodies found in 
the human serum (Schroeder and Cavacini, 2010). In this research, an extensive search was 
performed using the IMGT database to investigate the diversity of different antibody classes in 
clinical phases as well as manufacturing. The search criteria were specified to find all full-
length IgA, IgD, IgE, IgG and IgM antibodies while excluding fusion proteins and fragments. 
Of the total 555 antibodies that met the search requirements, 543 were of the IgG class (~98%). 
Due to these findings, IgG antibodies are the focus of this dissertation. The IgG class can be 
further divided into four subclasses or so-called isotypes: IgG1, IgG2, IgG3 and IgG4. Of these, 
the IgG1, IgG2 and IgG4 isotypes are further investigated in this chapter due to being the most 
common according to the IMGT search with 74% being IgG1, 12% being IgG2 and 13% being 
IgG4 out of all IgG antibodies. 
Figure 3.1 represents the structure of an IgG1 antibody. In general, the IgG antibody consists 
of four amino acid chains, of which two are heavy chains (50kDa and ~450 residues long each) 
and two are light chains (25 kDa and ~230 residues long each). The heavy chain can be divided 
into the four domains: the variable region (VH), first constant domain (CH1), second constant 
domain (CH2) and third constant domain (CH3) where a Hinge region connects the CH1 and CH2 
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domains of the heavy chain. The light chain can be divided in a similar manner into two 
domains: the light chain variable domain (VL) and a constant domain (CL). Like the heavy chain, 
the light chain has two naturally occurring isotypes: kappa and lambda. Each of the mentioned 
domains in the antibody contains ~110 residues whereas the hinge has 15 residues in the IgG1 
isotype compared to 12 residues in the IgG2 and IgG4 isotypes (Janeway Jr et al., 2001).  
3.1.1 The Fab region structure and function 
The VH and CH1 domains of the heavy chain together with the VL and CL domains of the light 
chain make up the Fab region of the antibody. This is also known as the binding region of the 
antibody that binds to a specific target protein (antigen) e.g. a membrane protein on a pathogen. 
The binding occurs specifically in the variable domains VH and VL which contain six sequence 
loops (three for each variable domain) called Complementarity-determining regions (CDRs) 
that bind to a specific antigen. Antibodies can be grouped into so called idiotypes based on a 
group of antibodies that bind to a specific antigen and share similar structural characteristics in 
the variable domains and CDRs.  
 
 
Figure 3.1. General structure of an IgG1 antibody. (a) Front view of the antibody showing the separate domains 
of the heavy chain (VH, CH1, Hinge, CH2 and CH3) depicted in blue as well as the separate domains of the light 
chain (VL and CL) depicted in orange. (b) Side view of the antibody structure with the two glycan structures 
highlighted with a red circle. Each glycan connects to Asn297 of each heavy chain (adapted from Vidarsson et al. 
(2014)). 
3.1.2 The Fc region structure and function 
The CH2 and CH3 domains of both heavy chains are called the Fc region of the antibody. The 
Fc region determines the type of response that is triggered in the immune system, the so-called 
Fc effector function, and has been covered elsewhere (Rajpal et al., 2014, Kizhedath et al., 
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2017). An important part of this region is asparagine 297, which is strictly conserved in all IgG 
isotypes. It serves as an attachment point for glycans in the CH2 domain of each heavy chain 
(see Figure 3.1b). The glycan structures have been shown to increase the overall stability of the 
IgG (Zheng et al., 2011) as well as playing an integral part in the activity of the antibody 
(Ferrara et al., 2011).  
3.1.3 Sequence variability in constant domains 
Most of the sequence variability between antibodies is found in the variable domains VH and 
VL. The variability is caused mainly by the unique structure of the CDR loops which gives them 
their high specificity to different antigens. Variability in sequences is also encountered in the 
constant domains when comparing the different isotypes in the heavy and light chain separately 
(see Figure 3.2). However, the extent of the variability is not as pronounced as when comparing 
sequences of the variable domains between antibodies. The amino acid differences between the 
isotypes in the heavy chain are illustrated in Figure 3.2a. EU numbering has been used to 
illustrate each of the residue positions in the sequence alignment (Edelman et al., 1969). The 
positions highlighted with red boxes are positions that play a vital role in the Fc effector 
function (Kizhedath et al., 2017). Positions coloured in red and underlined mark the positions 
of amino acids that vary between different allotypes and are slightly different in the sequence 
that can be found between different populations (Vidarsson et al., 2014). A more extensive view 
of allotypes occurring in the heavy chain isotypes is illustrated in Figure 3.2b. In total, including 
the allotypes, only 44 residues of a total of ~340 residues from the constant domains and hinge 
are different in the heavy chain between isotypes.  
In addition to the variations caused by the allotypes in the heavy chain, a common modification 
in design of IgG4 antibodies is the mutation of the wildtype hinge residue Serine 228 to a 
Proline. The mutation stabilises the hinge region which becomes more rigid and more similar 
to that of the IgG1 hinge (Aalberse and Schuurman, 2002). This also has the effect of increasing 
the efficacy of the IgG4 antibodies by preventing Fab arm exchange with other IgG4 antibodies 
(Silva et al., 2015).  
The sequence variability between  kappa and lambda is however more pronounced with 74 
residues being different out of the total ~110 residues in the CL domain, with reported allotypes 
positions marked as red an underlined (see Figure 3.2c). No allotypes have been reported for 
kappa and lambda but residue variability is present between different light chain isotypes which 
is illustrated in Figure 3.2d. All  information related to the allotypes in the heavy and light chain 
were acquired from the IMGT database (Lefranc and Lefranc, 2012). 
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3.1.4 Disulphide bonds 
The heavy and light chains are linked with a single disulphide bond between the CL and CH1 
domains that prevents the two chains from separating. In addition, the two heavy chains are 
also connected by disulphide bonds in the region surrounding the hinge. In IgG1 and IgG4 the 
heavy chains are linked with two disulphide bonds whereas IgG2 antibodies have a total of four 
disulphide bonds linking the two heavy chains (Liu and May, 2012). The structural differences 
and the sequence variability of the constant domains in the heavy and light chain are 
summarised in Table 3.1.  
Table 3.1. Summary of structural differences of the constant domains in the heavy and light chains (adapted from 
Lefranc et al. (2005) and Liu and May (2012)) 
Heavy Chain IgG1 IgG2 IgG4 
CH1 residues 98 98 98 
Hinge residues 15 12 12 
CH2 residues 110 109 110 
CH3 residues ~110 ~110 ~110 
Allotypes 7 4 3 
Disulphide bonds in hinge 2 4 2 
Light chain kappa lambda  
CL residues ~107 ~106  





Figure 3.2. Heavy and light chain isotypes and allotypes. (a) Sequence alignment of the constant domains CH1, 
Hinge, CH2 and CH3 in the heavy chain showing all structural differences between the isotypes IgG1, IgG2 and 
IgG4. Sequence numbering follows the EU numbering scheme and positions marked as bold, underlined and 
coloured red are positions with varying residues originating from different allotypes. Positions marked with red 
boxes highlight residues that are important in the Fc effector function (b) Comparison of the common allotypes 
with the positions in the primary sequence isolated to illustrate the varying residues based on given alleles. Allele 
names containing IGHG1 refer to IgG1, IGHG2 to IgG2 and IGHG4 to IgG4 (c) Sequence alignment of the 
constant domain CL in the light chain illustrating the structural differences between the isotypes kappa and lambda. 
Positions with varying residues in the sequences of known allotypes are marked as bold, underlined and coloured 
red. (d) Comparison of most common isotypes of the CL domain where only positions with varying residues are 
illustrated.  Allele names containing IGKC refer to the kappa isotypes while allele names containing IGLC refer 
to the lambda isotypes (adapted from Lefranc and Lefranc (2012)). 
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3.1.5 Sequence variation from humanisation 
Many antibodies are produced by using animal models such as house mouse. In this process 
antibodies are developed as part of the animal’s immune system when presented with an antigen 
of interest. B cells expressing antibodies specific to the antigen are harvested and antibodies 
with high specificity are retained for further evaluation (see Figure 3.3a) (Laffleur et al., 2012). 
However, these antibodies cannot be used due to slight differences in the structure of the Fc 
region which will cause undesired binding when presented in a human environment and thereby 
causing adverse effects (Hansel et al., 2010). Often in order to be able to use the antibodies 
clinically they first need to be modified to become more human-like. Boulianne et al (1984) 
circumvented this problem by replacing the constant domains (CH1, hinge, CH2, CH3 and CL) 
of a mouse antibody with those of human counterparts and thereby producing a chimeric 
antibody (see Figure 3.3b) with high specificity and lowered immunogenicity (Boulianne et al., 
1984). An improvement of this was made by Jones et al (1986) where instead of retaining the 
full variable domains of the animal antibody, a humanised antibody (see Figure 3.3c) could be 
produced by retaining only the CDRs which were grafted onto the framework regions of human 
variable domains (Jones et al., 1986). This has the effect of lowering the immunogenicity 
further by reducing the animal components that can cause adverse effects, but can also lower 
the specificity towards the antigen (Hwang and Foote, 2005). Fully human antibodies (see 
Figure 3.3d) can be expressed through the use of transgenic animals which have been modified 




Figure 3.3. Representation of antibody modification where orange domains are expressed domains from the animal 
model and blue domains are expressed from human genome. Level of modification is presented in increasing order 
from fully animal (a), to chimeric (b), to humanised (c) and finally to fully human (d) (adapted from Absolute 
Antibody (2018)). 
The humanisation of antibodies introduces an interesting artefact in the sequence variability of 
the variable domains which originates from the modification used to design the antibody 
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(animal, chimeric, humanised and human). In this dissertation, only antibodies with human 
constant domains will be used in order to decrease sources of variability. However, for chimeric 
antibodies there will be an effect originating from the species used to express the variable 
domains compared to that of humanised and human antibodies. As mentioned above, just as the 
chimeric antibodies can cause adverse effects through unwanted binding, it might also impact 
on the performance in operational units in a bioprocess e.g. binding in chromatographic 
columns.  
3.2 Descriptor generation 
All antibody sequences that were used in modelling in the subsequent chapters were obtained 
from the IMGT database unless another means of acquisition is specified. Figure 3.4 illustrates 
an overview of the applied workflow for the generation of descriptors. An initial isotype 
classification of the sequences was performed by using recognition sequences for each isotype 
based on the human hinge region and the beginning of the human constant CL domain to identify 
the isotype of the heavy and light chain, respectively. For IgG4, an additional recognition 
sequence was added to incorporate the Ser228Pro mutation. 
Descriptors were generated by either using 1) software to estimate protein properties with 
FASTA as input format or 2) conversion of each selected residue into numerical values with so 
called amino acid scales illustrated in Figure 3.4b. Prior to the descriptor generation, a sequence 
preparation step was performed in order to generate four different data sets illustrated in Figure 
3.4a which is explained further in Section 3.3. Explanation of the descriptor generation is given 
first in order to facilitate the comparison of the different sequence preparation strategies. 
3.2.1 Software based descriptors 
In order to generate meaningful descriptors from the sequences to be used in modelling, 
dedicated software was used. In this dissertation, ProtDCal 3.5 (Ruiz-Blanco et al., 2015) and 
a standalone version of EMBOSS Pepstats 6.5 (McWilliam et al., 2013) were considered and 
used to generate the descriptors presented in Table 3.2.  
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Table 3.2. List of generated descriptors from ProtDCal and EMBOSS Pepstats. The stars in the second and third 
columns represent which software was used for generation of each descriptor. 
Descriptor ProtDCal Pepstats Type Description 
𝑮𝑾(𝑼) ●  Folding energy Index of the contribution to the free energy 
from the entropy of the first shell of water 
molecules in an unfolded state 
𝑮𝒔(𝑼) ●  Folding energy Index of the interfacial free energy of an 
unfolded state 
𝑾(𝑼) ●  Folding energy Number of water molecules close to a residue 
in an unfolded state 
𝑴𝑾  ● Physiochemical Molecular weight of the protein 
𝑯𝑷 ●  Physiochemical Hydrophobicity by the Kyte-Doolittle scale 
𝑰𝑷  ● Physiochemical Isoelectric point of the protein 
𝚫𝑯𝒇 ●  Physiochemical Heat of Formation 
𝑬𝑪𝑰 ●  Physiochemical Electronic Charge Index 
𝑰𝑺𝑨 ●  Physiochemical Isotropic Surface Area 
𝑨𝒑𝒐𝒍𝒂𝒓 ●  Physiochemical Polar area of each amino acid in unfolded 
state 
𝑪𝒉𝒂𝒓𝒈𝒆  ● Physiochemical The sum of all charges in sequence 
𝑨𝑹𝑾  ● Physiochemical Average residue weight 
𝑹𝒆𝒔𝒊𝒅𝒖𝒆𝒔  ● Physiochemical Number of residues in sequence 
 
ProtDCal is a freely available tool specifically designed to generate descriptors for multivariate 
modelling of proteins by using either the primary sequences in FASTA format or 3D structures 
in PDB format. It has been applied successfully in machine learning environments for the 
identification of functional protein residues (Corral-Corral et al., 2017) and prediction of N-
glycosylation sites on proteins (Ruiz-Blanco et al., 2017) to mention a few. ProtDCal allows 
for generation of a variety of descriptors ranging from thermodynamic, topological (only for 
3D structures) to physiochemical properties. For the purposes of this research however, 
descriptors were selected focusing on properties present on the surface such as charge and 
polarity as well as descriptors for protein stability such as folding energies and hydrophobicity 
due to the interest in developing models can accurately predict external behaviour of mAbs 
























































































































































































































































































































































































It is important to note that ProtDCal will calculate physiochemical descriptors based on indexed 
values for each residue when using the primary sequences as input. This means that no 
assumptions are made in ProtDCal regarding environmental factors in the solution surrounding 
the protein. For calculation of full protein descriptors, ProtDCal provides different calculation 
modes or so-called aggregation techniques which determines how the descriptors are put 
together based the indexed residue values (Ruiz-Blanco et al., 2015). In this research 
considerations were given to two such methods: the sum and the Euclidean distance of the 
generated indices. The Manhattan distance was selected due to the descriptors being additive in 
nature, meaning that an approximation of a descriptor for the full protein is that of the 
summation of the individual amino acids. The Euclidean distance was used in addition to give 
more information of the magnitude of the descriptors when multiple residues are used for 
descriptor generation. Specifics on when the different aggregation methods were applied can 
be found in Section 3.3 below. The calculation of the folding energy descriptors in ProtDCal, 
on the other hand, is based on empirical equations which are dependent on adjacent residues as 
well as the temperature (Ruiz-Blanco et al., 2013). In this research, the default value of 25 ºC 
(298.15 ºK) was used. 
In addition, ProtDCal is also able to generate descriptors for specified groups of amino acids 
seen in Table 3.3. These groups are based on amino acid composition of secondary structure 
(Otaki et al., 2010) and classical amino acid classification according to the side chain polarity, 
charge, aromatic structure and so on (Taylor, 1986). By generating the ProtDCal descriptors in 
Table 3.2 based on selected amino acids specified in a group, greater utilisation of the input 
sequence is achieved as specific properties can be quantified more easily e.g. calculation of 
descriptor based only on polar residues (PLR).  All 12 presented groups in Table 3.3 were used 
to generate descriptors from ProtDCal thus resulting in 120 unique descriptors (10 descriptors 
per group) for each sequence input. 
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Table 3.3. Amino acid groups available in ProtDCal. RTR, BSR and AHR are based on common residues found 
in secondary structure. ALR, ARM, NPR, PLR, PCR, NCR and UCR are groups that conform to the classical 
amino acid classification. PRT represents the full sequence (adapted from Ruiz-Blanco et al. (2015)) 
Amino acid 
group 
Description  Residues 
RTR Common residues in reverse 
turn structure 
Secondary structure Asn, Asp, Gly, Pro and Ser 
BSR Common residues in Beta 
Sheet structure 
Secondary structure Ile, Phe, Thr, Trp, Tyr and 
Val 
AHR Common residues in Alfa 
Helix structures 
Secondary structure Ala, Cys, Gln, Glu, His, 
Leu, Lys and Met 
ALR Aliphatic residues Residue classes Ala, Gly, Ile, Leu and Val 
ARM Aromatic residues Residue classes His, Phe, Trp and Tyr 
NPR Non-polar residues Residue classes Ala, Gly, Ile, Leu, Met, Phe, 
Pro, Trp and Val 
PLR Polar residues Residue classes Arg, Asn, Asp, Cys, Gln, 
Glu, His, Lys, Ser, Thr and 
Tyr. 
PCR Positively charged residues Residue classes Arg, His and Lys 
NCR Negatively charged residues Residue classes Asp and Glu 
UCR Uncharged polar residues  Residue classes Asn, Cys, Gln, Ser,Thr,Tyr 
UFR Unfolding residues Residue classes Gly and Pro 
PRT Whole protein Whole protein All residues 
 
EMBOSS Pepstats was used to provide additional descriptors to the data set. Though not as 
extensive as ProtDCal, the total charge, the average residue weight and the number of residues 
in the sequence was calculated by Pepstats. In Pepstats, the molecular weight of the sequence 
was calculated with the assumption of no N- or C-terminal modifications being present in the 
sequence whereas the isoelectric point (pI) and charge were calculated based on the 
physiological pH of 7.4. 
3.2.2 Amino acid scale descriptors 
Many advancements have been made in developing new informative descriptors to be used in 
the QSAR modelling framework. For modelling of proteins and peptides, so called amino acid 
scales were first developed and introduced by Sneath in order to numerically convert the 
residues into meaningful values (Sneath, 1966). A large number of physiochemical descriptors 
were generated for the 20 naturally occurring amino acids. These were then reduced into four 
vectors (components) using PCA (see Section 2.2.1) for dimensionality reduction and thus 
allowing the components to capture the overall differences and similarities between the amino 
acids based on the used descriptors. This led to a reduction in the number of descriptors that 
were used in QSAR modelling due to a large number of descriptors being replaced by unique 
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values for each amino acid in the sequences. Many new and specialised amino acid scales have 
since been developed to capture different properties of the amino acids. A comparison of 13 
different scales was performed by van Westen et al (2013) in order to find complementary 
scales to be used in modelling (van Westen et al., 2013b, van Westen et al., 2013a). Based on 
these findings and for the purposes of this dissertation, the Z-scale (Hellberg et al., 1986, 
Hellberg et al., 1987b), the T-scale (Tian et al., 2007) and the MSWHIM scale (Zaliani and 
Gancia, 1999) were chosen to be used for numerical conversion of sequence residues as they 
capture physiochemical, topological and electrostatic properties, respectively (see Table 3.4). 
In total, 11 descriptors based on the three chosen amino acid scales were used for numerical 
conversion of each residue. 
Table 3.4. Amino acid scales used for descriptor generation and details on captured information of the individual 
components  
Scale Description Method Number of 
Components 
Component Component descriptions 
Z-Scale Physiochemical PCA 3 Z1 Contains information related 
to the hydrophobicity 
Z2 Contains information related 
to size, hydrophobicity and 
hydrophilicity 
Z3 Contains information related 
to pH and NMR values 
T-scale Topological PCA 5 T1 No information given 
T2 No information given 
T3 No information given 
T4 No information given 
T5 No information given 
MSWHIM Electrostatic 
potential 
PCA 3 MS1 Contains information related 
to the charge and size 
MS2 Contains information for 
further separation of 
positively charged residues 
MS3 Contains information for 
further separation of 
negatively charged residues 
3.3 Sequence preparation and conversion 
Normally, in any given problem statement where protein descriptors are used to develop a 
model with the goal of being able to predict some process related performance metric e.g. 
aggregation, retention time etc, a subset of specific structural features in the protein will be 
directly related to that output. Using the full antibody sequence to generate descriptors in such 
cases would confound the information due to the majority of the residues being redundant and 
more likely to introduce noise in the descriptors. Therefore, prior to the generation of the 
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descriptors, five novel preparation strategies were considered in order to address this issue of 
resolution: Domain based, Window based, Single Amino Acid based and Running Sum based 
strategies which are illustrated in Figure 3.4a. These five strategies were developed and 
considered in order to reduce the noise from the redundant residues and enhance the information 
from the residues related to an output of interest. 
3.3.1 Domain based 
In the Domain based approach, all sequences were split into smaller fragments corresponding 
to the antibody domains (VH, CH1, Hinge, CH2, CH3, VL and CL). The start and the end positions 
for each domain were generated based on the initial isotype classification, thus finding the 
positions of the hinge and the start of the constant domain CL and then using the specific domain 
lengths specified in Table 3.1. 
Descriptors were generated using both software and amino acid scales, see Figure 3.4b. In 
ProtDcal, descriptors were generated based on the 12 amino acid groups presented in Table 3.3 
resulting in 120 unique descriptors. This to further extract more information from the domains 
but also capture the slight differences in the amino acid compositions in the domains. Global 
versions of the amino acid scale descriptor were generated by summing the individual 
component values of all residues. This was as all components are orthogonal to each other in 
each of the amino acid scales due to have been generated from PCA (Bro and Smilde, 2014). 
This therefore allows each component to be additive without influencing the other components. 
In total 136 descriptor for each domain was generated for the Domain based approach (5 from 
EMBOSS Pepstats, 120 from ProtDCal and 11 from the amino acid scales). 
3.3.2 Window based 
In the Window based approach, a multiple sequence alignment (MSA) was first performed with 
all sequences used in a study of interest in order to overlap regions with high similarity between 
antibodies. BLOSUM80 was used as the amino acid substitution matrix due to the antibodies 
sharing high sequence similarity (Henikoff and Henikoff, 1992). When aligning antibodies, 
longer consecutive gaps are expected in the variable regions due to the unique structure and 
differences in length of the CDR loops. However, in order to avoid misalignment of more 
conserved regions in the variables domains, control checks were implemented to ensure that 
that conserved cysteine and tryptophan residues were aligned in the variable regions which are 
illustrated in Figure 3.5 (Lefranc et al., 2003). From the resulting alignment, a window was 
defined based the longest consecutive gap region plus two additional residues, one on either 
side of the gap region. The full sequence was then divided based on the specified window, thus 
86 
generating smaller fragments of sequences equal in size to the specified window. As an 
example, if the window was specified to 25 residues, the first fragment would contain residues 
1 to 25, the second fragment residues 26 to 50 and so on. The addition of the two extra residues 
to the window ensures that no single fragment would contain only gaps. 
Similar to the Domain based approach, descriptors were generated using both the software and 
amino acid scales. However, due to the sequence fragments being much smaller than the domain 
sequences only the PRT options from the amino acid groups was used to generating descriptors. 
Instead, both Manhattan distance and Euclidean distance were used as aggregation methods to 
generate descriptor in ProtDCal resulting in 16 unique descriptors. In total 32 descriptors were 
generated for each sequence fragment that was created in the Window based approach (5 from 
EMBOSS Pepstats, 16 from ProtDCal and 11 from the amino acid scales). 
3.3.3 Substructure Based 
In the Substructure based approach the identified domains were further broken down into 
smaller substructures which are consistent across all full chain IgG antibodies. For the variable 
domains, the CDR loops and frameworks (FRs) were identified by utilising highly conserved 
residues present in these domains as well as applying specified rules for CDR loop identification 
presented in (Lefranc et al., 2003). A breakdown of the substructures in the variable domains is 
illustrated in Figure 3.5 showing the IMGT numbering and usual residue length for each 
substructure as well as conserved cysteines and aromatic residues.  
In a similar manner, the identification of the substructural components in the constant domains 
were identified by using the IMGT numbering scheme presented in (Lefranc et al., 2005). The 
sequence splitting of the constant domains is more straight forward to implement due to amino 
acid composition and domain lengths being highly conserved in these domains. This resulted 
in 43 unique primary sequence fragments from a full-length mAb where 14 originated from the 
variables domains (VH and VL), 28 from the constant domains (CH1, CH2, CH3 and CL) and one 
from the hinge region.  
 
 
Figure 3.5. Breakdown of the variable domains into the smaller framework (FR) and CDR substructures. 
Conserved cysteines are represented as a yellow line while conserved aromatic residues are represented as blue 
lines (adapted from Lefranc et al. (2003)). 
87 
The descriptor generation in the Substructure based approach was identical to that of the 
Window based approach where a total of 36 descriptor were generated for each substructure 
sequence (5 from EMBOSS Pepstats, 20 from ProtDCal and 11 from the amino acid scales). 
3.3.4 Running Sum based 
In the Running Sum based approach, an alignment was first carried out by using the IMGT 
numbering scheme. To properly align the CDR loops, gaps was introduced in order to convert 
all corresponding CDRs to be of equal length. This was performed by assigning a constant 
maximum length to each CDR substructure and introducing gaps in sequences if the CDR 
sequence was shorter than the specified maximum length for the specific CDR loop. The lengths 
assigned were 15 residues for CDR1, 15 residues for CDR2 and 25 residues for CDR3. These 
lengths were based on the maximum observed CDR lengths of 297 mAb sequences taken from 
the IMGT mAb database where a maximum of 12, 12 and 23 residues were observed in CDR1, 
CDR2 and CDR3 loops, respectively. The lengths were rounded upwards to the closest whole 
five in order to account for future samples that might have longer CDR gaps. 
In comparison, the difference in the lengths of the framework substructures is caused by 
systematic addition/elimination of residues whose locations in the sequence are known (Lefranc 
et al., 2003). For sequences that were shorter than the maximum length of a framework 
substructure, gaps were systematically introduced in these positions thus conforming all 
sequences for a specified framework substructure to the same length. 
A window was defined similar to that of the Window based approach. The width of the window 
was set to 13 residues to be about half of the longest defined CDR loop of 25 residues. The 
window was then used to generate smaller fragments by sliding it upstream in the sequence one 
residue at a time from the beginning to the end of the alignments. As an example, the first 
fragment will contain residues 1 to 13, the second fragment will contain residues 2 to 14 and so 
on.  
In this approach, only the amino acid scales were used to generate descriptors for the antibodies. 
Each component from the individual amino acid scales was summed based on the amino acid 
composition of the input fragment as described in Section 3.3.1.  
3.3.5 Single Amino Acid based 
Similar to the Running Sum based approach all sequences were aligned by using the IMGT 
numbering scheme prior to extracting any information. In the Single Amino Acid based 
approach however, positions of individual residues that varied between mAb samples were 
identified in the resulting alignment and used for descriptor generation. To include positions 
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with gaps, smaller sequence fragments were generated in order to avoid information loss. For 
positions with systematic gaps such as in the variable domain frameworks and in the constant 
domains, fragments were generated by adding one residue before and after the start and end of 
the gap, respectively. The CDR loops was used directly without modification due to their high 
sequence variability and length.  
Similar to the Running Sum based approach, only the amino acid scales were used to generate 
descriptors. All identified positions with varying residues in the IMGT alignment were directly 
converted into numerical values using the amino acid scales. Generated fragments containing 
gaps and the CDR loops were converted using Manhattan distance to sum the up the individual 
components. 
3.3.6 Differences between strategies 
In the Domain based, Window based and Substructure based approaches descriptors were 
generated by using both software and amino acid scales Figure 3.4b due to the treatment of 
longer sequence fragments. Because of the long sequence fragments used in the Domain based 
approached there was a high probability that information from critical residues, important to 
the model output, would be confounded by redundant residues. The Window based approach 
was considered to improve the Domain based approach in order to reduce the amount of noise 
introduced by calculating the descriptors with fewer residues in each fragment e.g. 25 compared 
to that of the Domain based where the full domain, e.g. ~110 residues, was used to calculate 
descriptors. In this way, a data set with higher resolution of the impact from each residue could 
generated. However, a big disadvantage with the Window based approach is that the descriptors 
generated become unique to the samples in the data set which is caused by the multiple sequence 
alignment (MSA). More specifically, the MSA algorithm (BLOSUM80) will try to align 
provided sequences and maximise the alignment score by increasing residue matches and 
decreasing residue mismatches between sequences. This alignment becomes unique to the 
samples that were provided and will not necessarily be identical when new samples are added. 
This means the generated fragments from the Window based approach and the descriptors 
generated from these will be highly dependent on the form the alignment takes. This creates 
problems if descriptors for future samples need to be generated as these might not fit in in the 
previous alignment due to longer or shorter sequence regions and a manual alignment of these 
samples would be required. Due to this disadvantage, the Window based approach was 
discarded. Instead, the Substructure based approach was considered as an alternative to address 
this issue. By identifying and using the smaller substructures that make up the domains to 
generate descriptors, the resolution could be improved due to fewer residues being used 
89 
compared to the Domain based approach. This also ensures that comparable descriptors for 
future samples can be generated due the same substructures existing in all antibodies that are 
of the same conformation.  
The two remaining approaches Running Sum and Single AA were developed to investigate the 
impact of individual residues in the sequence. The use of the IMGT numbering scheme instead 
of MSA ensured that corresponding residues in different sequences would be aligned correctly 
and be reproducible. The Running Sum based approach can be considered as an alternative to 
the Substructure based approach due to larger fragments still being handled. The biggest 
difference however is that each residue was represented multiple times in slightly different 
sequence variations thus allowing important residues to have an increased impact in the model 
development. The Single AA based approach is fundamentally different from the previously 
mentioned strategies as only residues that varied between antibodies in the alignment were used 
for descriptor generation. This was to investigate if only the varying regions in the primary 
sequence were the only information necessary in order to produce models with high fit and 
accuracy. 
The impact of the sequence splitting on the number of descriptors per mAb can be observed in 
Table 3.5 for the different approaches. Table 3.5 also provides estimates of the potential number 
of descriptors per mAb based on which domains of the mAb are used for descriptor generation 
(VH/VL, Fab and Full length). It is important to note that, though higher resolution can be 
attained by reducing the length of the sequence fragments, the total number of descriptors 
increases in turn as a result of increased number of fragments which occurs in the higher 
resolution descriptor sets. The largest increase in descriptors can be seen in the Running sum 
due to more sequence fragments being generated in both the heavy and the light chains. This is 
more easily understood if considering descriptor generation for a full structure mAb with ~450 
residues in the heavy chains and ~230 residues in the light chains. This would generate closer 
to 700 unique fragments when including gaps introduced by the IMGT sequence alignment. 
Therefore, in this approach, only the amino acid scales were used to generate descriptors in 




Table 3.5. Representation of the expected number of descriptors generated for each mAb when using the Domain 
based, Window based, Substructure based, Single AA based and Running Sum based approaches to generate 
descriptors. A full-length mAb with 450 residues in the heavy chain and 230 residues in the light chain was 
considered in this case. The number of sequence fragments (Domain, Window, Substructure and Running Sum) 
or sequence positions (Single AA) are listed in the parenthesis  
Method VH/VL Fab Full length Input type Descriptors per 
input 
Domain 272 (2) 544 (4) 952 (7) (4) Domain 136 
Window (1) 320 (10) 640 (20) 896 (28) Fragment 32 
Substructure 448 (14) 896 (28) 1376 (43) Substructure 32 
Running Sum (2) 2486 (226) 4686 (426) 7216 (656) Fragment 11 
Single AA (3) 1452 (132) 1540 (140) 1628 (148) Position 11 
(1) Calculated with a window width of 25 residues 
(2) Calculated with a window width of 13 residues and without gaps in the sequence 
(3) Calculated based on 80% similarity between mAbs with the majority of the variability in the variable domains 
(4) 136 descriptors are generated for the Hinge which was treated as a domain 
 
3.4 Summary 
From the proposed methods able to generate descriptors described in this chapter it is clear that 
each strategy has its advantages and disadvantages. However, specific sequence preparation 
strategies might be better suited for different purposes as “no one size fits all”. This makes the 
proposed descriptor generation highly customisable and can be adapted to specific needs in the 
model development. The described workflow for descriptor generation using the primary 
sequence of mAbs has been applied as described in Chapter 4 where the intrinsic variation 
originating from the mAb isotypes and species origins has been explored. The suitability if 









Chapter 4  
 
Impact of mAb isotypes and species origins on 
primary sequence-based descriptors 
In this chapter, the potential structural variations in the generated primary sequence-based 
descriptors presented in the previous chapter was investigated with regards to the mAb isotypes 
and species origins. Due to many residues being conserved in individual isotypes based on the 
sequence alignment in the previous chapter, it was expected that descriptors generated from the 
constant domains of the heavy or light chain would impact on the generated descriptors. This 
was more uncertain in the case of the species origins due to the variable domains containing the 
majority of the sequence variability in the mAb primary sequence and therefore critical residues 
were likely to be confounded. Exploration was performed with PCA to characterise the impact 
of the heavy and light chain isotypes while more dedicated classification methods such as PLS-
DA and SVC were used to establish potential correlation between the sequence structure and 
the species origins.  
4.1 Material and Methods 
4.1.1 Sequence gathering 
Primary sequences of therapeutic based mAbs were collected from the IMGT database accessed 
in March 2017. Only sequences of full chain mAbs were collected where mixed heavy chain 
isotypes, such as IgG2/4, and mixed species origins, such as chimeric-humanised samples, were 
excluded. In total, 273 mAb sequences were collected and stored in a database along with key 
information pertaining to the heavy and light chain isotypes as well as the species origin (see 
Table A.2 in Appendix A). Table 4.1 lists the number of mAbs out of the collected 273 
belonging to a specific isotype or species origin. 
 
94 
Table 4.1. Summary of isotype and species origin diversity of the 273 gathered mAb sequences from the IMGT 
database. 













4.1.2 Descriptor Generation 
Structural descriptors for the 𝑿 block were generated using the methodology presented in 
Section 3.2 with four unique primary sequence-based descriptor (PSD) sets prepared: Domain 
based (PSD1), Substructure based (PSD2), Single AA based (PSD3) and Running Sum based 
(PSD4). 
4.1.3 Modelling Methods 
4.1.3.1 Principal Component Analysis 
Principal Component Analysis (PCA) was used as an exploratory analysis tool to investigate 
the four descriptor sets and the relationship between descriptors and different chain isotypes 
and species origins. Each model was selected to contain 90% of the total variation contained in 
the descriptor set of interest. PCA implementation was performed using the PLS Toolbox 
version 8.6.1 (Eigenvector Research, Inc). For more details on PCA, see Section 2.2.1.  
4.1.3.2 Partial Least Square Discriminant Analysis 
The NIPALS algorithm was used to develop a PLS regression model for predicting the dummy 
variables generated from the class information pertaining to the species origin of the mAbs. 
Discriminant Analysis (DA) was then applied to create decision thresholds in order to classify 
the predictions of the developed PLS model. For more information on PLS-DA, refer to Section 
2.3.1. 
4.1.3.3 Support Vector Machines for Classification 
The LibSVM toolbox was used and implemented in MATLAB 2016a for SVC model 
development (Chang and Lin, 2011). The C-SVM function in LibSVM uses by default the One-
vs-One (OvO) strategy for multiclass classification problems. A shell script was developed to 
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implement the One-vs-Rest (OvR) classification strategy instead in order to reliably compare 
SVC to PLS-DA and this is presented in Appendix B.1. Optimisation of the model parameter 
𝐶 was performed using a grid search approach on defined points over specified ranges for each 
parameter (for details on parameters see Section 2.3.2). The grid points used for 𝐶 was  
[10-5, 10-4, 10-3, 10-2, 10-1, 100, 101, 102, 103, 104]. 
4.1.4 Data Curation and Pre-treatment 
All descriptor sets were first curated by removing columns containing null values, coded as -
999. Furthermore, descriptors with a standard deviation below 0.0001 were also removed as 
they did not contain sufficient variation for the model development. The standard deviation for 
a descriptor, 𝑘, was calculated according to equation 4.1 where 𝑁 is the number of samples in 
the dataset and ?̅?𝑘 is the average value of the descriptor 𝑘. All data blocks were auto-scaled 
before being used in model development in order to centre the data around zero as well as to 
scale all descriptors to unit variance (see Section 2.7). 








4.1.5 Model Training and Validation 
4.1.5.1 Structured data splitting 
Prior to model development with PLS-DA and SVC the data set was split into a calibration set 
and an external test set to represent future samples. The Kennard-Stone (CADEX) algorithm 
was used for this purpose which divides the samples according to structural similarity, in the 
form of Euclidean distance, between samples in the descriptor space (see Section 2.5.1 for more 
details). 80% of the samples were retained for model calibration and the remaining 20% were 
kept for external testing and model validation. 
4.1.5.2 Cross Validation 
A repeated k-fold cross validation scheme was applied for model development for PLS-DA and 
SVC where k was chosen to be five in order to get an 80/20 sample split ratio between training 
and validation samples, respectively. 20 iterations were performed to better utilise the data set 
and decrease the potential impact of outliers in the data on the cross validation. 
96 
4.1.5.3 Model Validation 
Validation PLS-DA and SVC models were performed using the overall error rate (ER) in 
eq.(2.62) and the Matthews Correlation Coefficient (MCC) in eq.(2.66) based on the confusion 
matrices of the developed models. Model parameters in PLS-DA and SVC were selected based 
on the minimum ER value observed in the cross validation.  
4.2 Results and Discussion 
4.2.1 Domain based selection of descriptors 
Exploratory analyses of the HC and LC isotypes as well as the species origin were performed 
by first selecting descriptors that were known to be closely related to the investigated response 
in question based on sequence difference between isotypes described in Section 3.1.3. Figure 
4.1 illustrates the selection of descriptors based on their domain of origin. For the HC isotypes, 
only the heavy chain domains: VH, CH1, CH2 and CH3 were used and are marked in red 
illustrated in Figure 4.1a. Similarly, investigation of the LC isotypes was performed with 
descriptors from the light chain domains: VL and CL (see Figure 4.1b). For the Species origins, 
only the VH and VL were used, (see Figure 4.1c), due to these structural differences being 




Figure 4.1. Descriptor selection based on the structural origin of investigated response for (a) heavy chain isotypes, 
(b) light chain isotypes and (c) species origin. Descriptors from the mAb domains used in structural exploration 
are coloured red while excluded domains are coloured grey in the three presented cases. 
PCA was used as an exploratory tool to capture and visualise the information contained in the 
generated descriptor sets presented in Section 3.2. As PCA is scale dependent, the descriptors 
were auto-scaled before analysis (Bro and Smilde, 2014). The PCA models were built to capture 
approximately 90% of all variations contained in the individual descriptor sets. A summary of 





Table 4.2. PCA model summary of heavy chain (HC) descriptors and light chain descriptors (LC) according to the 
four descriptor resolutions PSD1, PSD2, PSD3 and PSD4. Models were developed to capture approximately 90% 











PSD1 543 19 89.96 
PSD2 817 27 90.14 
PSD3 1625 68 90.02 
PSD4 4367 41 90.02 
LC 
PSD1 272 12 90.20 
PSD2 490 20 90.19 
PSD3 1601 43 90.06 
PSD4 2387 26 89.92 
 
4.2.2 Exploration of HC Isotypes 
In the case of the heavy chain, all samples formed three clearly defined groups when analysing 
the scores from the PCA models. The PCA results of PSD1 is illustrated in Figure 4.2 where 
the scores and loadings of the two first components were enough to characterise the structural 
difference between the heavy chain isotypes. It can be observed that IgG1 samples are separated 
from IgG2 and IgG4 samples in the first PC which explains 34.34% of the total data variation 
in the descriptor set illustrated in Figure 4.2a. The second component further separates IgG2 
from IgG4 samples and explained an additional 17.03% of the total data variation in the PSD1 
descriptor set. The subsequent components showed no further separation of the heavy chain 
isotypes but instead captured varying degrees of variation linked to the sequence variability of 
the variable domain, VH (data not shown). From the loadings of the first and second PCs 
illustrated in Figure 4.2b and Figure 4.2c it can be observed that the constant domains: CH1, 
CH2 and CH3 contribute more significantly to the separation observed in the score plot while 
the loadings of the descriptors in the variable domain VH remain close to zero. This 
phenomenon is explained by investigating the VDJ gene recombination responsible for 
expressing the heavy and light chain of the mAbs. All genes encoding for the full heavy chain 
are located on chromosome 14 in the human genome where the VDJ region codes for the 
diversity of the VH domain. Genes encoding for constant domains are located further 
downstream and contain information for encoding all heavy chain isotypes (Jung and Alt, 2004, 
Schroeder and Cavacini, 2010). This means the primary sequence of the VH domain cannot be 
used to infer the isotype of the heavy chain due to being shared between IgG1, IgG2 and IgG4 
98 
and it is therefore the reason for the low contribution of the VH domain in the loadings plots 
illustrated in Figure 4.2b and Figure 4.2c. 
Identical observations were made for the other descriptor sets: PSD2 (see Figure C.1a and 
Figure C.1b), PSD3 (see Figure C.1c and Figure C.1d) and PSD4 (see Figure C.1e and Figure 
C.1f) presented in Appendix C, where the structural differences between the HC isotypes 
formed distinct groups in the score plots. Some differences in explained data variation was 
however observed. When using PSD1, PSD2 and PSD4, the first two PCs explained between 
35-50% of the total data variation. In the PSD3 descriptor set however, PC1 and PC4 contained 
the information for heavy chain isotype separation which also had a lower cumulative explained 
variation of 17.08% of the total data variation. PC2 and PC3 described variation pertaining to 
the sequence variability in the variable domain, VH (data not shown). The primary reason for 
the lower explained variation in PSD3 compared to the other descriptor sets was due to the high 
resolution where each amino acid is represented individually. This led to a higher exclusion of 
descriptors from the constant domains during the data curation with more static descriptors 
being removed in PSD3 compared to the descriptor sets PSD1, PSD2 and PSD4. In the latter 
descriptor sets all descriptors are a sum of multiple residues and therefore contain more 
variation. A summary of the PCA analysis of the four descriptor sets exploring the components 
involved in the separation of the HC isotypes is presented in Table 4.3. 
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Figure 4.2. PCA exploration of VH, CH1, CH2 and CH3 descriptors from PSD1. (a) Score plot of the first two 
principal components (PCs). The isotypes IgG1 are coloured red, IgG2 coloured green and IgG4 coloured blue. 
(b) Loadings of the first PC. (c) Loadings of the second PC. 
Table 4.3. Summary of PCA analysis listing the principal components used to observe separation of HC and LC 
isotypes together with the corresponding explained data variation for each descriptor set. The last column shows 













PSD1 1, 2 51.37 543 74.95 
PSD2 1, 2 42.93 817 70.13 
PSD3 1, 4 17.08 1625 45.17 
PSD4 1, 2 35.57 4367 68.26 
LC 
PSD1 1 52.23 272 50.00 
PSD2 1 54.29 490 50.20 
PSD3 1 49.81 1601 47.09 
PSD4 1 52.61 2387 47.47 
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4.2.3 Exploration of LC Isotypes 
Similarly to the heavy chain, a very clear separation of the light chain isotypes, kappa and 
lambda, was observed in the first PC for the PSD1 descriptor set seen in Figure 4.3a which 
explained 52.23% of the data variation. However, contributions to the separation were not only 
caused by the constant domain CL but the variable domain VL also contributed to the separation 
of kappa and lambda seen in Figure 4.3b. Identical trends of PCA scores and loadings were also 
observed in the other three descriptor sets: PSD2 (see Figure C.2a and Figure C.2b), PSD3 (see 
Figure C.2c and Figure C.2d) and PSD4 (see Figure C.2e and Figure C.2f) presented in 
Appendix C where the first principal component explained 54.29%, 49.81% and 52.61% of the 
data variation, respectively. The contribution of the VH domain to the separation is due to the 
fact that the VJ gene recombination of the light chain occurs at two separate chromosomes 
where lambda is encoded on chromosome 2 and kappa on chromosome 22. Both chromosomes 
have an individual VJ region for encoding the VL domain whose primary sequence thus 
becomes dependent on the isotype that is expressed (Jung and Alt, 2004, Schroeder and 
Cavacini, 2010). It therefore becomes possible to infer the light chain isotype based on the 
primary sequence of the VL domain alone. This is further supported by the fact that the 
explained variation of the first PC in all descriptor sets is larger than the percentage of 
descriptors originating from the constant domain CL as presented in Table 4.3.  
 
 
Figure 4.3. PCA analysis of VL and CL descriptors from the PSD1 descriptor set. (a) Score plot of the first two 
principal components (PCs). The isotype kappa is coloured red and lambda is coloured green. (b) Loadings of the 
first PC. 
4.2.4 Exploration of species origin 
Compared to previous observations on HC and LC isotype analysis, the PCA analysis of the 
VH and VL domain descriptors did not yield a clear separation between chimeric, human and 
humanised samples as can be observed for the PSD1 descriptor set in Figure 4.4a. Instead, 
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structural features related to the LC isotypes had a big influence on the captured data variation 
and this was a driving force in the separation of samples as can be observed in Figure 4.4b for 
descriptor set PSD1. Similar observations were made for the three other descriptors sets and are 
presented in Appendix C for PSD2 (see Figure C.3a and Figure C.3b), PSD3 (see Figure C.3c 
and Figure C.3d) and PSD4 (see Figure C.3e and Figure C.3f). This was not unexpected 
however due to the contribution of the VL domain descriptors observed in Figure 4.3b and that 
the expression of kappa and lambda light chain occurs at different Chromosomes. Another 
impacting factor is the high diversity of the CDR regions in the variable domains which are the 
main source of data variation in the four descriptor sets and therefore makes it difficult to 
observe any species origin related separation with PCA. Even when exploring principal 
components of higher order, no defined separation of the species origins can be observed in the 
descriptor sets. Therefore, PLS-DA was used for classification in order to explore the extent of 
data variation related to the species origins. SVC was also applied as an additional classification 




Figure 4.4. PCA scores of the first and second principal components (PCs) from VH and VL domain descriptors of 
PSD1. (a) chimeric (red), human (green) and humanised (blue) samples. (b) I LC isotypes kappa (red) and lambda 
(green)   
4.2.5 Species origin classification 
To evaluate developed supervised models, the sample set was split into a calibration and test 
sets with an 80/20 ratio using the CADEX algorithm in order to retain the majority of samples 
and data variation for training. Using the CADEX algorithm also assured that samples in the 
test set would be structurally similar to the samples in in the calibration set with regards to the 
descriptor space. Table 4.4 lists the splits of the four descriptor sets with regards to the species 
origins. It can be observed that the ratio of test set samples was retained at around 0.2 for the 
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three individual species origins in the four descriptor sets thus retaining representation in the 
test set. 
Table 4.4. Sample split with CADEX of the descriptor sets: PSD1, PSD2, PSD3 and PSD4. The number of samples 
belonging to each individual species origin is listed for both the calibration and test sets. 
Descriptor Set 
Number of  
Descriptors 




chimeric 28 7 0.20 
human 95 27 0.22 
humanised 95 21 0.18 
PSD2 488 
chimeric 26 9 0.26 
human 98 24 0.21 
humanised 94 22 0.19 
PSD3 1738 
chimeric 28 7 0.20 
human 92 30 0.25 
humanised 98 18 0.16 
PSD4 2640 
chimeric 29 6 0.17 
human 93 29 0.24 
humanised 96 20 0.17 
 
A summary of the performance of the developed PLS-DA and SVC models is shown in Table 
4.5 for each of the four descriptor sets. In general, models developed with SVC showed a little 
higher performance compared to PLS-DA in both the cross-validation and test set, thus 
indicating slightly better generalisation which was most pronounced in the PSD1 and PSD2 
descriptor sets. A potential reason for this may be due to the fact that all samples impact on the 
on the regression prediction in PLS-DA model and therefore it is more likely to be influenced 
by noisy samples. On the other hand, SVC models are developed only on an optimal subset of 
the samples (support vectors) used for defining the decision boundary which thereby reduces 
the influence of noisy samples on the model performance. Notwithstanding this, all models had 
excellent performance in the external test set with MCC values well above 0.7 except for the 
PLS-DA model developed using PSD1. Due to the differences in sample sizes between 
chimeric, human and humanised samples, the MCC metric is preferred as it gives fair 
representation of all classes regardless of samples size  (Jurman et al., 2012). The high MCC 
values are therefore an indication of strong correlation between the structural descriptors of the 
VH and VL domains and the species origin. As no descriptor reduction or selection has been 
performed on the descriptor sets prior to model development, a strong correlation between the 
primary sequence and the species origin can be assumed.  
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In addition, the developed PLS-DA models also give an indication of the extent of the data 
variation in the VH and VL domain descriptors that are correlated to the species origin. From 
Table 4.5 it can be observed that roughly a quarter of the total data variation in PSD2, PSD3 
and PSD4 is used for class prediction by the models whereas the variation used inPSD1 is 
slightly higher with 35.93%. Thus, an estimation of the structural variation from the VH and VL 
domains correlated to species origin can be inferred based on the used data variation by the 
developed PLS-DA models.  
Table 4.5. Summary of model performance of PLS-DA and SVC developed on the descriptor sets: PSD1, PSD2, 





Explained 𝑿  
Variation (%) 
Cal  CV  Test 
MCC ER  MCC ER  MCC ER 
PLS-DA 
PSD1 35.93 0.82 0.11  0.68 0.19  0.68 0.20 
PSD2 22.21 0.77 0.14  0.62 0.23  0.79 0.13 
PSD3 28.70 0.95 0.03  0.75 0.15  0.96 0.04 
PSD4 24.41 0.88 0.07  0.71 0.18  0.91 0.05 
SVC 
PSD1 - 0.92 0.05  0.72 0.17  0.85 0.09 
PSD2 - 0.93 0.04  0.72 0.17  0.94 0.04 
PSD3 - 0.99 0.01  0.74 0.15  0.94 0.04 
PSD4 - 0.95 0.03  0.79 0.13  0.94 0.04 
 
In addition, individual classification performance in relation to the chimeric, human and 
humanised samples was assessed with receiver operating characteristics (ROC) curves on the 
cross-validation results in order to understand the slightly lower MCC values compared to those 
in the calibration and test set. More specifically, the area under the curve (AUC) was used as a 
performance metric with a value of 0.5 indicating poor classification accuracy and a value of 
one indicating perfect classification (Fawcett, 2006). The AUC values obtained from the cross-
validation on PLS-DA model developed using PSD3 data set are illustrated in Figure 4.5a and 
the equivalent SVC model in Figure 4.5b. The black dashed line represents the AUC value of 
0.5 thus indicating a reference border where no discrimination between classes are possible (see 
Section 2.6.2). Clearly these were all above 0.9 thus indicating high accuracy. It can be observed 
that most of the misclassification occurs in the humanised samples (blue line) whose AUC 
values are lower compared to those of the chimeric and human samples. This is the cause for 
the lower MCC values in the cross-validation compared to the calibration and external test set, 
where the misclassification of humanised samples was lower (data not shown). This trend was 
also observed in the cross-validation results of PLS-DA and SVC ROC curves for the remaining 
three descriptor sets of PSD1, PSD2 and PSD4, illustrated in Figure C.4 in Appendix C.  A 
104 
closer inspection of the resulting confusion matrices from the cross-validation of the four 
descriptor sets showed that the misclassified humanized samples were classified as a mix of 
chimeric and human (data not shown). Therefore, no particular preference was observed of the 
misclassified samples that leaned more towards the chimeric class or the human class. A 
potential reason for this could be due to the mix of chimeric CDRs and the human framework 




Figure 4.5. ROC curves and AUC for chimeric (red line), human (green line) and humanised (blue line) samples 
developed on prediction data from the cross-validation of PSD3 in (a) PLS-DA and (b) SVC. The black dashed 
line represents the AUC value of 0.5 where no discrimination between classes can be made. 
4.3 Summary 
Based on the results presented in this chapter, the developed primary sequence-based 
descriptors from Chapter 3 work well for identifying more apparent structural differences such 
as the HC and LC isotypes through exploration techniques such as PCA. More advanced 
supervised methods had to be used, however, to successfully separate and classify the species 
origin of the used samples in order to reach higher accuracy. These exploration and 
classification results were not unexpected based on the evident differences in the primary 
sequence of the constant domains and the structural variation originating from humanisation of 
mAbs presented in Section 3.1.5 (see Figure 3.2). Instead, the descriptor sets applicability to 
these problems indicates that the developed descriptors reflect the underlying biological 
features and thus the development of more advanced predictive models can be attempted. The 
next logical step would be to try to develop models for prediction of mAb behaviour in more 
complex experimental environments where the structural correlation to the response might be 
more elusive.  
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The second important finding in this chapter is the characterisation of sources of structural 
variation correlated to mAb isotypes and species origins that greatly impact the descriptors. The 
described workflow in this chapter can therefore be used to determine sources of systematic 
variation that is present in the mAb structure. Characterisation of such variation becomes vital 
in model development as it can negatively impact model performance if the variation is 






Chapter 5  
 
QSAR Model development: Primary sequence-based 
descriptors 
In Chapter 3, a novel workflow was presented for the generation of descriptor sets, capturing 
varying sequence resolutions, were developed from the primary sequences of mAbs. In this 
chapter the four primary sequence-based descriptor sets were investigated and applied in the 
prediction of HIC retention times and mAb yields. These were chosen as response vectors for 
model development due to being important parameters in pharmaceutical industries for the 
assessment of productivity and product stability, respectively. The structural variation related 
to the heavy and light chain isotypes as well as species origins present in the primary sequence-
based descriptor sets observed in Chapter 4 were further explored with regards to the chosen 
responses. A benchmarking scheme for sequential improvement and comparison of the models 
with regards to descriptor reduction and selection is also developed and presented in this 
chapter.  
5.1 Material and Methods 
5.1.1 Response Data 
In this research, the quantitative process data published by Jain et al. (2017) was used to develop 
predictive models (Jain et al., 2017). It is important to note that all constant domains in the 
heavy chain were expressed as IgG1 for the heavy chain with allele IGHG1*01. The original 
isotype of the light chain was retained in the explored samples where two alleles were used for 
expressing either kappa (IGKC*01) or lambda (IGLC1*01) conformation.  
The diversity of the of Jain dataset is illustrated in Figure 5.1 which shows the distribution of 
Kappa and Lambda mAbs (Figure 5.1a), the distribution of human, humanized and chimeric 
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mAbs (Figure 5.1a) as well as the distribution of mAbs in the different clinical phases: phase 
II, phase III and phase IV (approved) (Figure 5.1c). 
 
Figure 5.1. General summary of mAbs in the dataset from Jain et al. (2017) according to (a) the light chain 
isotypes, (b) species origins and (c) clinical phase distribution. 
Out of the 12 characterised biophysical properties available in the publication of Jain et al. 
(2017), the mAb yields from the HEK cell line cultivations and the HIC retention times were 
selected as model responses as discussed in Section 1.5. A brief description of the experimental 
setup for both responses is explained below according to the description provided by the 
authors. No triplicates were given for either for mAb yield or HIC retention times for the 137 
mAb. 
5.1.1.1 mAb expression and extraction 
The 137 mAbs were expressed in HEK293 cells under identical cultivation conditions. After 6 
d of growth, the cell culture supernatant was harvested by centrifugation and passed over 
Protein A agarose (MabSelect SuRe from GE Healthcare Life Sciences). The bound mAbs were 
then washed with PBS and eluted with buffer (200 mM acetic acid/50 mM NaCl, pH 3.5) into 
1/8 volume 2 M Hepes, pH 8.0. The final products were buffer-exchanged into 25 mM Hepes 
and 150 mM sodium chloride at pH 7.3.  
5.1.1.2 HIC 
5 μg of IgG samples (1 mg/mL) were mixed with a mobile phase A solution (1.8 M ammonium 
sulphate and 0.1 M sodium phosphate at pH 6.5) to achieve a final ammonium sulphate 
concentration of about 1 M before analysis. A Sepax Proteomix HIC butyl-NP5 column was 
used with a linear gradient of mobile phase A and mobile phase B solution (0.1 M sodium 
phosphate, pH 6.5) over 20 min at a flow rate of 1 mL/min with UV absorbance monitoring at 
280 nm. 
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5.1.1.3 Exclusion of samples 
Out of the 137 available mAbs in the data set, 6 mAbs were excluded based on one of the 
following reasons:  
1) Original mAb was not of IgG class e.g. IgM 
2) Original mAb was of a hybrid conformation e.g. IgG2/4 
3) Experimental data for mAb was not available 
This resulted in 131 mAbs being selected for further evaluation and are listed in Appendix A, 
Table A.3 with corresponding experimental measurements for HIC retention times and mAb 
yields. 
5.1.2 Descriptor Data Generation 
Structural descriptors for the 𝑿 block were generated based on the methodology presented in 
Chapter 3 where four unique descriptor sets were attained: Domain based (PSD1), Substructure 
based (PSD2), Single AA based (PSD3) and Running Sum based (PSD4) where PSD is short 
for “Primary sequence-based descriptors”. All sequences for the variable domains VH and VL 
were provided as supplementary information in the study from Jain et al (2017). Final heavy 
chain sequences for descriptor generation were prepared by attaching the allele sequence 
IGHG1*01 representing IgG1 isotype to the VH domains. The allele sequences IGLK1*01 and 
IGLC1*01 were used and attached to VL domains of kappa and lambda isotype, respectively. 
5.1.3 Modelling Methods 
5.1.3.1 PLS 
Partial Least Squares regression was performed using the NIPALS algorithm. The first 20 latent 
variables were calculated to allow for a majority of the data variation in 𝑿 and 𝒀 to be captured. 
A higher number of latent variables is usually not recommended as they commonly only 
improve fitting of individual samples, thus causing over-fitting (Wold et al., 2001). For more 
information on PLS, refer to Section 2.4.1. 
5.1.3.2 SVR 
Optimisation of the model parameters 𝐶 and 𝜖 was performed by using a grid search approach 
on defined points over specified ranges for each parameter (for details on parameters see 
Section 2.4.2). The grid points used for 𝐶 were [10-5, 10-4, 10-3, 10-2, 10-1, 100, 101, 102, 103, 
104] whereas the grid points used for 𝜖 were [10-3, 10-2.5, 10-2, 10-1.5, 10-1, 10-0.5, 100, 100.5, 101]. 
This resulted in 90 different parameter permutations that were evaluated in the cross validation. 
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5.1.4 Model Training and Validation 
5.1.4.1 Structured data splitting 
Prior to model development the data set was split into a calibration set and an external test set 
to represent future samples. The Kennard-Stone (CADEX) algorithm was used to divide the 
samples according to structural similarity in the form of Euclidean distance between samples 
in the descriptor space (see Section 2.5.1 for more details). 80% of the samples were retained 
for model calibration where the remaining 20% was kept for external testing and model 
validation. 
5.1.4.2 Cross-Validation scheme 
A repeated k-fold cross validation scheme was applied for model development where k was 
chosen to be five in order to get an 80/20 sample split ratio between training and validation 
samples, respectively. 20 iterations were performed to better utilise the data set and decrease 
potential impacts of outliers in the data on the cross validation. For more information, see 
Section 2.5.2. 
5.1.4.3 Model Validation 
All models were validated adhering to the OECD guidelines for 𝑅2 and 𝑄2 in QSAR/QSPR 
models (Veerasamy et al., 2011, Alexander et al., 2015). The guidelines state that 𝑅2 and 𝑄2  
should be greater than 0.5 and 0.6 in the cross-validation and external prediction, respectively. 
The thresholds for 𝑅2 and 𝑄2 in the OECD guidelines are intended to be used for early model 
development to explore potential correlation of factors and descriptors related to the modelled 
responses. Once characterised, additional descriptor development and adjustments can be 
performed to further improve model performance. For more information on 𝑅2 and 𝑄2, refer to 
Section 2.6.1. 
5.1.4.4 Y-Randomisation 
Y-randomisation was used to evaluate the presence of random correlation between a descriptor 
set and a randomised response vector. The response vector was randomised 50 times and an 
individual model was developed on each permutation. Calculated 𝑅2 and 𝑄2 values from the 
50 models were then averaged. If no chance correlation is present in the descriptor set both the 
averaged 𝑅2 and 𝑄2 values will be low. For more details on Y-randomisation, refer to Section 
2.6.3. 
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5.1.5 Descriptor reduction and selection 
The placement of the unsupervised V-WSP reduction algorithm in the model development 
pipeline needed to be considered in order to generate an unbiased test set, as discussed in 
Section 2.5.1. Two approaches were considered where the first scenario places the V-WSP 
reduction prior to the structured data splitting using CADEX illustrated in Figure 5.2a. This 
sequence however, introduces a bias due to collinearity reduction of descriptors with all 
available samples in the data set. This means, that even after splitting the data set into a 
calibration set (black box) and a test set (red box), the selection of the test set samples might 
have been affected by the descriptor reduction of all samples. The descriptor reduction is thus 
influenced by all samples and therefore becomes biased. Instead, the second scenario illustrated 
in Figure 5.2b has the V-WSP reduction placed after the data splitting which ensures that only 
selected calibration samples influence the descriptor reduction. This approach is thus unbiased 
as it keeps the external test set samples separate throughout the model development pipeline 
where descriptor reduction and selection were performed only on the calibration set. For these 
reasons, development of all models in this chapter was performed adhering to the workflow 




Figure 5.2. Overview and placement consideration of the V-WSP algorithm in regards to the data splitting and the 
variable selection (VS). (a) Placement of V-WSP reduction prior to structured sample splitting results in a biased 
selection of descriptors due to influence from all samples. (b) Structured splitting performed before V-WSP 
reduction results in an unbiased selection of descriptors due to being independent from the test set samples. Vertical 
arrows represent selection of descriptors in the test set to match the calibration set.  
5.1.5.1 V-WSP 
The V-WSP algorithm was applied as an unsupervised reduction method to reduce the number 
of descriptors in the 𝑿 block by only keeping descriptors with low correlation between them 
(Ballabio et al., 2014). Procrustes goodness of fit was used as a metric to investigate how much 
of the information between the original and reduced data was retained after the variable 
reduction with the V-WSP algorithm (Peres-Neto and Jackson, 2001, Kendall, 1989). A 
Procrustes value of zero means that the information in the data sets is identical and a value of 
one means that the data sets a completely dissimilar. In the absence of any published acceptable 
correlation thresholds, the thresholds for each domain were selected by empirically testing all 
values from 0.5 to 0.99 with increments of 0.01. The correlation threshold was chosen based 
on guidelines from Ballabio et al. (2014) where the goal of the reduction is the elimination of 
redundant information and not the preservation of the data structure.  
To this end, the correlation thresholds were chosen on a case by case basis for each individual 
group of descriptors defined by the domains in PSD1 or the substructures in PSD2, PSD3 and 
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PSD4 therefore corresponding to inherent structural blocks in the mAbs. This was done in order 
to preserve vital information present in each individual structural block of the mAb structure 
and at the same time reduce the number of redundant descriptors. Reduction with V-WSP was 
performed prior to any supervised variable selection method used in this research according to 
Figure 5.2b. 
5.1.5.2 rPLS 
Supervised variable selection with rPLS was performed with PLS Toolbox 8.6.1 (Eigenvector 
Research Inc) together with MATLAB 2016a (Mathworks®). An initial PLS model was 
developed with selected descriptors from V-WSP reduction and the latent variable with the 
smallest RMSECV was selected as a starting point for the rPLS selection. For more information 
on rPLS, refer to Section 2.9.1. 
5.1.5.3 GA 
Supervised variable selection with Genetic Algorithm (GA) was performed using PLS Toolbox 
8.6.1 (Eigenvector Research Inc) together with MATLAB 2016a (Mathworks®) and PLS as 
the fitness function. A population size of 100 was used and the maximum number of generations 
was set to 100. The convergence for the GA algorithm was set to 50%. Default values for the 
mutation rate and the ratio of kept variables in the initial models was kept as 0.5% and 30%, 
respectively. For more information on the GA algorithm, refer to Section 2.9.2. 
5.1.5.4 LASSO 
Supervised variable selection with L1-norm regularisation (LASSO) with SVR was applied 
using the function fitrlinear in MATLAB 2016a (Mathworks®) where SVR was set as the 
learner and lasso set as the regularisation method. A grid search was performed similar to that 
of SVR method in Section 5.1.3.2 above in order to optimise the parameter selection. The 
fitrlinear function uses 𝜆 according to eq.(5.1) instead of 𝐶 as a regularisation term as 













The relationship between 𝐶 and 𝜆 is described in eq.(5.2) where 𝑛 is the number of samples 









For more details on the LASSO method, refer to Section 2.9.3. 
5.1.6 Model Benchmarking 
In this research, descriptor reduction and selection were performed and evaluated in subsequent 
steps (Figure 5.3) in order to better investigate their impact on the model performance. For each 
descriptor set, the CADEX algorithm was applied to split the available samples into a 
calibration set for training (80%) and a test set for model validation (20%). Following the 
outline in Figure 5.3, an initial model was developed with all descriptors in the descriptor set 
of interest. A second model was then developed after V-WSP reduction had been performed on 
the descriptor set. A final model was then developed after variable selection with either rPLS, 
LASSO or GA had been performed on the V-WSP reduced descriptor set. The performance 
metrics of 𝑅2 and 𝑄2 of the cross-validation and the test set from each of the three model were 
then compared to evaluate the effect of the descriptor reduction and selection methods. This 
process was repeated for each of the four descriptor sets: PSD1, PSD2, PSD3 and PSD4 when 
using either PLS or SVR as modelling method. 
In total, 32 models were developed in order to compare the performance of different 
permutations of the presented methods. It is important to note that LASSO was only applied 
when SVR was used as modelling method whereas rPLS was only applied when PLS was used 




Figure 5.3. Sequential model development and evaluation for investigation of changes in performance with 
descriptor reduction and selection methods. Three models are developed on 1) all available descriptors, 2) the V-
WSP reduced descriptor set and 3) the descriptor set after supervised variable selection (VS).  
5.1.7 Statistical testing 
In Chapter 4, strong correlations were observed between the individual chains and their 
corresponding isotypes based on exploratory analysis with PCA (see Section 4.2.2 for the heavy 
chain and Section 4.2.3 for the light chain). A strong correlation was also observed between the 
variable domains and the species origin when explored with PLS-DA and SVC (see Section 
4.2.5). Statistical models were therefore used to establish if any significant differences were 
present between groups (statistical factors) of responses. In this research the factors were 
defined as the heavy chain, the light chain and the species origin of the mAbs. The heavy chain 
factor consisted of three levels being: IgG1, IgG2 or IgG4. The light chain factor consisted of 
two levels being: kappa or lambda. Finally, the species factor consisted of three levels being: 
chimeric, human or humanised. Figure 5.4 illustrates a decision tree for choosing an appropriate 
test depending on the normality and the available number of levels in the investigated factor.  
Normality was tested using the Anderson-Darling test with a significance level of 0.05 
(Anderson and Darling, 1952). H0 is the hypothesis that the data is normally distributed whereas 




Figure 5.4. Decision tree for statistical testing of response data based on normality and number of available levels 
for the investigated factor. 
5.1.7.1 Parametric methods 
Two different parametric tests were used for data that conformed to a normal distribution where 
the number of available levels in the factor of interest determined which test to use. If two levels 
were available, a 2-sample t-test was used to test for any significant differences between the 
group means whereas if three levels were available, a 1-way Analysis of Variance (ANOVA) 
was used (Krzywinski and Altman, 2014a). 
5.1.7.2 Non-parametric methods 
Non-parametric tests were used if the data did not conform to a normal distribution. Similar to 
the parametric methods, the number of available levels in the factor of interest determined 
which statistical test would be performed. A Mann-Whitney rank test was performed for factors 
with two levels and a Kruskal-Wallis test was performed for factors with three levels 
(Krzywinski and Altman, 2014b).  
5.1.7.3 Multiple comparison 
Two statistical tests were performed for each individual response, one for testing the significant 
difference between the heavy chain isotypes and the other to test the significant differences 
between the light chain isotypes. However, performing multiple inferences on the same data set 
can cause Type I error (incorrectly rejecting H0). This is due to that fact that when the number 
of statistical tests increases, the probability of any one of them being significant increases. To 
adjust for this, the Bonferroni correction was used to modify the significance level according 
to eq.(5.3) which gives the effective significance level for which each test needs to be tested 
against (Sedgwick, 2014). 
 






where 𝛼 is the desired significance level, 𝑚 is the number of performed tests and  
𝛼(𝑝𝑒𝑟 𝑐𝑜𝑚𝑝𝑎𝑟𝑖𝑠𝑜𝑛) is the effective significance level. 
5.2 Results and discussion 
5.2.1 Selection of samples for model development 
From Chapter 4 it was observed that much of the data variation in the descriptors had a strong 
relationship to the heavy chain and light chain isotypes according to the PCA score plots 
illustrated in Figure 4.2 and Figure 4.3, respectively. This variation is systematic and originates 
from the unique structure and amino acid composition found in the individual mAb isotypes 
illustrated in Figure 3.2 in Chapter 3. This is of importance as systematic variation in the 𝑿 
block that is unrelated to the responses can have a negative impact on the developed models 
and cause large prediction errors (Wold et al., 1998, Trygg and Wold, 2002). Therefore, prior 
to model development a statistical analysis was performed to test if a significant difference was 
present between response measurements related to different isotypes of the heavy and light 
chain. Due to the lack of samples in the IgG2-lambda and IgG4-lambda permutations (two 
samples in each group), two-factor hypothesis testing methods such as the parametric two-way 
ANOVA (Fisher, 1992) or its non-parametric equivalent, the Schreier-Ray-Hare test (Sokal and 
Rohlf, 1969) could not be reliably used. The unequal samples sizes can lead to a decrease in 
statistical power, meaning that it becomes increasingly difficult to correctly reject H0 and thus 
causing a Type II error (Rusticus and Lovato, 2014). Instead, multiple comparisons of single 
factors (heavy or light chain) were performed in order to increase the sample sizes in each factor 
level. Appropriate statistical tests were chosen according to the decision tree illustrated in 
Figure 5.4. 
Normality testing was performed for all mAb isotypes groups (kappa, lambda, IgG1, IgG2 and 
IgG4) for both the HIC retention times and the mAb yields with the results presented in Table 
5.1. For the HIC retention times data, normality could not be assumed for the IgG1 and IgG2 
isotypes in the heavy chain as well as the kappa isotype in the light chain due to 𝑝 <  0.05. 
Due to the lack of normality, non-parametric statistical methods were applied were a Kruskal-
Wallis test and a Mann-Whitney test were used for significance testing of the heavy chain 
isotypes and the light chain isotypes, respectively. For the mAb yield data, normality could be 
assumed in all isotypes and thus parametric statistical methods were applied in these instances. 
A one-way ANOVA and a two-Sample t-test were used for significance testing of the heavy 
chain isotypes and the light chain isotypes, respectively. 
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Table 5.1. Hypothesis testing of heavy and light chain isotypes using Anderson-Darling Normality Test with a 






HIC   Yield 
p Decision   p Decision 
LC 
kappa 119 0.0005 Reject H0  
0.4310 Keep H0 
lambda 12 0.1498 Keep H0  
0.0648 Keep H0 
HC 
IgG1 89 0.0005 Reject H0  
0.1709 Keep H0 
IgG2 20 0.0097 Reject H0  
0.8839 Keep H0 
IgG4 22 0.1990 Keep H0  
0.9414 Keep H0 
 
Results of the statistical tests are presented in Table 5.2. The effective significance level for 
each test was set to 0.025 according to the Bonferroni correction due to two multiple 
comparison being performed for each response. The analysis showed that the isotype had no 
significant impact on the measured responses for either the HIC retention times or the mAb 
yields. Due to these findings only IgG1-kappa samples were kept for model development due 
to being the most numerous in the present data set. In addition, this is also the predominantly 
preferred conformation of new mAbs in clinical trials according to the IMGT database search 
in Chapter 3. This resulted in 81 samples being selected from the 131 samples in the original 
data set.  
Table 5.2. Hypothesis testing of with a significance level of 0.025 according to the Bonferroni correction for 
multiple comparisons. H0 is the hypothesis that there is no significant difference between means of different 











HC 3 NP Kruskal-Wallis - 0.1201 Keep H0 
LC 2 NP Mann-Whitney - 0.0721 Keep H0 
Yield 
HC 3 P 1-Way ANOVA Yes (p=0.2270) 0.8532 Keep H0 
LC 2 P 2-Sample T-test Yes (p=0.8052) 0.6326 Keep H0 
 
It is important to remember that the heavy chain constant domains in all mAbs in the study of 
Jain et al (2017) were expressed as IgG1, which introduces a bias in the statistical testing of the 
heavy chain isotypes. As for the light chain, as the original isotypes were kept mostly intact 
through expression with one allele for kappa and another for lambda, the impact of the light 
chain isotypes on the measurements becomes more representative. As the statistical testing 
above was performed through the partitioning of mAbs according to their original isotype, the 
lack of significance might not hold true if identical experiments were to be performed with 
unaltered mAbs. The selection of IgG1-kappa mAb samples in this case therefore ensures that 
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the measurements are more representative in terms of the original mAb structures due to less 
sequence alteration. 
In retrospect, even though the alteration of the original mAbs introduced a bias in the statistical 
testing of the heavy chain, it gives an alternative approach for investigation of potential 
variation when combined with exploratory analysis methods such as PCA, PLS-DA or SVC. 
This to better control the introduction of potential systematic variation in the 𝑿 block prior to 
use in model development in order to improve the prediction accuracy of the resulting models. 
This becomes more relevant in environments such as industrial or clinical settings where the 
original mAb structures are kept intact in order to infer information.  
5.2.2 Impact of species origin 
Multiple models were developed on the retained 81 IgG1-kappa samples according to the 
benchmarking scheme presented in Section 5.1.6 which resulted in unique 32 models. The 
model performance of each individual model is presented in Table C.4a and Table C.5a in 
Appendix C for the HIC retention times and mAb yields, respectively. As can be observed, 
models developed from the full descriptor set or the V-WSP reduced descriptor sets resulted in 
a poor fit in terms of the cross validation 𝑅2 (0.04 – 0.22) and 𝑄2 (-0.06 – 0.15) suggesting that 
the models were unable to capture the underlying correlation within the data. Adequate 
improvements were first seen after a variable selection step had been performed with the GA 
selection proving to be superior compared to that of rPLS and L1-SVR variable selection in 
both PLS and SVR generated models. A concern, however, is the poor 𝑅2 and 𝑄2 values of the 
external test set, which never reached satisfactory levels for models with adequate cross 
validation metrics. All developed models therefore failed the OECD criteria of having a 𝑅2 and 
𝑄2 >  0.5 in the cross validation as well as a 𝑅2 and 𝑄2 >  0.6 in the external test set. 
5.2.2.1 Behaviour of species origins in PLS models 
PLS was used as a diagnostic tool to further investigate the cause of the poor validation in the 
test set. It was observed that initial of models for HIC retention time prediction developed on 
the V-WSP reduced descriptor sets only had one component. From the error plots generated by 
PLS, it was observed that the lowest RMSE value was attained with one component which 
otherwise increased with higher model complexity for PSD1 (Figure 5.5a), PSD2 (Figure 5.5b), 
PSD3 (Figure 5.5c) and PSD4 (Figure 5.5d). The same trends in the error was also observed 
for PLS models developed for prediction of mAb yields and is presented in Figure C.5 in 




Figure 5.5. PLS error for prediction of HIC retention times in the calibration (blue line) and the cross-validation 
(red line) with regards to the number of latent variables developed from the V-WSP reduced descriptor sets of (a) 
PSD1, (b) PSD2, (c) PSD3 and (d) PSD4.  
Further investigation was performed where a PLS models with two components were developed 
for each descriptor set in order to closer investigate the samples residuals and scores. This 
showed that the residuals and PLS scores were greatly affected by the species origin of the 
mAbs which is illustrated in Figure 5.6 for the HIC retention times. Models used in the Figure 
5.6 were developed after V-WSP reduction had been performed and they show the impact of 
the species origin for the individual descriptor sets. From the influence plots for PSD1 (Figure 
5.6a), PSD2 (Figure 5.6c), PSD3 (Figure 5.6e) and PSD4 (Figure 5.6g) it can be observed that 
the chimeric samples tend to have higher residual values compared to humanised and human 
samples. This becomes increasingly apparent with higher primary sequence resolution 
illustrated in PSD2 (Figure 5.6c), PSD3 (Figure 5.6e) and PSD4 (Figure 5.6g) where the 
chimeric samples are further removed from the humanised and human samples compared to 
PSD1 (Figure 5.6a). As discussed in Section 3.1.5, this variation originates from the species 
origin that was used to design the mAbs where mAbs originating from mouse will differ slightly 
in amino acid composition compared to human mAbs in the framework regions of the variable 
domains. The retained data variation from the descriptor sets used in the trained PLS models is 
also affected by the systematic variation caused by the different species origins. This is 
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illustrated as score plots for PSD1 (Figure 5.6b), PSD2 (Figure 5.6d), PSD3 (Figure 5.6f) and 
PSD4 (Figure 5.6h). The same trends in the residuals and PLS scores were also observed for 
PLS models developed for the prediction of the mAb yield measurements where the chimeric 
samples separated from the human and humanised samples which is presented in Figure C.6 in 
Appendix C. 
The PLS scores (𝑻) were used in this analysis as they provide better insight into the rotation of 
the Latent variables e.g. what is captured by the model with respect to the PLS loadings (𝑾∗) 
in the descriptor space according to the relationship 𝑻 =  𝑿𝑾∗ (Wold et al., 2001).The PLS 
algorithm tries to maximise the co-variance between 𝑿 and 𝒀 but can become confused if there 
is a systematic variation in 𝑿 unrelated to 𝒀 (Trygg and Wold, 2002). A separation of chimeric 
samples can be observed through groupings in the lower right quadrant which is most evident 
in PSD3 and PSD4 with the highest sequence resolution. This illustrates that the PLS model 





Figure 5.6. Impact of species on PLS models developed using the HIC retention times as the modelled response 
where chimeric samples are coloured red, human samples in green and humanised in blue. PLS Influence plots for 
PSD1 (a), PSD2 (c), PSD3 (e) and PSD4 (g). PLS scores (T) for the individual samples for PSD1 (b), PSD2 (d), 
PSD3 (f) and PSD4 (h). 
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5.2.2.2 Significance of species origins 
As the variable domains were kept unaltered in the study of Jain et al (2017), additional 
significance testing according to the species origins was performed to investigate potential 
differences in the responses between chimeric, human and humanised samples. The study was 
performed in the same way as described previously in Section 5.2.1 and is therefore only 
covered briefly here. From the study, it was shown that no significant difference between the 
HIC retention time means of mAbs from various species origins was observed (Table C.2 in 
Appendix C) whereas a significant difference (𝑝 =  0.0093 <  0.0133) was observed between 
chimeric and humanised samples for the mAb yield measurements (Table C.3 in Appendix C). 
In Section 4.2.5 it was shown that classification of the chimeric, human and humanised samples 
was possible with PLS-DA and SVC due to systematic structural differences in the primary 
sequences of the VH and VL domains. Therefore, combined with the supporting evidence from 
the diagnostic PLS models in Section 5.2.2.1 and the statistical significance testing of the 
species origins, an additional sample selection was performed. For the development of models 
with the HIC retentions time measurements only the humanised samples were retained (𝑁 =
 45). For model development the mAb yield measurements, only chimeric and humanised 
samples were retained (𝑁 =  55). 
5.2.3 HIC model development on humanised samples 
The cross validation and test set validation for all developed models for the HIC retention time 
prediction is presented in Table C.4b in Appendix C. Models developed with PLS and SVR 
using the full and V-WSP reduced descriptor sets still show a poor fit in the Cross-validation 
with values around or below 0.3 and 0.2 for 𝑅2 and 𝑄2, respectively, for all descriptor sets. 
Adequate Cross-validation performance was first observed after variable selection where GA 
especially performed well with both PLS and SVR according to the OECD guidelines 
(Veerasamy et al., 2011, Alexander et al., 2015). The SVR models developed after variable 
selection with LASSO never attained good cross-validation performance in any of the data sets. 
A potential cause to this might be due to that the descriptor sets contains redundant descriptors 
with differing levels of collinearity toward response correlated descriptors. For the LASSO 
algorithm to work properly, only a small degree of collinearity can exist between redundant and 
response correlated descriptors in order for appropiate selection to be performed which is 
known as the “Irrepresentable Condition” (Meinshausen and Yu, 2009).  
Out of the four benchmarked descriptor sets, only the PLS and SVR models developed using 
PSD1 (Domain based) and PSD4 (Running sum) passed the OECD criteria for both cross 
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validation (𝑅2 and 𝑄2  >  0.5) and external testing (𝑅2 and 𝑄2  >  0.6). Due to similar model 
performance between the PLS and SVR, model selection was based on diagnostic capabilities 
where the PLS models are preferred due to easier evaluation of residuals and descriptor 
contribution towards 𝒀. PSD1 was selected as the preferred descriptor set due to two reasons:  
1. The interpretability of descriptors in PSD1 is higher due to most of them being 
physiochemical in nature. The PSD4 descriptor set in comparison consists entirely of 
descriptors generated from three amino acid scales (Z-scale, T-scale and MS-WHIM). 
Each descriptor represents a score generated from PCA on a set of physiochemical (Z-
scale), topological (T-scale) or electrostatic (MS-WHIM) properties and is thus a linear 
combination of larger descriptor sets (see Section 3.2.2 for more details).  
2. The PLS model developed on PSD1 had a lower model complexity compared to the 
PLS model developed on PSD4 based on the selection of Latent variables (LVs) from 
the cross validation. Three LVs were selected for the PLS model developed on PSD1 
compared to 12 LVs for the PLS model developed on PSD4. This makes interpretability 
of the contribution from the individual LVs more difficult in the case of PSD4 due to 
the fact that deflation of 𝑿 and 𝒀 occurs each time a LV is extracted in the PLS algorithm 
and models with lower complexity are preferred (Wold et al., 2001).  
From the original 272 descriptors present in the full PSD1 descriptor set, 51 were retained from 
the V-WSP reduction thus effectively reducing the number of descriptors by ~80%. Procrustes 
index was used to evaluate the loss of information when comparing the full and V-WSP reduced 
PSD1 descriptor sets. A value of 0.1434 was obtained, thus indicating that only a small portion 
of the information was lost in the reduction step (Ballabio et al., 2014). This can also be 
observed in Table C.4b in Appendix C for PSD1 where the of 𝑅2 and 𝑄2 values in the cross 
validation and the test set remained mostly unchanged after the reduction. Out of the 51 
remaining descriptors, GA selected a subset of 17 descriptors used to develop the final PLS 
model. Model predictions of the calibration and test set samples are shown in Figure 5.7a as a 
measured vs predicted plot. The test samples are further illustrated in Figure 5.7b as a bar plot 
for easier comparison of the measured and predicted values. The model performance is 
summarised in Table 5.3. The PLS regression coefficients for the selected descriptors are 




Figure 5.7. HIC retention time predictions of 45 IgG1-kappa humanised mAbs with PLS model (3 LVs) developed 
on the PSD1 descriptor set after reduction with V-WSP and selection with GA. (a) Measured versus predicted plot 
with calibration (grey) and test (red) samples. (b) Predicted and measured HIC retention times of test set samples.   
 
Figure 5.8. Regression coefficients of the PLS model (3 LVs) developed on the PSD1 descriptor set after reduction 
with V-WSP and selection with GA. 
Table 5.3. PLS model summary developed for HIC retention time prediction using the PSD1 descriptor set. Root 
Mean Square Error (RMSE), R2, Q2 and model bias are listed for Calibration, Cross validation, Test set and Y-
randomisation 
  PLS 
 
RMSE R2 Q2 Bias 
Calibration 0.47 0.84 0.84 0.00 
Cross Validation 0.67 0.63 0.62 0.01 
Test 0.51 0.78 0.69 -0.27 
Y-scrambled 
(Average) 
1.42 0.05 -0.63 0.01 
 
Many of the test set samples were slightly over predicted which resulted in a negative bias (-
0.27). The reason for this is not known but could be a slight indication of over-fitting of the 
calibration samples due to the difference in bias between the cross-validation and test set (Hastie 
et al., 2009a). 
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A general trend observed in the descriptors showed that residue groups consisting mainly of 
polar and charged residues such as AHR (common residues in alfa helix), NCR (negatively 
charged residues) UCR (uncharged residues), PLR (polar residues), and RTR (common 
residues in reverse turn/loops) had a negative contribution on the prediction, thus indicating 
that mAbs with a high number of polar residues tend to have lower retention times. This is 
illustrated by the negative coefficients values of the isoelectric point (Ip), charge (ECI), and 
hydrophobicity (HP) where lower values in these descriptors increases the predicted retention 
time. This is supported by literature where higher concentrations of salts are required to 
neutralise the protein polarity in order to expose hydrophobic patches that can bind to the HIC 
column (Gagnon, 1996a).  
The summed molecular weight of the residues in the UCR group in the VH chain had a positive 
contribution to the HIC retention time. The UCR group contains tyrosine which has the highest 
weight among all the group constituents and is also the only residue with a benzene ring, thus 
making it slightly hydrophobic. This indicates that with increasing number of tyrosine residues, 
the HIC retention time will increase. This is supported by the descriptor describing the 
theoretical number of water molecules surrounding a residue, W(U), for the UCR residues in 
the VH chain where more polar residues tended to have more surrounding water molecules 
compared to tyrosine. W(U) was also shown to have a strong negative correlation to the 
retention time in both the VH and VL chain for polar residues further indicating a correlation 
between hydrophobic residues and longer retention times, which is supported by literature 
(Kennedy, 1990). 
The polar area of residues (Ap) was also shown to be an important factor where larger areas 
contributed to lower retention times for RTR and PLR residues due to these groups containing 
mostly polar residues (see Table 3.3 in Section 3.2.1). The opposite was observed in the VL 
chain where the polar area of aliphatic residues (ALR) contributed to higher retention times. 
Glycine has the highest indexed polar area value in ProtDCal of all residues in the ALR group 
(see Table 3.3 in Section 3.2.1) which indicates that a higher number of glycine residues in the 
VL chain contributes to a higher retention time. Glycine and proline are known as unfolding 
residues which indicates that a higher number of glycine residues aids in decreasing the protein 
stability and thus increase binding in HIC due to exposure of the hydrophobic patches. This is 
supported by literature where glycine was shown to have a negative impact on alfa helix 
stability when introduced (Scott et al., 2007). This is further supported by the model where the 
molecular weight (Mw) of ALR residues in the VL chain has a negative correlation to the 
retention time indicating that other residues besides glycine contribute to lower retention times. 
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Also, a potential reason for the higher performance achieved with PSD1 compared to higher 
resolution datasets, such as PSD2 (substructure based) and PSD3 (single amino acid based), 
could be due to the introduction of more redundant descriptors in PSD2 and PSD3 which has 
been shown to negatively impact model performance and descriptor selection algorithms 
(Donoho, 2000, Fan and Lv, 2010). This is especially true for descriptors generated based on 
the amino acid composition of the sequence where each residue in the mAb structure equally 
impacts the resulting descriptors. Therefore, through generation of descriptors based on the 
individual domains, a reduction of the number of redundant descriptors present in the datasets 
can be achieved compared to descriptor generation for each substructure (PSD2) or each amino 
acid in the sequence (PSD3). 
Y-Randomisation (or Y-Scrambling) was used as a final validation step to evaluate the selection 
of the descriptors (Rücker et al., 2007). A PLS model was trained on a randomised (scrambled) 
HIC response vector while the sample order in the PSD1 descriptor set was kept unchanged. 
This was repeated 50 times and the average of 𝑅2 and 𝑄2 for the cross validation was calculated. 
A 𝑅2 value of 0.05 and a 𝑄2 value of -0.63 was obtained. This indicates that no chance 
correlation is present and that the selected descriptors are important to describe the relationship 
between the structure of the mAbs and HIC responses. Results are summarised in Table 5.3. 
In order to appropriately evaluate if a mAb can cause potential problems in processing, a 
threshold needs to be defined based on the mAb HIC retention times. In the research of Jain et 
al (2017) the authors defined an upper threshold for the HIC retention time as a confidence 
interval of 11.7 ± 0.6 minutes which was based on the retention times of 48 approved mAbs in 
their full data set of 137 mAbs. The remaining 89 mAbs in the data set are all pending in clinical 
phase II or phase III.  Thus, any mAbs with a predicted HIC retention time falling above the 
lower confidence limit (11.1 minutes) could be flagged due to potential risk of being 
problematic in process development while mAbs falling below can be considered well-behaved. 
When applying the threshold on the predictions from the PLS-GA model developed on the 
PSD1 descriptor set, eight mAbs were flagged due to above the lower confidence limit: 
atezolizumab, bevacizumab, certolizumab, enokizumab, obinutuzumab, otlertuzumab, 
ranibizumab and tildrakizumab. Five of these mAbs have been approved while three are still in 
clinical trials. However, this does not necessarily indicate that predictions falling inside or 
above the threshold confidence interval will definitely fail in process development as there are 
a number of factors involved that are not accounted for in this evaluation. However, historical 
data in this context from approved products can be used to develop predictive models that would 
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allow for risk evaluation in early process development and thereby reduce the load on the 
bioprocess pipeline.   
5.2.4 mAb yield model development on humanised samples 
The cross validation and test set validation for all developed models for the prediction of the 
mAb yields are presented in Figure C.5b in Appendix C. The developed models behaved 
similarly to the models for the prediction of the HIC retention times, where adequate 
performance in the cross validation was only achieved after variable selection had been 
performed. GA selection and rPLS achieved good performance for all descriptor sets while 
LASSO selection suffered due to collinearity between redundant and response-correlated 
descriptors explained in Section 2.9.3.   
Unfortunately, no model performed well on the external test set. PLS-GA model developed 
using PSD3 had a high 𝑅2 value of 0.69 but a 𝑄2 value of 0.35 in the test set thus indicating a 
high offset of the predictions compared to the measured values. The difference between 𝑅2 and 
𝑄2 is also greater than 0.3 thus failing the OECD criteria of |𝑅2 − 𝑄2| < 0.3 (Veerasamy et al., 
2011). PLS-GA model developed using PSD4 had similar 𝑅2 and 𝑄2 values of around 0.5 in 
the test set, but this is below the desired value of 0.6 according to the OECD guidelines. 
Predictions of PLS-GA model developed using PSD4 are illustrated in Figure 5.9a. It can be 
observed that all calibration samples fall directly on the parity line whereas the predictions of 
the test set samples have large differences between predicted and measured values as illustrated 
in Figure 5.9b. This is usually an indication of the model being overfitted where the model fits 
the random pattern in the noisy variables of the calibration data set (Lever et al., 2016). The 




Figure 5.9. mAb yield predictions of 55 IgG1-kappa humanised and chimeric mAbs with PLS model (3 LVs) 
developed on the PSD4 descriptor set after reduction with V-WSP and selection with GA. (a) Measured versus 
predicted plot with calibration (grey) and test (red) samples. (b) Prediction and measured HIC retention times of 
test set samples. 
Table 5.4. PLS-GA model summary developed for mAb yield prediction using the PSD4 descriptor set. Root Mean 
Square Error (RMSE), R2, Q2 and model bias are listed for Calibration, Cross validation and Test set. 
  PLS 
 
RMSE R2 Q2 Bias 
Calibration 1.51 1.00 1.00 0.00 
Cross Validation 15.58 0.95 0.94 -0.68 
Test 47.56 0.51 0.50 1.90 
 
Several factors might impact the model development. All mAbs were expressed recombinantly 
using mammalian expression vectors where the heavy and light chain were expressed from 
individual cassettes (Jain et al, 2017). It has been shown that excess expression of the LC chain 
compared to the expression of the HC chain facilitates higher cell productivity and mAb yield 
(Bayat et al., 2018, Bhoskar et al., 2013). However, due to the unique structure of the variable 
domains in the mAbs, differences in folding efficiency in the endoplasmic reticulum might 
prevent an excess expression of the LC chain (Braakman and Bulleid, 2011). This is especially 
important in the model development which assumes that all measured yields had identical 
experimental setup which probably does not hold true as the HC:LC expression ratios will be 
different between mAbs. The HC:LC ratio might therefore be an important measurement 
needed for the improved model performance and can be used either as an extra input in the 𝑿 
block along with the structural descriptors or, used as an additional dependent variable along 
with the mAb yields.  
Another potential cause for the poor performance in the test set might be the lack of necessary 
variation in the data. In the case of the 𝑿 block, by using the primary sequence to generate 
structural descriptors, no information can be gained regarding higher order structural 
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information such as secondary or tertiary structure and potential intra-protein interactions. More 
samples might also be needed to better represent the range of 𝒀 responses, but also to introduce 
more structural variation in the 𝑿 block. Noise and descriptor collinearity are also influencing 
factors in the model development where the descriptor selection methods can suffer and the 
wrong descriptors are thus selected (Fan and Lv, 2010). 
5.3 Summary 
The regulatory and quality assurance requirements for the process development of therapeutic 
mAbs are becoming more stringent to ensure high product specificity and clinical safety. This 
has in turn led to an increase in the number of experiments needed to characterise the design 
space of a process in order to investigate the impact of process parameters on the product 
quality. Today, platform approaches are becoming increasingly popular for process 
development of therapeutic mAbs which limits the number of operational units that needs to be 
characterised (Shukla et al., 2017). However, even with platform approaches the number of 
experiments needed for process characterisation is still cumbersome and costly. This is 
especially true in early process development where uncertainty is high with regards to the 
manufacturability of the mAb and where the effective processing routes might not be clear. 
Over recent years, the QSAR framework for in silico model development has become 
increasingly popular for end point predictions of aggregation (Obrezanova et al., 2015) as well 
as downstream applications (Robinson et al., 2017, Woo et al., 2015a). This makes the QSAR 
framework a potentially valuable tool that can aid risk assessment in early process development 
to better direct experimental designs and thus reduce costs (Karlberg et al., 2018). The use of 
in silico approaches allows for more informed estimates of the potential behaviour of an mAb 
in different unit operations of the process. This becomes possible by efficiently making use of 
historic process data from previously established mAb manufacturing processes and therefore 
constructing an expert system. 
In this Chapter the importance of exploring systematic variations as a source of noise in QSAR 
model development has been shown and should be considered as a critical step in the model 
development. A combination of PLS and statistical testing of the responses was performed to 
decrease the impact of systematic variation originating from the chain isotypes and species 
origin. This had a beneficial effect on the model performance in both the cross validation and 
external test set prediction after sample reduction with regards to the species origin. However, 
due to the alteration of the constant domains in the original mAb structures, no conclusive 
results could be drawn regarding the impact of systematic variation related to the heavy chain 
isotypes IgG2 and IgG4 and the light chain isotype lambda. The workflow presented in this 
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Chapter, however, provides a structured approach for selecting samples and reducing 
systematic variation that could negatively impact the model performance. In the work of 
Andersen and Bro (2010), the authors stated that removal of outliers is a vital step prior to 
variable selection due to the high sensitivity these methods have towards outliers. Thus, the 
removal of samples with systematic variation uncorrelated to the response greatly aids variable 
selection and reduces the risk of potential selection of uncorrelated variables. 
Further, an efficient benchmarking scheme is presented here to validate several modelling 
methods, descriptor sets and incremental descriptor reduction and selection. A model was 
successfully developed for predicting HIC retention times and conformed to the model 
validation scheme presented in the OECD guidelines for cross-validation (𝑅2 and 𝑄2  >  0.5) 
and the test set (𝑅2 and 𝑄2  >  0.5). Though not all variation has been explained by the model, 
the presented workflow is intended as an early model development step to evaluate useful 
descriptors and factors affecting model performance. Additional descriptor generation and 
modification might therefore help in improving model accuracy further. Based on the defined 
confidence interval of 11.7 ± 0.6 from Jain et al (2017), sample predictions can easier be 
assessed as potentially problematic if the prediction falls above the lower confidence limit (11.1 
minutes). This however does not indicate that they are certain to fail but that caution should be 
exercised and further studies are needed to characterise potential problems.   
Unfortunately, no satisfactory model could be developed for the prediction of mAb yields as 
indicated by the signs of overfitting evidenced by the poor test set results. A potential cause 
could be the simplicity of the descriptor generation based on the primary sequence which does 
not take into account higher ordered structure and stability. This is investigated further in 







Chapter 6  
 
3D Structure Descriptors 
In this chapter descriptor generation with regards to the protein structure and dynamics is 
assessed as an alternative to the primary sequence descriptors generated in Chapter 3. An 
overview of protein structure model development is presented and key aspects such as the 
linkage of cysteines to form disulphide bridges and structure evaluation are assessed. The 
generated protein structures were used as inputs to molecular dynamics simulations in order to 
relax the protein structure as well as to capture conformational dynamics of the mAbs. The 
theory and implementation of molecular dynamics has been assessed in detail in order to create 
a wide knowledge base to produce more realistic simulations of the mAb structures that were 
used in this research but as well for future applications. In addition, strategies for modification 
of protein charges with regards to the pH as well as addition of co-solvents to the simulation 
system has been proposed. 
The methodology for generating 3D structure descriptors follows the same approach as in 
Section 3.3 in order to generate descriptor set of different resolutions. Three resolutions were 
generated for the 3D structure descriptors based on the full chains, the individual domains and 
the substructures. ProtDCal was implemented to generate the 3D structure descriptors but were 
modified with the solvent accessible surface area of the superficial residues in order to represent 
the surface properties of the mAbs. 
6.1 Structure Generation 
In order to generate meaningful descriptors for model development, structures need to be 
available. Usually structure determination of proteins is performed by using either X-ray 
crystallography or Nuclear Magnetic Resonance (NMR) which both can give a very high 
atomistic resolution of the structure. Another method called Cryogenic-Electron Microscopy 
(Cryo-EM) has been making its impact within this area as well due to the many improvements 
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that has been made over the years to the method and the analytical software to refine the 
atomistic resolution (Carroni and Saibil, 2016, Merk et al., 2016). These methods are however 
very time consuming and expensive due to the specific requirements of the methods and are not 
always guaranteed to succeed (Krishnan and Rupp, 2012). Instead, the use of in silico methods 
provides an alternative to estimate the protein structure and has therefore become popular in 
structure determination.  
6.1.1 Background on in silico methods 
In silico structure prediction can roughly be divided into two schools:  
1. Ab initio methods where the secondary and tertiary structure is predicted directly from 
the primary sequence 
2. Comparative or homology modelling where templates of existing structures are used to 
predict the structure of proteins of interest.  
Due to the high complexity in protein folding, pure ab initio methods do exist today but have 
low accuracy and are limited to smaller proteins (< 120 residues). Extremely high 
computational resources are also required in order to predict the protein folding with ab initio 
methods (Lee et al., 2017). More recently, a new method based on deep learning called 
AlphaFold has shown promising results and predicts likely distances between residues as well 
as potential angles between chemical bonds (Evans et al., 2018).  
Instead, homology modelling has been shown to offer good prediction accuracy when protein 
templates exist and can be used. The high structural accuracy in homology modelling is based 
on the principle that high primary sequences similarity results in high tertiary structure 
similarity  (Venclovas, 2011). 
6.2 Homology Modelling 
The approach for predicting structures in homology modelling can be broken down into five 
individual steps (Marti-Renom et al., 2000):  
1. Identification of evolutionary related proteins to a target protein that can be used as 
templates (also known as homologs). 
2. Alignment of the target protein sequence to the template. 
3. Model building of target protein structure based on available structural information in 
the template. 
4. Error estimation of target model structure. 
5. Scoring of models for comparison 
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Step one and two can usually be done in parallel where many different techniques exist to find 
templates. Depending on the sequence identity that can be achieved between the target protein 
and template however, alternative approaches need to be considered. When the sequence 
identity is greater than 40% which is also known as the daylight zone (Rost, 1999), the search 
and selection of templates can be performed using pairwise sequence alignment tools  such as 
Basic Local Alignment Search Tool (BLAST) (Johnson et al., 2008) or FASTA (Pearson, 1998) 
from the National Centre for Biotechnology Information (NCBI). At lower sequence identity 
(25-40%, also known as the twilight zone), methods such as position-specific iterated BLAST 
(PSI-BLAST) (Altschul et al., 1997) or Hidden Markov Models (HMMs) (Eddy, 1998) can be 
used instead for more sensitive searches to find homologs.  
Different approaches exist to build the target model from the templates in step three. Commonly 
used approaches are modelling by assembly of rigid bodies (Sutcliffe et al., 1987), modelling 
by segment matching or coordinate reconstruction (Levitt, 1992) and modelling by satisfaction 
of spatial restraints (Sali, 1995).  
An initial error estimation of the produced model can usually be carried out by inspecting the 
differences between the target protein sequence and that of the template. It is commonly known 
that when the similarities in the alignment between the template and the target protein decrease, 
the errors in the model will increase in turn. These errors originate from five sources (Fiser, 
2010) related to: 
1. Side-chain packing 
2. Structural prediction of regions in the target protein that has shifted but otherwise 
correctly aligned with the template structure 
3. Structural prediction of regions in the target protein that does not have an alignment 
4. Structural prediction of regions in the target protein that are misaligned in the template 
structure 
5. Structural prediction of target protein with wrong templates 
As mentioned, the error is highly dependent on the sequence identity of the target protein and 
the template. If the sequence similarity is greater than 40%, approximately 75-90% of the 
predicted model structure will overlap, with an offset error of the peptide chain atoms of roughly 
1 Å from their true positions. If sequence similarity goes lies in between 30-40%, the structure 
overlap decreases in turn and drops to 50-75% with an offset of 3 Å in the peptide chain atoms 
(Sanchez and Sali, 1998). This therefore shows the importance of appropriate selection of good 
templates to be used in homology modelling. It has also been shown that the model accuracy 
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increases by using multiple templates to estimate the target protein structure (Fernandez-
Fuentes et al., 2007). 
Table 6.1 lists some of the most commonly used software for model generation for mAbs. This 
list is by no means exhaustive of all the different web services and stand-alone software used 
for homology modelling.  
Table 6.1. Commonly used homology modelling software for structure prediction of mAbs.  
Software Description Reference 
Web Antibody Modelling 
(WAM) 
Canonical modelling of CDR loops L1-3 and H1-
2 and template search for H3. CDRs are grafted 
onto template frameworks 
(Whitelegg and Rees, 
2000) 
Prediction of ImmunoGlobulin 
Structure (PIGS) 
Canonical modelling of all CDR loops and 
grafted onto template frameworks. 
(Marcatili et al., 
2014) 
Rosetta Antibody Grafts selected CDR templates onto template 
framework regions and energy optimises all 
residues in model. Further refinement of resulting 
model is performed using Monte Carlo 
minimisation. 
(Sircar et al., 2009) 
Molecular Operating 
Environment (MOE)  
Antibody Modeller 
Grafts selected CDR templates onto framework 
templates. Energy minimisation with AMBER99 
forcefields is performed to relax structure and 
resolve steric clashes in grafted regions. 
(Almagro et al., 
2011) 
Modeller One or more templates used to represent the full 
structure. Imposes conformational and sterically 
restraints in the target model according to the 
templates.  
(Webb and Sali, 
2014) 
 
All software packages in Table 6.1, except Modeller, are specialised model generation for mAbs 
and perform a separate template search for the individual framework regions and CDRs. Both 
WAM and PIGS are very similar in execution when generating a target model as both methods 
use canonical structure prediction of the CDR loops. This means that the CDR loops can only 
assume a limited number of conformations based on the length of the loop and on the identity 
of specific residues at key positions (Chothia and Lesk, 1987). The PIGS web service is, 
however, more preferable as its reference database and canonical structure definitions are 
frequently updated (Marcatili et al., 2014). Compared to the canonical approaches, Rosetta 
Antibody focuses on resolving steric clashes in the target model that arises from the grafting of 
the CDR loops onto the framework regions as well as residue overlap caused by the use  
different templates (Sivasubramanian et al., 2009). The MOE Antibody Modeller is similar to 
that of Rosetta Antibody, but does not perform such an extensive refinement and focuses mostly 
on the regions where the CDRs were grafted onto the framework regions.  
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Research published in Almagro et al. (2011) benchmarked four antibody structure prediction 
tools where PIGS, Rosetta Antibody and MOE Antibody Modeller were included and tested on 
nine Fv antibody structures (VH and VL). The authors showed that accurate predictions could be 
generated for most of the structure except for the H3 loop, which was distinctly different 
compared to the experimental structures. It was also shown that Rosetta Antibody produced 
models with fewer steric clashes compared to PIGS and MOE Antibody Modeller. 
In this research, Modeller (version 9.20) was selected to generate structures for the mAbs due 
to the in-house expertise available in the School of Natural and Environmental Sciences at 
Newcastle University. Modeller can also be locally installed and prediction of structures can be 
performed without connecting to the web server. This is usually desirable for Contract 
Manufacturing Organisations (CMOs) that deal with third party sequences and therefore face 
restrictions in the use of web services. Though the use of PIGS and Rosetta Antibody may have 
been preferred for better accuracy in the structures of the CDR loops, these methods were 
excluded due to being web services. However, further molecular dynamics simulations were 
performed of the generated structures to minimise the structure energy and resolved steric and 
conformational clashes (see Section 6.4). 
6.2.1 Antibody Template Selection 
To simplify the structure generation, it was decided to only model the Fab regions (VH, CH1, 
VL and CL domains) of the mAbs due to two reasons: 
1. The mAb data sets used in this research were modified and expressed with selected 
allotypes (see Section 5.1.1). The heavy chain was expressed as IgG1 with allotype 
IGHG1*01 whereas in the light chain the allotypes IGKC*01 and IGLC2*01 were used, 
respectively, for kappa and lambda chains (Jain et al., 2017). Thus, except for the 
sequence variability originating from the CL, the main source of variability originated 
from the variable domains VH and VL. 
2. Structure preparation of full-length mAbs is much more complex due to consisting of 
four individual chains and two glycans attached in the Fc region. Information about the 
glycan profiles is also extremely limited. 
The template search was performed using BLAST where homologs with high sequence identity 
and existing structures in the Protein Data Bank (PDB) (Berman et al., 2000) were identified. 
Individual searches of the heavy and light chain of the Fab fragments always yielded template 
candidates with more than 80% sequence identity. Based on this, it was decided to select a 
single template for each isotype permutation of the Fab fragments for simplicity and due to 
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further simulations to be performed. Quality assessment of the templates was based on their R-
factor value which is a measurement of similarity between the crystal structure and 
experimental X-ray diffraction data. A value of zero indicates a perfect fit while a value of 0.6 
or higher is obtained if a random structure is used. For larger proteins such as mAbs, values 
around 0.2 or below are a good indication of well-defined structures (International Union of 
Crystallography, 2017). The resulting templates are displayed in Table 6.2 where 2FGW and 
7FAB were the only structures used in this research due to the mAbs being expressed as IgG1. 
The sequence identity listed as SeqID remained high with greater than 70% identity when 
aligned with the mAbs in the data sets. 5SX4 and 5DK3 are listed as potential candidates, 
respectively, for IgG2 and IgG4. 
Table 6.2. List of templates PDB structures to be used as templates for different isotype permutations.  
PDB HC LC Resolution R-factor Modifications SeqID 
2FGW IgG1 kappa 3 Å 0.176 Loop refinement 
(H3: 101-108) 
>70% 
7FAB IgG1 lambda 2 Å 0.169 None >70% 
5SX4 IgG2 kappa 2.8 Å 0.223 Ligand and 
solutes removed 
- 




6.2.2 Pairwise Cysteine Distance Restraints 
Five naturally occurring disulphide bonds will always be present in the Fab region of the mAb 
with two in the light chain, two in the heavy chain and one interchain bridge between the heavy 
and light chains. MODELLER by default will not restrain the distances between cysteines 
involved in disulphide bridges and can be observed in Figure 6.1a where distance between the 
sulphur atoms are more than 15 Å. By adding individual restraint for pairwise cysteines in the 
homology model the positions of the sulphur atoms can be adjusted to form the disulphide 
bonds as sown in Figure 6.1b. Figures were generated in UCSF Chimera (version 1.13) 




Figure 6.1. Distance restraint of cysteines in adalimumab generated. Structure coloured as orange depicts the light 
chain and structure coloured as blue depicts the heavy chain (a) Homology model without added distance restraints 
to the interchain cysteines. (b) Homology model with restraint between the interchain cysteines.  
6.2.3 Model Assessment 
Due to the difference in the amino acid composition and the length between the template and 
the mAb sequences used in this research, direct comparison with root mean square deviation 
(RMSD) of atom positions is not possible. Instead initial model assessment was performed with 
the inherent metric Discrete Optimised Protein Energy (DOPE) in Modeller (Shen and Sali, 
2006) which is used to assess the energy of a structure or the residues in a structure. It is often 
used to select a model or structure from several predictions where a lower DOPE value relates 
to a more stable structure. 
Figure 6.2 illustrates the normalised DOPE profiles for the template 2FGW (green line) and 
adalimumab (orange line) for the heavy and light chain. As can be observed, the DOPE profiles 
of the template and predicted structure overlap in most regions. The largest differences between 
the template and predicted model can be observed in the regions containing the CDR loops (H1, 
H2, H3 and L3) which have the highest deviation from template and thus are structurally 
different. This is, however, expected due to differing amino acid compositions in the CDR 
regions between adalimumab and the template. To date, accurate prediction of the CDR loops 
with homology modelling is still very difficult, especially in the case of the H3 loop which has 
the highest degree of varying amino acid composition and length when compared between 
mAbs (Almagro et al., 2011). In comparison, the structure of the constant domains CL and CH1 
overlaps in Figure 6.2a and Figure 6.2b, respectively, due to a higher sequence identity between 
the template and protein target. The trends observed between the generated structure of 





Figure 6.2. DOPE score for generated model (orange line) and template (green line) for the light chain (a) and 
heavy chain (b) for the aligned residues. Positions of CDR loops regions are marked by name and arrows in both 
the heavy and light chain. 
6.2.4 Structure considerations 
It is possible to use the generated homology structures of the mAbs to generate structural 
descriptors. However, four key considerations of the generated structured needed to be 
addressed before doing so: 
1. Origin of the templates 
2. The structure is biased towards the template 
3. The structure is not completely relaxed 
4. Residue states in the structure might not be accurately represented 
The first point involves faults or assumptions that are present in the acquired experimental 
structures which might not necessarily represent reality. In the case of X-ray crystallography, 
the mAbs are never naturally packed in close proximity to each other in a physiological 
environment. The close proximity as a result of the crystallisation might introduce structural 
artefacts in the generated 3D structures and therefore may not be completely accurate. In the 
case of NMR, the structures are determined in a dynamic system where the proteins have less 
self-interaction. However, the acquired 3D structures will be heavily biased towards the 
environment in which the structure determination was performed e.g. pH, temperature, molality 
etc.  
Point two and three originate from structure generation in Modeller which estimates the target 
protein structure based on the used template. Compared to specialised software, such as Rosetta 
Antibody and PIGS which use unique templates for individual framework regions and CDR 
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loops in the mAbs, Modeller was used to predict the mAb structure with a single template. This 
constrains the structure towards the used template and might not necessarily represent the true 
structure, especially of the CDR loops. It can also cause the structure to not be in a non-relaxed 
state, especially in regions where a difference in length exists between the target protein and 
template. Caution thus needs to be exercised as these differences might have an impact on the 
generated descriptors if the homology model if used directly for descriptor generation. 
The fourth point relates to the impact of the environmental factors that can change structural 
conformation and dynamics of the mAbs. In mAb manufacturing, drastic changes in the 
environment are common in many operational units in the downstream process. The pH and 
molality are common process factors that are changed to enhance binding and elution of mAbs 
in different chromatographic columns that can drastically impact the conformation of the 
protein structure. 
6.3 Protein dynamics 
Proteins have since long ago been described as being static structures with a specific function. 
The reality however is that proteins are dynamic in nature with small structural fluctuations 
over time. This is highly related to the folding energy landscape of a protein, where at a stable 
conformation, many structurally similar states exist separated by small thermodynamic free 
energy barriers (Bryngelson et al., 1995). Figure 6.3a illustrates a simplified example of the 
energy landscape of a protein. As can be observed, fluctuations between the different states 
depends heavily on the magnitude of the free energy barrier where transitions to similar state 
are more frequent due to a smaller energy barrier (𝛥𝐺𝐿𝑜𝑐𝑎𝑙) whereas larger conformational 
changes require more energy (𝛥𝐺𝐺𝑙𝑜𝑏𝑎𝑙). The magnitude of time is also an important factor that 
needs to be considered where transition between larger conformational states takes longer due 
to the cumulative kinetic energy required to overcome the large energy barriers. Figure 6.3b 
illustrates changes in structural states related to the different timescale and was adapted from 
the work of Henzler-Wildman and Kern (2007) as well as the work of Adcock and McCammon 
(2006). It can be observed that smaller changes, such as bond vibrations and methyl rotations, 
occurs at shorter timescales whereas rotation of larger solvent accessible side-chains and loop 
motions lies on a timescale of nanoseconds due to larger energy differences in the barriers. 
Changes in environmental factors, such as temperature, pH and molality to name a few, are also 
important to consider, as they will inevitably result in a change of the energy landscape of the 
protein which is illustrated as a shift from its original conformation (green line) to that new 
conformation (orange line) in Figure 6.3a. This can also have an effect on the protein function 
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Figure 6.3. Potential dynamics of a protein. (a) A simplified energy landscape for an arbitrary protein. 
Environmental changes can drastically change the landscape as shown in the shift from the green line to the orange 
line with a different conformation occupying the energy minima. (b) The time scale needed to observe local as 
well as global conformational changes in a protein (adapted from Henzler-Wildman and Kern (2007) and Adcock 
and McCammon (2006)). 
6.3.1 Describing the system dynamics 
Accurate insight into the protein dynamics can today be gained through the use of 
computational simulations. The complexity of the simulations can usually be divided into four 
levels of resolutions to observe a system where a short description on each has been given 
below. 
Quantum mechanics  
The atom nuclei and electrons of a system can be described by solving the time-dependent 
Schrödinger equation (TDSE) for a single particle.  
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where Ĥ is the Hamiltonian operator which corresponds to the total energy of the system, ψ the 
wave function, 𝒓 the position vector of the particle (𝒓 = 𝑥𝒊 + 𝑦𝒋 + 𝑧𝒌), 𝑡 the time, ħ the reduced 
Planck constant, m the mass of the particle, 𝑉 the potential energy and 𝑖 the imaginary number. 
However, the TDSE is not practical for describing structure dynamics due to being 
computationally intensive and it is more commonly applied for studies of faster phenomena 
such a light emission absorption and emission. Instead, the time-independent form is more 






∇2 + 𝑉}𝜓(𝒓) = 𝐸𝜓(𝒓) (6.2) 
 
The quantum mechanics (QM) simulations provide highly detailed information about the 
dynamics of the system but are also able to incorporate chemical reactions due to the 
approximations of the electron orbitals. However, only smaller systems with a few atoms can 
be simulated with QM due to the high complexity and computationally cumbersome 
calculations (Leach, 2001d). 
Classical/Molecular mechanics 
Simulate the atomistic positions and movement in space by solving Newtons equations of 
motion for individual particles in the system: 
 
 





where 𝑭 is the force, 𝑚 the mass of the atom, and 𝒂 the acceleration of the particle. The 
atomistic interactions are approximated by using empirical force fields that describe the 
potential energies of the system (see Section 6.4.1). This allows for longer simulation times up 
to the scale of microseconds and even milliseconds when coarse-grained force fields are used. 
A drawback with molecular mechanics (MM) is its inability to break or create covalent bonds 
(Adcock and McCammon, 2006). Molecular mechanics simulations are also referred to as 
Molecular Dynamics (MD). 
Hybrid QM/MM 
Can be used to simulate systems that are too computational expensive for standard QM but 
where chemical reactions are important such as enzymatic reactions. The protein structure or 
system is divided into two parts where a smaller part is simulated with QM which encloses the 
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structure responsible for the chemical reaction whereas the larger part is simulated with MM 
(Liu et al., 2001). 
Monte Carlo 
Instead of using a deterministic system such as MD which is reliant on a time component, 
Markov Chain Monte Carlo (MCMC) is a statistical approach that samples the conformation 
space by randomly moving the system atoms. This means that the atom movement in a MCMC 
simulation is only dependent on its immediate predecessor and therefore no temporal 
relationship exists between the trials (Leach, 2001e). A drawback with MCMC is that the 
simulation can become computationally expensive with increased number of atoms in the 
systems due to the exponential increase in degrees of freedoms in the system if not properly 
restrained.  
Selection of simulation resolution 
Information gained through computational molecular simulations can answer many questions 
regarding the protein dynamics due to the high level of detail captured. Most commonly used 
are the MD simulations which allows for longer simulation times and the ability to follow 
conformational events due to being deterministic. In this research, the focus has been placed on 
MD simulations due to being faster and that chemical reactions are not required for the 
descriptor generation. 
6.4 Molecular Dynamics 
Many advancements have been made over the years to MD simulations such as theoretical 
improvements with new empirical force fields as well as practical improvements of simulation 
speed and increase the system size (Rauscher et al., 2015). One such advancement is the 
incorporation of Graphical Processing Units (GPUs). State-of-the art graphics cards contains 
thousands of cores which can be used to divide the molecular system into smaller parts which 
can be run in parallel. This shifts the workload from the Central Processing Unit (CPU) to the 
GPU which calculates the forces on the atoms whereas the CPU is free to allocate data and 
combine the results of the smaller parts (Loukatou et al., 2014).  
Improvements in simulation time can also be gained through simplification of the system with 
a so-called coarse-grained approach. Instead of representing all atoms in the system (referred 
to as all-atom or atomistic), a coarse-grained simulation may represent each amino acid side-
chain as a single cluster with their corresponding force fields. This drastically reduces the 
degrees of freedom in the system (see Section 7.2.2.1) which in turn decreases the necessary 
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number of calculations that needs to be performed (Kmiecik et al., 2016). One of the most 
commonly used coarse-grained force fields is MARTINI which has been shown to achieve 
simulation results close to that of atomistic simulations (May et al., 2013). Figure 6.4 illustrates 
the applicability domains of atomistic and coarse-grained models with regards to the system 
size and simulation time (adapted from Kmiecik et al (2016)).  
 
 
Figure 6.4. The relationship between the system size and possible simulation times for QM, atomistic and coarse-
grained simulations. Loss of information is inevitable when moving to simplified estimation of the system such as 
atomistic and coarse-grained representation which are illustrated by the green and orange graphs, respectively 
(adapted from Kmiecik et al. (2016)). 
As shown, larger systems and longer simulation times become possible when moving from 
more computationally intensive QM calculations towards system approximations with MM 
calculations. With further decrease in degree of freedoms in a system resulting from the move 
from an atomistic to a coarse-grained setup, the system size and simulation times can be 
increased even further. However, caution needs to be exercised as a system simplification step 
inevitably leads to a loss of information of protein dynamics which will no longer be captured 
in the simulations. This can easily be visualised when comparing the energy landscapes of an 
atomistic model to those of a coarse-grained model represented as the green and orange energy 
graphs in Figure 6.4, respectively. In the atomistic model, the rotations of the side chains and 
bond vibrations will more or less be intact resulting in many local conformational minima in 
the energy landscape. In a coarse-grained model however, side-chains are treated as a single 
cluster and therefore lack many of the local motions. The energy landscape of a coarse-grained 
will therefore be smoother but will follow the general trend of an atomistic model. Therefore, 
it is advised to choose the simulation resolution based on the area of investigation where an 
atomistic model is recommended to capture local motions and a coarse-grained model 
recommended to capture global motions. 
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A popular approach to increase the resolution is to use multiscale modelling where major events 
are first captured with a coarse-grained model. Events of interest can be further modelled by 
reconstructing the coarse-grained model to atomistic resolution at specified time points (Heath 
et al., 2007). This allows for more detailed information about the system to be captured and 
avoids the need of performing longer atomistic simulations in the beginning. 
A list of commonly used MD software packages is presented in Table 6.3. For the purpose of 
this research, GROMACS (version 5.1.4) was selected due to the in-house expertise available 
at Newcastle University. In addition, GROMACS is able to incorporate the MARTINI force 
field used for coarse-grained modelling. This is of added benefit due to the increasing popularity 
of MARTINI and the many advancements made to the force field which have increased the 
model accuracy to almost rival that of atomistic (Marrink and Tieleman, 2013). 





OS Availability Reference 
AMBER YES NO YES Window, 
Linux 
Commercial (Salomon‐Ferrer 
et al., 2013) 
CHARMM YES NO YES Linux Commercial (1) (Brooks et al., 
2009) 
GROMACS YES YES (2) YES Linux Free (Van Der Spoel 
et al., 2005) 
MOE YES NO YES Windows, 
Linux 
Commercial (MOE, 2018) 
NAMD YES YES (2) YES Windows, 
Linux 
Free (Phillips et al., 
2005) 
(1) A reduced version of CHARMM can be acquired for free. 
(2) Uses the MARTINI force fields 
 
6.4.1 Force Fields 
In order to calculate the forces acting in a system, the potential energy, 𝑈(𝒓𝑁), for each atom 
needs to be defined where 𝒓𝑁 = (𝒓1, 𝒓2, … , 𝒓𝑁) are the Cartesian coordinates for the N atoms 
in the system. The molecular interactions can be approximated with mathematical expressions 
to represent different interactions of the system. An equation for approximation of the total 
potential energy in a system can be written as (Leach, 2001b): 
 
 𝑈(𝒓𝑁) = 𝑈𝑏𝑜𝑛𝑑𝑠 + 𝑈𝑎𝑛𝑔𝑙𝑒𝑠 + 𝑈𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠 + 𝑈𝑐𝑜𝑙𝑢𝑚𝑏 + 𝑈𝑣𝑑𝑤 (6.4) 
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As shown, the interactions can be divided into two categories of bonded (green solid lines) and 




Figure 6.5. (a) The bonded interactions originating from bond stretching, angle bending and bond torsion 
(rotation). (b) The non-bonded interactions originating from electrostatic and van der Waals potentials (adapted 
from Allen (2004) and Leach (2001b)). 
The bonded interactions represent the potential energies originating from the covalent bonds 
and steric conformation of the structure in the form of bond stretching, angle bending and 
torsion from bond rotations. Resulting potential energies from the bonded interactions are 
shown in Figure 6.6 and were adapted from the GROMACS manual 5.1.4 (Abraham et al., 
2016). 
The potential from the bond stretching between two atoms is approximated using Hooke’s law 







𝑏 (𝑟𝑖𝑗 − 𝑟𝑒𝑞)
2 (6.5) 
   
 where 𝑟𝑖𝑗 = |𝒓𝑖𝑗| and 𝒓𝑖𝑗 = 𝒓𝑖 − 𝒓𝑗  
 
which in turn takes on the following expression for the force: 
 
 𝑭𝑏𝑜𝑛𝑑𝑠
𝑖 (𝒓𝑖𝑗) = −𝑘𝑖𝑗







𝑏  is the spring constant where a higher value prevents greater bond stretching. 
The variable 𝒓𝑖𝑗 is the bond vector between two atom positions with the magnitude or bond 
length 𝑟𝑖𝑗. The constant 𝑟𝑒𝑞 is usually referred to the natural bond length where the potential 
energy is at its lowest.  
The potential energy from angle bending (see Figure 6.6b) is also frequently described using 







𝜃 (𝜃𝑖𝑗𝑘 − 𝜃𝑒𝑞)
2 (6.7) 
 




























𝜃  is the spring constant where higher values prevent bending making the 
structure more rigid. The variable 𝜃𝑖𝑗𝑘 is the angle between two connecting bonds from three 
atomic positions. The constant 𝜃𝑒𝑞 represents the natural angle based on the atom types of the 
three atoms.  
The torsion potential is almost always expressed as a cosine Fourier series expansion with m =
1,2,… ,M (Leach, 2001b). The torsion is defined by three connecting bonds and therefore 












The expression for the resulting torsion force is not shown due to being much more extensive 
than previous forces. The constant 𝑘𝑖𝑗𝑘𝑙
𝛷,𝑚
 is the magnitude of the torsion potential, m represents 
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the which series in the series expansion, the variable 𝜑𝑖𝑗𝑘𝑙 is the torsion angle and 𝛾𝑚 is the 
phase factor which describes at which angle the potential energy is at its lowest. Figure 6.6c 
shows the potential energy from the torsion of an arbitrary molecule bond where the energy is 
at its lowest when with less steric clashes occurs (staggered conformation) and at its highest 
when more steric clashes occurs (eclipsed conformation). 
 
 
Figure 6.6. Potential energy of bonded interactions. (a) An approximation of the potential energy in the bond 
stretching using Hooke’s law as a function of the distance between two bonded atoms. (b) The potential energy 
from angle bending as a function of the angle between two connecting bonds and approximated with Hooke’s law. 
(c) Approximation of the potential energy from bond torsion as a function of the bond angle. Highest potential is 
observed in eclipsed conformation and lowest in staggered conformation (adapted from the GROMACS manual 
5.1.4). 
The non-bonded interactions represent the potential energies originating from electrostatic and 
van der Waals interactions. These include both internal interactions in the protein as well as 
external interactions from the solvate. Resulting potential energies from the non-bonded 
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interactions are shown in Figure 6.7 and were adapted from the GROMACS manual (Abraham 
et al., 2016). 
Potential energies originating from van der Waals interactions are commonly described by 
using the Lennard-Jones (Jones, 1924) equation: 
 
 



























The constant 𝜀 defines the depth of the potential well whereas the constant 𝜎 defines the 
distance between two atoms when the potential is at a minimum. It can be observed in Figure 
6.7b that an arbitrary attraction occurs when the distance is 3 Å between two atoms, this is 
similar to that of the Morse potential seen in Figure 6.6a but lacks a physical bond. The 
magnitude of the Lennard-Jones potential is also much lower compared to that of the Morse 
potential. 
The electrostatic potential energy between two charged atoms in the system can be described 










The electrical potential takes on the familiar expression of coulombs law when converted into 














The variable 𝑞 is the charge of the atom and 𝜀0 is known as the permittivity constant. It can be 
observed through Figure 6.7b that the potential energy increases with shorter distance between 
charges. When of same charge the atoms will repel each other while different charges will 
attract each other. 
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Figure 6.7. Potential energy of non-bonded interactions. (a) The electric potential as a function of distance between 
two charged points. (b) The van der Waals potential approximated with Lennard-Jones potential (green line) as a 
function of the distance between two non-bonded atoms. Consists of one repulsion (orange dashed line) and one 
attraction (orange full line) component (adapted from the GROMACS manual 5.1.4). 
It should be mentioned that the hydrogen bond, which is a common non-bonded interaction in 
proteins, is not treated as a separate bond type in the force fields but rather as a combination of 
Lennard-Jones and electrostatic potential instead. 
In comparison to the bonded interactions, the number of non-bonded interactions that needs to 
be evaluated in a system increases with the order of 𝑁2 due to the fact, that any pair of atoms 
in the system can interact. To avoid time-consuming simulations or, in worst cases, system 
crashes, cut-off schemes are used to reduce the number of potential long-range calculations that 
needs to be performed. Commonly applied is Particle Mesh Ewald (PME) summations which 
consists of short-range contributions and long-range contributions. Short-range interactions are 
determined by a predefined cut-off radius (commonly 1 nm) to identify neighbouring atoms to 
the atom of interest. If the distance is less than the defined cut-off radius, the atom is included 
in the force calculation and a so-called neighbours list is created that specifies the neighbouring 
atoms to the atom of interest which was first proposed by Verlet (1968). Long-range 
interactions are atoms with distances exceeding the defined cut-off radius from the atom of 
interest and are instead calculated with Fourier transform from the real space to the reciprocal 
space which allows for faster computation.  
As can be observed, equations (7.5), (7.7), (7.9), (7.10) and (7.12) contain parameters for 
optimal bond lengths, angles, potential wells, force constants etc that needs to be specified. Put 
in simple terms, a force field is a list of parameter values for different atom types with 
corresponding equations that are used to calculate the potential energy of the system (Allen, 
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2004). Ii is important to note that an atom type should not be confused with an element from 
the periodic table. The definition of an atom type here involves the hybridisation state and/or 
the charge of the atom as well as the type of connected atoms. For example, carbon will have 
several atom types which describe different hybridisation states and surroundings. This in turn 
means that they will behave slightly different from each other and therefore need to be described 
with a unique set of parameters for each atom type. This also makes the number of atom types 
listed in the force fields much more numerous than the number of elements in the periodic 
system.  
Table 6.4 gives a non-exhaustive list of popular force fields that are used in MD simulations 
currently where several different versions of the AMBER, CHARMM and GROMOS force 
fields exists. Only slight variations exist between the different force fields which include 
differences in parameter values or slight differences in the potential energy equations, usually 
in the non-bonded interactions (Allen, 2004). The estimation of the parameters for different 
atom types are almost always carried out with QM calculations or taken from experimental 
measurements (Kmiecik et al., 2016).  
Table 6.4. Non-exhaustive list of popular force fields. 
Force Field Parameter determination Reference 
AMBER Multi-purpose force field widely used for proteins and DNA 
simulations 
(Cornell et al., 1995) 
CHARMM Multi-purpose force field widely used for both small and 
macromolecule simulations 
(Brooks et al., 1983) 
GROMOS First developed for simulations of protein or DNA in 
hydrophobic solvent. Now the force field is multi-purpose. 
(Oostenbrink et al., 
2004) 
OPLS-AA Multi-purpose force field  (Jorgensen et al., 1996) 
 
In this research, the atomistic amber99sb-ILDN force field was used to simulate the dynamics 
of the antibody Fab fragments. The authors Lindorff‐Larsen et al. (2010) modified the original 
amber99sb force field to more accurately describe side chain torsions in a protein. 
6.4.2 The MD Algorithm and Time Integration 
The global MD algorithm is shown in Figure 6.8 and consists of four steps (adapted from the 
GROMACS User Manual 5.1.4 (Abraham et al., 2016)).  
In the initial step of any MD simulation, the positions and velocities for each atom in the system 
need to be specified. Atom positions can be acquired through PDB files from either 
experimental data or a predicted structure (see Section 6.2). Usually no velocities are available 
when starting a new simulation project unless it is a continuation of a previous simulation. In 
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these cases, the Maxwell-Boltzmann distribution can be used to randomly assign initial 












Lastly, a force field needs to be selected to describe the potential energy function and 
interactions in the system and will not be changed throughout the simulation. 
The forces in the system are then calculated from the potential energy of the system in step two. 
The resulting force on each atom is calculated as a vector sum based on all interactions from 
surrounding atoms (see Section 6.4.1). This step also involves all corrections applied to the 
system in order to maintain or change the thermodynamic macrostate by controlling the system 
volume, temperature and pressure. This is further explained in Section 6.4.4. 
 
 
Figure 6.8. Four steps of the global MD algorithm. Step 1) Positions and initial velocities are assigned and a force 
field chosen. Step 2) Calculation of resulting forces on all atoms in the system. Step 3) Updates the positions and 
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velocities of all atoms in the system. Step 4) Saves specified information to a log file (adapted from the 
GROMACS User Manual 5.1.4).  
The third step in the MD algorithm updates the positions of all atoms in the system based on 
the calculated forces in step two. This is done by numerical integration in order to approximate 
the resulting velocities and positions of the atoms in the system. Two popular approaches that 
commonly used to perform the integration are the Verlet velocity algorithm (Swope et al., 1982) 
and the Verlet leapfrog algorithm (Hockney and Eastwood, 1988) where the later will be 














   
 
𝒓𝑖(𝑡 + ∆𝑡) = 𝒓𝑖(𝑡) + 𝒗𝑖 (𝑡 +
1
2
∆𝑡) ∆𝑡 (6.16) 
 
where 𝒗𝑖 and 𝒓𝑖 are the velocity and the position of atom 𝑖 and ∆𝑡 is the timestep used in the 
numerical integration. In the leapfrog algorithm, positions are updated at each full time-step 
(𝑡 + ∆𝑡) (6.15) while the velocities are updated at each half time-step (𝑡 + ∆𝑡/2) (6.16) thus 
making the atomic position and velocity jumping over each other like two leaping frogs. This 
allows for more accurate calculations of the velocities as compared to if the positions and 
velocities would have been synchronised. 
In MD simulations, the time step ∆𝑡 needs to be sufficiently large in order to efficiently simulate 
the protein dynamics without unnecessary resampling of the conformational space. However, 
if a too big a time step is selected it can cause instability and inaccuracies when the subsequent 
atom positions are calculated resulting in unfavourable conformations and high potential 
energies. A rule of thumb is to adapt the time step to the smallest local motion in the system in 
order to avoid this problem. Usually, a default time step of 2 fs is used in MD simulations today. 
It is important to note that the vibration period of the hydrogen bonds is shorter than the timestep 
of 2 fs and therefore cannot be accurately sampled. In order to avoid instability, the hydrogen 
bonds are constrained with the LINCS algorithm which keeps the length of the hydrogen bond 
constant throughout the simulation. 
6.4.3 Periodic Boundary Conditions 
Even with advancement of computational power the actual size of the system to be simulated 
is extremely small compared to a real-world setting. This also means that the surface to volume 
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ratio in the simulation is much higher compared to a real experimental setup which can 
introduce artefact caused by surface effects. Unless this is the aim with the simulation, a way 
to avoid this problem is to use so called Periodic Boundary Conditions (PBCs). In the event 
where a molecule exits the simulation box it will automatically re-enter the system on the 
opposite side with its trajectory preserved as can be seen in Figure 6.9a. This effectively means 
that the system has been enlarged by infinity. Caution needs to be exercised in order to avoid 
self-interaction of example a protein. This is commonly avoided by making sure that the 
distance between the protein to the edge of the simulation box is at least three solvation layers 
wide which roughly translates to 0.9 – 1.0 nm (González, 2011). This concept is shown in 
Figure 6.9b where the cut-off radius is illustrated as the dashed red circles surrounding a particle 
of interest. The system size is adequately chosen in this case where the particle of interest will 
not self-interact as well as overlap between the circles have been avoided thus making sure that 
potential water molecules in the systems are not affected by the particle from adjacent boundary 
cells (adapted from (González, 2011)). 
 
 
Figure 6.9. The application of the periodic boundary condition in a simulation. (a) Movement of particles out of 
the simulation box will enter the opposite. (b) Depicts the cut-off radius for long-range interactions as the dashed 
red circle and the importance of choosing a proper box size in order to avoid overlap and self-interaction (adapted 
from González (2011)). 
The shape of the PBC can also be changed in order to optimise the simulation if a rectangular 
box introduces too many water molecules into the system when solvated. Preferably, the shape 
of the PBC should be chosen so it reflects the underlaying geometry of the macromolecule e.g. 
a Truncated Octahedron or a Rhombic Dodecahedron can be used for simulation of globular 
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proteins whereas a hexagonal prism can be used for simulation of a rod like protein or DNA 
(Leach, 2001a). 
6.4.4 Thermodynamic macro and microstates 
In order to properly simulate a system, it is important to make sure that the simulation accurately 
captures its thermodynamic properties. So far, the main discussion has been about atom 
interactions and motions in a system of interest. The positions and velocities of the atoms are 
commonly referred to as thermodynamic microstate variables, which in turn define the 
thermodynamic macrostate properties of volume, pressure and temperature in a system. It is 
important to remember that a macrostate with a set volume, temperature and pressure can be 
described by several different microstates whereas the opposite is not possible where instead 
one microstate will have single corresponding macrostate. This is easier understood when 
considering a smaller system containing a few atoms with defined positions and velocities. If 
two of the atoms were to swap velocity directions and magnitudes, the microstate of the system 
would change due to the change in the microstates variables whereas the macrostate will still 
be conserved. 
This is an important aspect that needs to be considered in order to correctly simulate a real-
world experiment where a specific temperature, volume and pressure are used. The absolute 














(3𝑁 − 𝑁𝐶) (6.17) 
 
𝑘𝐵is Boltzmann’s constant, 𝑁𝐶 is the number of constraints applied on the system and 3𝑁 − 𝑁𝐶 
is the total number of degrees of freedom in the system. The pressure, 𝑝, can be calculated by 
using the total kinetic energy and the virial of the system shown in (6.18) below. 
 
 
𝑝 =  
2
3𝑉
(𝐸𝐾𝑖𝑛 − 〈𝑇〉) (6.18) 













𝑉 is the system volume and 〈𝑇〉 is the virial or the expected value of the sum of products between 
atom coordinates and the forces acting on them (Berendsen et al., 1984). The brackets represent 
the average value over time. 
When performing a MD simulation, several different simulation ensembles are available that 
that restrains the system by keeping some of the thermodynamic properties constant while 
allowing other to fluctuate. The choice of which ensemble to use depends heavily on how the 
system should behave and the aim of investigation.  Three commonly used ensembles are NVE, 
NVT and NPT where all ensembles have a constrained number of atoms (N). The NVE 
ensemble is a so-called micro-canonical ensemble with constrained volume (V) and energy (E) 
and is most often used to study the conformational energy landscape. The NVE ensemble 
should never be used to equilibrate a system as the desired temperature can never be reached 
when the energy is conserved. The NVT ensemble is a canonical ensemble and thus in thermal 
equilibrium with constrained volume and temperature (T). This type of ensemble is often used 
to simulate biological reactions. The NPT ensemble is an isothermal–isobaric ensemble with 
constrained pressure (p) and temperature and is commonly used to simulate chemical reactions 
in environments where the pressure is maintained such as open atmosphere reactions. Both the 
NVT and NPT ensembles are commonly used for system equilibration to reach specified 
temperature and pressure in order to replicate experimental environments. More detailed 
descriptions on the different ensembles are reviewed elsewhere (Brown and Clarke, 1984). 
In order to maintain the desired thermodynamic parameters of a system in a simulation, the use 
of so-called coupling schemes becomes necessary in order to control parameters of interest such 
as the temperature and pressure of the system.  
The temperature can be controlled by using thermostats. The Berendsen (Berendsen et al., 1984) 
and Velocity-rescaling thermostats (Bussi et al., 2007) controls the temperature by directly 
scaling the velocities of the atoms in the system through first-order decay. The Berendsen and 
Velocity-rescaling thermostats are known as coupling methods. Alternatively, the Nosé-Hoover 
thermostat (Nosé, 1984, Hoover, 1985) can be used and works by adding an extra correction 
term to the Newton’s equation of motion seen in Figure 6.8 which subtracts or adds to the atom 
velocities in the system if the temperature is too warm or too cold, respectively. The Nosé-
Hoover thermostat is a so-called extended system dynamics method. The three listed 
thermostats are virtually linked to a heat bath with constant temperature through which heat is 
exchanged as illustrated in Figure 6.10. This also means that the energy will no longer be 
conserved in the system and will change depending on the temperature difference between the 




Figure 6.10. A system coupled to a virtual heating bath illustrating the heat exchange between the heat bath and 
the system of interest (adapted from Ghiringhelli (2014)). 
The pressure, similarly to the temperature, is controlled by using barostats. A commonly used 
weak coupling method is the Berendsen barostat (Berendsen et al., 1984) which is similar to 
the Berendsen thermostat but instead scales the dimensions of the system in order to achieve 
the desired reference pressure. Alternatively, the Parrinello-Rahman barostat is an extended 
system dynamics method similar to that of the Nosé-Hoover thermostat where the volume 
becomes and extra variable (Parrinello and Rahman, 1981). This allows the system size to vary, 
thus contracting or expanding the system if the pressure is too low or too high, respectively, 
compared to the desired reference pressure. 
6.4.5 GROMACS System Equilibration 
In this research, the GROMACS guidelines for system equilibration were used prior to any 
production runs in order to emulate real-world experimental conditions (Abraham, 2014). Four 
equilibration steps were performed with a final production run at the end according to the steps 
below: 
1. Solvation of the system 
2. Energy minimisation (EM) 
3. Temperature increase to target value through NVT ensemble 
4. Adjustment of pressure to target value through NPT ensemble 
5. MD production run 
The first step involves specifying the periodic boundary conditions to define the simulation box 
and then filling the empty space with water molecules and counter ions to buffer the system. A 
common practice is to add chloride and sodium ions to counter the charges of the protein to get 
a system with a net charge of zero. 
The EM is a crucial step that prevents the system from “blowing up” when equilibrated due to 
potential close proximities and steric clashes between atoms which can result in large forces. 
These clashes originate partly from the protein structure that, if predicted, might not be 
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completely relaxed and therefore structurally unfavourable (see Section 6.2.4). Another source 
is clashes originating from the addition of the solvate to the system where potentially some 
water molecules might have been placed too close to the protein. The energy minimisation 
conformationally resolves these clashes by relaxing the system through rotational and 
directional motions of the clashing atoms, thus lowering the energy of the system (Leach, 
2001c). Several methods exist to perform the EM where derivative minimisation methods are 
most commonly used. First-order methods such as steepest descent and conjugate gradient are 
fast methods that use the first derivative or gradient to find the energy minima but with the 
drawback that they can get stuck in local minima. Second-order derivative methods, such as 
quasi-Newton and L-BFGS, include information about the energy curvature and are less likely 
to get stuck at local minima but are more computationally intensive due to the need to calculate 
the Hessian matrix (second derivative matrix). For more detailed information on the listed 
minimisation methods, refer to the following work (Schlick, 1992). The steepest descent 
minimisation was used in all simulations due to its speed compared to quasi-Newton and L-
BFGS.  
In the third equilibration step, an NVT ensemble was used to raise the temperature of the system 
to a desired target value. Initial velocities in the system were assigned with the Maxwell-
Boltzmann distribution presented in eq.(6.14) according to a target temperature of 300 ºK. 
Position restraints were added to the backbone of the proteins in order to avoid structural 
collapse due to the rapid heating of the system. The restraints added followed Hooke’s law 
where a virtual spring was attached between the backbone atoms and their original position in 
space as described by eq.(6.6). A high value was used for the spring constant to keep the 
backbone rigid. This allowed for further relaxation of the protein side-chains and solvent 
molecules while the system is heated as well as avoids large conformational changes of the 
protein structure caused by rapid heating. The ensemble was allowed to run until the 
temperature of the system had reached the desired target value with little fluctuation. This step 
was performed using the Velocity-rescaling thermostats in all simulations.  
Due to the volume being kept constant in the NVT ensemble, the resulting pressure will be 
offset compared to the desired target value at the end the NVT run. Therefore, in the fourth 
equilibration step, a NPT ensemble was used to adjust the pressure in the system to 1 bar with 
the Parrinello-Rahman barostat. The system temperature was kept constant through continued 
use with the Velocity-rescaling thermostat. By correcting the pressure, the volume of the system 
will inevitably change and will no longer conform to the initially defined dimensions. This 
however is of little consequence as the goal is to emulate the temperature and pressure in a real-
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world experiment. Additionally, similar to the previous step the backbone was kept restrained 
in order to avoid structural collapse while equilibrating the pressure. 
In the fifth and final step, a production run was performed as a continued NPT ensemble with 
a temperature of 300 ºK and a pressure of 1 bar. The backbone constraints on the proteins were 
removed to allow the protein to adjust to the environment. In order to capture the dynamics of 
the system a simulation time of 50 ns was used. 
6.5 Modifications of protein structure and solvent  
In addition to steps described in Section 6.4.5, two more considerations were made to increase 
the fidelity of the performed simulations.  
6.5.1 Co-solvent preparation 
The standard simulations in GROMACS are performed in water together with the counter ions 
sodium and chloride. Real experiments however will usually have additional ions and 
molecules that are added to either influence the stability of the protein or due to being necessary 
in particular experiments/process steps. A workflow depicting the preparation of small 
molecule co-solvents is illustrated in Figure 6.11a. In this research the ChemSpider database 
was used to find structural information of co-solvents of interest (Pence and Williams, 2010). 
ChemSpider provides the SMILE format for all listed small molecules which describes the 
connectivity properties between the atoms in the compound. The Build Structure feature in 
USCF Chimera (version 1.13) was then used to convert the SMILE format into a MOL2 format 
which in addition to describing the connectivity have generated space coordinates for the atoms 
in the compound (Pettersen et al., 2004). Alternatively, OpenBabel can be used instead of 
Chimera which is more specialised and allows for conversion of nearly all the chemical formats 
for small molecules (O'Boyle et al., 2011).  
In GROMACS when reading in a protein structure, the software will generate a corresponding 
structure file (e.g. protein.gro) as well as a topology file (topol.top). The structure file will 
contain the coordinates for all atoms in the system, including all atoms in the protein, solvate 
and co-solvents. If a previous simulation of the system has been performed such as EM, NVT 
or NPT, the structure file will also contain the initial velocities for each atom in the system that 
will be used for the next chronological simulation. The topology file on the other hand is a list 
that describes the properties of all the atoms in the system such as the atom types, masses and 
charges. The topology file also lists the connectivity of the atoms in the system to describe all 
pair-wise bonds (two atoms), angles (three atoms) and torsions (four atoms) with corresponding 
force field parameters. These are used to perform the calculations of the potential energies 
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described in Section 6.4.1. Any additions to the simulation system in the form of solvents or 
other particles will also be included in the topology file and their properties described. For 
proteins that consist of multiple chains that are connected with disulphide bonds such as mAbs, 
all chains can be merged into a single structure. This allows for cysteines between chains to be 
connected and is necessary in order to properly represent the mAb structure. This in turn will 
generate a single topology file for the merged structure. Alternatively, multiple chains can be 
represented by using multiple topology files that describe the individual chains. However, 
interchain disulphide bonds cannot be defined if used, thus increasing the risk of system 
instability. 
In the last step when adding a custom co-solvent, the AnteChamber PYthon Parser interface 
(ACPYPE) was used in order to generate additional structure and topology files for the co-
solvent that could be used in the simulation (Sousa da Silva and Vranken, 2012). For the 
purposes of this research the topologies were generated using the General Amber Force Field 
(GAFF) for small molecules with AM1-BCC calculations for estimation of charges (Wang et 
al., 2004). The co-solvent topology file was then referenced in the protein topology file in order 
for GROMACS to be able to use the new co-solvent. 
To acquire the correct concentration of co-solvent in the simulation there was a need to calculate 
the number of molecules to be added to the simulation box. This was based on the total number 
of water molecules present in the simulation box and calculated according to stoichiometric 








𝑁𝑐𝑠 is the total number of co-solvent molecules, 𝑁𝑤𝑎𝑡𝑒𝑟 is the total number of water molecules, 
𝑀𝑤𝑎𝑡𝑒𝑟 is molar mass of water (18.0153 g/mol), 𝜌𝑤𝑎𝑡𝑒𝑟 is the water density at 300 ºK (997 g/l) 
and 𝐶𝑐𝑠 is the target concentration of the co-solvent (mol/l). The calculated number of molecules 
were then added to the simulation box by using the insert-molecule function in GROMACS 



















































































































































































































































































































































































6.5.2 Modification of residue protonation states 
Another parameter that is often likely to change is different experimental setups and operational 
units in industrial processes is the pH which affects the protonation states of ionisable residues. 
Most often when running a MD simulation, the default protonation states in the acquired 
structure are used. This might not, however, represent the true protein structure due to 
differences between the protonation states in an experiment and that of the simulation. This can 
have a negative impact on the dynamics due to wrong assumptions are made in the electrostatic 
interactions.  
The workflow illustrated in Figure 6.11b was used to modify the protein structure to better 
conform to a specific pH. In this research, a local installation of the ProteinPrepare suite which 
is part of the High-Throughput Molecular Dynamics (HTMD) environment (Acellera Ltd) was 
used to modify the protonation states of acidic and basic residues in the protein structures prior 
to simulations (Martinez-Rosell et al., 2017). More specifically, ProteinPrepare makes use of 
PROPKA (version 3.1) to predict the pKa values of any acidic and basic residues that are present 
in the protein  (Olsson et al., 2011, Sondergaard et al., 2011). The PROPKA tool takes into 
consideration the locations of the acid/base residues as well as surrounding residues that can 
impact on the pKa. For buried residues the pKa value is adjusted in order to drive charged 
residue to become more neutral. Buried negatively charged residues (acids) have increased pKa 
values while buried positively charged residues (bases) have their pKa value lowered. This is 
also impacted by proximity of other ionisable residues which further modifies the pKa values 
of the residues. ProteinPrepare then compares the predicted pKa values towards that of a target 
pH value in order to assign the protonation states of the residues. Table 6.5 lists all ionisable 
residues together with the three-letter code for the different protonation states. 
Table 6.5. List of residue protonation states  
Amino acid Type 
Protonation states 
Positive Neutral Negative 
Aspartic acid Acid - ASH ASP 
Cysteine (1) Acid - CYS/CYX CYM 
Glutamic acid Acid - GLH GLU 
Tyrosine (2) Acid - TYR TYM 
Arginine (3) Base ARG AR0 - 
Histidine Base HIP HID/HIE - 
Lysine (3) Base LYS LYN - 
(1) Cysteines involved in disulphide bridges are coded as CYX while free cysteine is coded as CYS. 
(2) Does not naturally occur as negatively charged which requires very high pH values 
(3) Does not naturally occur as neutral which requires very high pH values 
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If two cysteines are in close proximity then ProteinPrepare will assign them as CYX, meaning 
that they are involved in a disulphide bridge. The software will assign a pKa value of 99 to all 
CYX residues in order to avoid deprotonation in the event when a high target pH is used. 
Caution should be exercised as well when a high target pH value is used that drives tyrosine to 
become charged as well as arginine and lysine to become neutral. The resulting structure will 
not be useable in any MD simulation due to that the topologies for these protonation states will 
not exist in any force field. 
Protonation of residues according to the predictions from PROKPKA were performed with 
PDB2PQR (version 2.1) inside of ProteinPrepare (Dolinsky et al., 2004, Dolinsky et al., 2007). 
As a final step, PDB2PQR performed an energy minimisation of the structure by rotating and 
flipping the side-chains to allow the structure to become more relaxed where the AMBER99 
force field was used. The final structure was then exported as a PDB file. 
The effect of assigning different environmental pH values is illustrated in Figure 6.12 where 
the electrostatic surface of adalimumab Fab fragment is shown with positive charges depicted 
in blue, neutral in white and negative charges in red. When the pH is low (=2) the negatively 
charged residues (acids) become neutral due to becoming protonated resulting in a highly 
positively charged surface. Through incremental increase of the pH it can be observed the 
negatively charged residues and positively charged residues (bases) become deprotonated 
resulting in a more negatively charged surface. 
 
 
Figure 6.12. Impact of pH on the electrostatic surface of adalimumab Fab fragment. At a pH of 2 the surface is 
predominately positively charged (blue) and shift to become more negatively charged (red) with increasing pH. 
The figure was generated from surface renderings using USCF Chimera (version 1.13). 
The structure optimisation step with PDB2PQR is not necessarily needed due to the energy 
minimisation that is performed when equilibrating the system in GROMACS. An alternative 
approach would be to use PROPKA3.1 to predict the pKa values for the residues and manually 
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assign the protonation states of the residues according to a target pH by using the optional inputs 
in the pdb2gmx function in GROMACS. 
6.6 Descriptor Generation 
A summary of the software packages that have been used in this research for the preparation 
and the simulation of proteins structures and dynamics is listed in Table 6.6. A general overview 
of the protein preparation and simulation is also illustrated in Figure 6.13 which shows the 
protein structure prediction with MODELLER, the protein dynamic simulation with 
GROMACS as well as the descriptor generation from the resulting output from GROMACS.  
In order to generate meaningful descriptors, it was necessary to first extract a structure from the 
production run simulations that were in conformational equilibrium. This section describes in 
detail how the final structure was acquired from the GROMACS simulations as well as how 3D 
structure descriptors were generated.  
Table 6.6. List of software packages used in this research to prepare and simulate the protein structure and 
dynamics. 
Software Version Description 
MODELLER 9.20 Used for structure prediction from primary sequence with the help of PDB 
templates. Implemented to restrain distances between cysteines involved in 
disulphide bridges. 
GROMACS 5.1.4 Simulation software to estimate the protein dynamics of a target protein 
structure in a defined environment. 
CHIMERA 1.13 Visualisation and analysis software. Useful for editing structure and fill in 
missing loops. 
VMD 1.9.2 Visualisation and analysis software. Useful for calculation of protein 
RMSD and RMSF as well as visualising the dynamic of the protein 
through a playback function of the trajectories. 
ACPYPE 0.1.0 Software that simplifies the generation of small molecule topologies and 
parameters that are compatible with many existing forcefields such as 
AMBER and CHARMM. 
PROPKA 3.1 Software for the prediction of pKa values of acidic and basic residues in a 
protein structure. PROPKA takes into account if the residue is buried or 
accessible on the surface in order to perform more accurate calculations. 
PDB2PQR 2.1 Fills in any missing heavy atoms and adds hydrogen atoms according to 
protonation states computed from PROPKA. Also optimises structure by 
















































































































































































































































































































6.6.1 Time frame selection 
Due to the constraints placed on the backbone in production run, relaxation of the structures 
occurred in the beginning of the simulation for each mAb. This is illustrated in Figure 6.14 
which shows the conformational change of adalimumab simulated in water. It can be observed 
in Figure 6.14a that a conformational shift occurs from its original conformation (t=0) to a more 
relaxed conformation (t=5) which is then retained throughout the rest of the simulation 
indicating that an equilibrium has been reached. The RMSD used in the figure is a measurement 
of atomistic deviation over time from a reference structure where the constrained structure from 
the previous NPT equilibration was used. This conforms to the idea of the energy landscape 
illustrated in Figure 6.3a where the protein structure will strive to attain as low conformational 
energy as possible. It also illustrates the structure bias from MODELLER where the predicted 
structure is biased towards the template and not necessarily in a relaxed state. 
Further analysis showed that the smaller fluctuations (vibrations) observed in Figure 6.14a were 
due to local motions of the loops and turns in the mAb and are illustrated as the peaks in Figure 
6.14b and Figure 6.14c for the light chain and heavy chain, respectively. The RMSF values 
used in the figures are temporal averages of the atomic trajectories (i.e. motions) in space of the 
residues, thus capturing the residue fluctuation over time. The RMSF values in the figures were 
calculated from the protein motions acquired after equilibrium had been reached until the end 
of the simulation.  
Based on these facts, the extraction of the structure was therefore performed by selecting a time 
frame located in the equilibrium interval of the simulations. The timeframe was selected 
towards the end of each simulation in order to allow the structures to relax and reach 
conformational stability. This was due to the fact that relaxation times between mAbs varied, 
thus introducing uncertainty of conformational stability if earlier timeframes were used. This is 
covered more in detail in Section 7.1.2 which discusses the simulation results for the 137 mAbs 
in the publication of Jain et al. (2017). 
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Figure 6.14. MD simulation result for adalimumab. (a) The conformational change of adalimumab evolving over 
time in the production run. (b) The average fluctuations of the individual residues in the light chain between t=5 
ns and t=50 ns. (c) The average fluctuations of the individual residues in the heavy chain between t=5 ns and t=50 
ns. 
6.6.2 Descriptor software and calculations 
Similar to the primary sequence-based descriptors, ProtDCal was used for generation of 3D 
structure descriptor by using the acquired PDB structures from the MD simulations as input 
(Ruiz-Blanco et al., 2015). GROMACS was used to generate the solvent accessible surface area 
(SASA) for the residues in the mAbs which were used as basis or modification of many of the 
generated descriptors. Table 6.7 lists the descriptors. Focus was placed on descriptors pertaining 




Table 6.7. List of energy and topological descriptors used to describe the protein structure 
Descriptor ProtDCal GROMACS Type Description 
𝑮𝒄(𝑭) ●  Energy Contribution to the free energy from the 
conformational entropy in a folded state 
𝑮𝑾(𝑭) ●  Energy Contribution to the free energy from the 
entropy of the first shell of water 
molecules in a folded state 
𝑮𝒔(𝑭) ●  Energy Interfacial free energy of a folded state 
𝑾(𝑭) ●  Energy Number of water molecules close to a 
residue in a folded state 
𝑯𝑩𝒅 ●  Energy Number of hydrogen bond in the 
backbone of the protein 
𝚫𝑮𝒔 ●  Energy Variation of the interfacial free energy 
between folded and unfolded states 
𝚫𝑮𝑾 ●  Energy Contribution to the folding free energy 
of the first shell off water molecules 
𝚫𝑮𝒆𝒍 ●  Energy Free energy contribution of the charge 
distribution within the protein 
𝚫𝑮𝑳𝑱 ●  Energy Contribution of the Van der Waals 
interaction to the folding free energy 
𝚫𝑮𝒕𝒐𝒓𝒔 ●  Energy Contribution of the dihedral torsion 
potential to the folding free energy 
𝑺𝑨𝑺𝑨𝒑𝒐𝒍𝒂𝒓   ● Topological The total solvent accessible surface area 
from the polar residues 
𝑺𝒑𝒐𝒍𝒂𝒓  ● Topological The effective surface polarity from the 
charged and polar residues  
𝑺𝑨𝑺𝑨𝒏𝒐𝒏−𝒑𝒐𝒍𝒂𝒓  ● Topological The total solvent accessible surface area 
from the non-polar residues 
𝑺𝒏𝒐𝒏−𝒑𝒐𝒍𝒂𝒓   ● Topological The effective surface hydrophobicity 
from the non-polar residues 
𝒍𝒏(𝑭𝑫) ●  Topological Logarithm of the folding degree 
 
In addition, 37 Transferable Atom Equivalent (TAE) descriptors were used in order to describe 
electron and charge densities of the mAbs. TAE is in simple terms a library of empirical atomic 
charge density components that are used to construct electron densities able to describe the 
protein surface of individual amino acids (Breneman and Rhem, 1997). 
The TAE descriptors used in this research were available in ProtDCal as listed value for each 
amino acid. This meant that the generated TAE descriptors were based on the amino acid 
composition in ProtDCal rather than feature of the protein and therefore no different from using 
the primary sequence as input. In order to conform these descriptors to represent the surface of 
the mAb the generated SASA values from GROMACS were used according to eq.(6.21). The 
equation calculates the fraction of each amino acid that is accessible to solvent and is known as 
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 is the resulting 𝑘𝑡ℎ TAE descriptor for the surface, 𝑆𝐴𝑆𝐴𝑖 is the solvent accessible 
surface area of residue 𝑖, 𝑀𝑎𝑥𝐴𝑆𝐴𝑖 is the maximum accessible surface area of a residue 𝑖, 
𝑇𝐴𝐸𝑖𝑘 it the 𝑘𝑡ℎ listed TAE descriptor for residue 𝑖 and 𝑅𝑆𝐴𝑖 is the relative surface area of 
residue 𝑖. The 𝑀𝑎𝑥𝐴𝑆𝐴 value is defined as the accessible surface area of an amino acid X in a 
Gly-X-Gly tripeptide conformation. Published empirical values from Tien et al. (2013) were 
used to calculate the descriptor in this research.  
In a similar fashion, descriptors for describing the hydrophobicity, eq.(6.22), and the polarity, 
eq.(6.23), of the surface were generated by using the Kyte-Doolittle scale. Specifically, the 
hydrophobicity of the surface was calculated by using the nine in the NPR amino acid group in 





















𝑆𝑛𝑜𝑛−𝑝𝑜𝑙𝑎𝑟is the surface descriptor describing the hydrophobicity, 𝑆𝑝𝑜𝑙𝑎𝑟is the surface 
descriptor describing the surface polarity and 𝑘𝑖
𝐾𝐷 is the Kyte-Doolittle value for residue 𝑖. 
No treatment was needed for the generated energy descriptors from ProtDCal as these are 
calculated based on the surrounding environment.  
6.6.3 Descriptor resolution 
Similar to the primary sequence-based descriptor, strategies for defining the descriptor 
resolution was used where selection of residues to use were based on the intrinsic structural 
features of all mAbs (see Section 3.3). Three different resolutions were considered when 
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generating 3D structure descriptors: Chain, Domain and Substructure. Table 6.8 lists the 
number of generated descriptors for the three resolution in a VH/VL and a Fab configuration. 
Table 6.8. Number of generated descriptors based on resolution type and size of the mAb.  
Method VH/VL Fab Input type Descriptors per 
input 
Chain Skipped (1) 104 (2) Chain 52 
Domain 104 (2) 208 (4) Domain 52 
Substructure 728 (14) 1456 (28) Substructure 52 
(1) Is identical to the domain resolution when VH/VL is used 
6.7 Summary 
In this chapter a workflow for generating and simulating mAb structures has been presented. 
Due to the high structural similarities shared between mAbs and availability of structure 
templates, the homology modelling approach with MODELLER was selected for initial 
prediction of the mAb structure. However, due to the high sequence dissimilarity in the variable 
regions between the predicted structure and the template it was assumed that predicted 
structures would have an unfavourable energetic state and therefore not be relaxed. MD 
simulations with GROMACS was therefore performed as a subsequent step after the homology 
modelling in order to relax the predicted structures.  
Descriptor were then generated with ProtDCal but modified with residue SASA values from 
GROMACS in order to only capture the surface properties. Generated descriptors presented in 
this chapter has been applied and assessed on prediction of HIC retention times and mAb yields 






Chapter 7  
 
QSAR Model Development: 3D Structure 
Descriptors 
In Chapter 6, a workflow for the generation of novel 3D structure descriptors was presented 
which provided an alternative approach to describe the mAb structure compared to the 
previously explored descriptors generated from the primary sequences described in Chapter 3. 
The 3D structure descriptors were designed to represent the surface properties as well as the 
stability properties of the mAbs. Three different 3D structure descriptor resolutions were 
investigated which were generated based on the full chains, the individual domains and the 
individual substructures present in the mAb structure (from the lowest to the highest resolution). 
The new 3D structure descriptors were first evaluated for potential systematic variation 
originating from the unique structure of the light chain isotypes with the use of PCA. In 
addition, the potential variation originating from the species origins was also explored with 
classification methods such as PLS-DA and SVC. These were important factors in the 
development of the predictive models presented in Chapter 5 where the primary sequence-based 
descriptors contained systematic variation uncorrelated to the investigated responses.  
HIC retention times and mAb yields were chosen as response vectors for model development 
due to being important parameters in pharmaceutical industries for the assessment of 
productivity and product stability, respectively. All models were developed according to the 
benchmarking scheme first presented in Chapter 5. PLS and SVR were used as modelling 
methods. Model optimisation was performed in incremental steps where V-WSP was used for 
initial variable reduction. rPLS, LASSO and GA was then applied for subsequent variable 
selection on the V-WSP reduced descriptor set in order to increase correlation between 
descriptors and responses. 
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7.1 Material and Methods 
7.1.1 Response Data 
In this research quantitative process data published by Jain et al (2017) was used to develop 
predictive models for HIC retention times and mAb yields. For more details on the dataset and 
experimental setup of the mAb yield and HIC, refer to Section 5.1.1. Out of the 137 available 
mAbs in the data set, 131 were retained based on the reasoning discussed in Section 5.1.1.3. 
7.1.2 Descriptor Data Generation 
Fab fragments of the mAbs were prepared for simulation using the available sequences of the 
variable domains VH and VL provided as supplementary information in the study of Jain et al 
(2017). The heavy chain was prepared by attaching an IgG1 CH1 sequence obtained from allele 
sequence IGHG1*01 to the provided VH domains. Similarly, the light chain was prepared by 
attaching a CL domain sequence to the provided VL domains obtained from either allele 
sequence IGLK1*01 (kappa) or IGLC1*01 (lambda).  
Homology models were generated using MODELLER version 2.17 (Webb and Sali, 2014) with 
a single template where PDB 2FGW and 7FAB were used for Fab fragments of kappa and 
lambda isotypes, respectively (see Table 6.2 in Chapter 6). Pair-wise cysteines involved in 
disulphide bridges were restrained where the sulphur atoms were placed at a distance of 2 Å 
from each other in order to properly connect the cysteine residues. Two mAbs (muromonab and 
teplizumab) were excluded in this process due to having cysteines in the CDR regions which 
caused MODELLER to form incorrect disulphide bridges, thus misrepresenting the structure. 
Atomistic simulations of the Fab fragments were performed with GROMACS (version 5.1.4) 
and simulated in water with a concentration of 0.1 M NaCl in order to stabilise surface charges. 
Prior to the production run, the system was equilibrated to a temperature of 25 oC and pressure 
of 1 bar. In this research, the high-performance computing (HPC) service ROCKET at 
Newcastle University was used run the production simulation. Each Fab fragment was 
simulated for a total of 50 ns to allow structure to reach conformational equilibrium described 
in Section 6.6.1. Atezolizumab was excluded in this process due to causing critical failures in 
the simulation. Several attempts were performed to re-simulate atezolizumab but all failed due 
to high system instability.  
Structural descriptors for the remaining mAbs were generated based on the methodology 
presented in Section 6.6 where three unique descriptor sets were obtained: Chain based 
(MSD1), Domain based (MSD2) and Substructure based (MSD3) where MSD is short for 
“Molecular Structure Descriptors”. In total, this resulted in 128 mAbs being selected for further 
175 
evaluation as listed in Table A.3 in Appendix A with corresponding experimental 
measurements for HIC retention times and mAb yields. 
7.1.3 Modelling Methods 
7.1.3.1 PCA 
PCA was used as an exploratory analysis tool to investigate the three descriptor sets and the 
relationship between descriptors and the light chain isotypes as well as the species origins. PCA 
implementation was performed using the PLS Toolbox version 8.6.1 (Eigenvector Research, 
Inc). For more details on PCA, see Section 2.2.1. 
7.1.3.2 PLS-DA 
The NIPALS algorithm was used to develop a PLS regression model for predicting the dummy 
variables generated from the class information pertaining to the species origin of the mAbs. 
Discriminant Analysis (DA) was then applied to create decision thresholds in order to classify 
the predictions of the developed PLS model.  For more details on PLS-DA, see Section 2.3.1. 
7.1.3.3 SVC 
The LibSVM toolbox was used and implemented in MATLAB 2016a for SVC model 
development (Chang and Lin, 2011). The C-SVM function in LibSVM was used for multiclass 
classification problems. A shell script was developed to implement the OvR multiclass strategy 
in SVC instead of using the default OvO strategy in LibSVM in order to reliably compare SVC 
to PLS-DA. The shell scripts for model fitting and prediction are presented in Appendix B, 
Code B.1 and Code B.2, respectively. Optimisation of the model parameter 𝐶 was performed 
using a grid search approach on defined points over specified ranges for each parameter (for 
details on parameters see Section 2.3.2). The grid points used for 𝐶 were  
[10-5, 10-4, 10-3, 10-2, 10-1, 100, 101, 102, 103, 104]. 
7.1.3.4 PLS 
Partial Least Squares regression was performed using the NIPALS algorithm. The first 20 latent 
variables were calculated to allow for a majority of the data variation in 𝑿 and 𝒀 to be captured. 
A higher number of latent variables is often not recommended as they usually only improve 
fitting of individual samples, thus causing over-fitting (Wold et al., 2001). For more information 
on PLS, refer to Section 2.4.1. 
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7.1.3.5 SVR 
The optimisation of the model parameters 𝐶 and 𝜖 was performed by using a grid search 
approach on defined points over specified ranges for each parameter (for details on parameters, 
see Section 2.4.2). The grid points used for 𝐶 were [10-5, 10-4, 10-3, 10-2, 10-1, 100, 101, 102, 103, 
104] whereas the grid points used for 𝜖 were [10-3, 10-2.5, 10-2, 10-1.5, 10-1, 10-0.5, 100, 100.5, 101]. 
This resulted in 90 different model parameter permutations that were evaluated in the model 
cross validation. 
7.1.4 Data curation and pre-treatment 
An initial data curation step was performed where descriptors with a standard deviation lower 
than 0.0001 were removed as they were considered to be static and thus not contributing 
informational content to the model. 
Both the descriptor set (𝑿 block) and the response vector (𝒀 block) were autoscaled when used 
in regression models in order to allow the descriptors to influence the resulting model equally 
(see Section 2.7). In classification models, only the 𝑿 block was autoscaled whereas the class 
labels were assigned as zero and one in PLS-DA and minus one and one in SVC. 
7.1.5 Model Training and Validation 
7.1.5.1 Structured data splitting 
Prior to model development the data set was split into a calibration set and an external test set 
to represent future samples. The Kennard-Stone (CADEX) algorithm was used to divide the 
samples according to structural similarity based on the Euclidean distance between samples in 
the descriptor space (see Section 2.5.1 for more details). 80% of the samples were retained for 
model calibration and the remaining 20% were used for external testing and model validation. 
7.1.5.2 Cross-Validation scheme 
A repeated k-fold cross validation scheme was applied for model development where k was 
chosen to be five in order to get an 80/20 sample split ratio between training and validation 
samples, respectively. 20 iterations were performed to better utilise the data set and to decrease 
the potential impacts of outliers in the data on the cross validation. For more information, see 
Section 2.5.2. 
7.1.5.3 Model Validation 
The validation of PLS-DA and SVC models was performed using the overall error rate (ER) 
and the Matthews Correlation Coefficient (MCC) based on the confusion matrices of the 
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developed models. The appropriate model complexity of the PLS-DA and SVC models was 
determined through the selection of model complexity with the lowest ER in the cross 
validation. For more information on the classification metrics, refer to Section 2.6.2. 
All regression models were validated using the OECD guidelines for 𝑅2 and 𝑄2 for QSAR 
models (Veerasamy et al., 2011, Alexander et al., 2015). The guidelines state that 𝑅2 and 𝑄2 
should be greater than 0.5 and 0.6 in the cross-validation and external prediction, respectively. 
In addition, the difference between 𝑅2 and 𝑄2 should not exceed 0.3. The thresholds 𝑅2 and 
𝑄2 in the OECD guidelines are intended to be used for early model development to explore 
potential correlation of factors and descriptors related to the modelled responses. Once 
characterised, additional descriptor development and adjustments can be performed to further 
improve model performance. For more information on the regression metrics, refer to Section 
2.6.1. 
7.1.5.4 Y-Randomisation 
Y-randomisation was used to evaluate the presence of random correlation between a descriptor 
set and a randomised response vector. The response vector was randomised 50 times and an 
individual model was developed on each permutation. Calculated 𝑅2 and 𝑄2 values from the 
50 models were then averaged. If no chance correlation is present in the descriptor set, both the 
averaged 𝑅2 and 𝑄2 values will be low. For more details on Y-randomisation, refer to Section 
2.6.3. 
7.1.6 Variable reduction and Selection 
7.1.6.1 V-WSP 
The V-WSP algorithm was applied as an unsupervised variable reduction method to remove 
collinear descriptors present in the 𝑿 block. Implementation of V-WSP was performed in the 
same way as described in Section 5.1.5.1.  
In order to avoid removal of collinear descriptors belonging to different chains, domains or 
substructure, the V-WSP reduction was performed on groups of descriptors defined by the 
resolution of the descriptor set. In MSD1, the groups were defined as individual chains. In 
MSD2, the groups were defined as individual domains. In MSD3, the groups were defined as 
individual substructures. This was done in order to avoid excessive information loss and to 
represent each group individually. Reduction with V-WSP was performed prior to any 
supervised variable selection method. 
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7.1.6.2 rPLS 
Supervised variable selection with rPLS was performed using PLS Toolbox 8.6.1 (Eigenvector 
Research Inc) together with MATLAB 2016a (Mathworks®). An initial PLS model was 
developed with selected descriptors from V-WSP reduction and the latent variable with the 
smallest RMSECV was selected as a starting point for the rPLS selection. For more information 
on rPLS, refer to Section 2.9.1. 
7.1.6.3 GA 
Supervised variable selection with Genetic Algorithm (GA) was performed using PLS Toolbox 
8.6.1 (Eigenvector Research Inc) together with MATLAB 2016a (Mathworks®) and PLS as 
the fitness function. A population size of 100 was used and the maximum number of generations 
was set to 100. The convergence for the GA algorithm was set to 50%. Default values for the 
mutation rate and the ratio of kept variables in the initial models was kept as 0.5% and 30%, 
respectively. For more information on GA, refer to Section 2.9.2. 
7.1.6.4 LASSO 
The LASSO algorithm was implemented using the function fitrlinear in MATLAB 2016a 
(Mathworks®) where SVR was set as the learner and LASSO selected as the regularisation 
method. A grid search was performed in the same fashion to that of SVR described in Section 
5.1.5.4 in order to optimise the parameter selection. 
7.2 Results and Discussion 
7.2.1 Analysis of protein dynamics 
The evaluation of the simulations was performed by observing the generated RMSD plots for 
the 128 mAb simulations which are shown in Figure 7.1. The majority of the mAb structures 
reached conformational stability after 15 ns which can be observed as the plateaus in Figure 
7.1a. However, four mAb structures failed to reach conformational stability during the 
simulation where the RMSD value instead kept increasing as illustrated in Figure 7.1b. 
Interestingly, three of these mAbs: briakinumab, fezakinumab and tralokinumab are of lambda 
conformation whereas eldelumab is of kappa conformation. It has been shown in research that 
light chains of the lambda isotype in general are more unstable than kappa which might explain 
why conformational stability were not reached in the simulations (Rouet et al., 2014).  
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Figure 7.1. RMSD plots of GROMACS simulations where (a) mAbs have reached conformational stability and 
(b) mAbs that have not reached conformational stability. 
In addition to the plots, the standard deviation of the RMSD, 𝜎𝑅𝑀𝑆𝐷, was calculated from the 














where 𝑁𝑓𝑟𝑎𝑚𝑒𝑠 is the number of snapshots between 15 ns and 50 ns, 𝑅𝑀𝑆𝐷𝑡 is the RMSD value 











The 𝜎𝑅𝑀𝑆𝐷 value thus represents the variability of the RMSD curve in the simulation interval 
between 15 ns and 50 ns where stability had been reached for the majority of mAb structures. 
Therefore, in a more indirect manner, the 𝜎𝑅𝑀𝑆𝐷 value can be used to infer conformational 
stability of a protein where a low value represents a stable conformation whereas a high value 
represents conformational change. The four mAb structures: briakinumab, fezakinumab, 
tralokinumab and eldelumab illustrated in Figure 7.1b had 𝜎𝑅𝑀𝑆𝐷 values above 0.12 with the 
highest value of 0.21 (fezakinumab). The mAb structures that were considered stable all had 
values below 0.07, thus having less conformational variation occurring after the structure had 
been relaxed (data not shown). Further inspection of eldelumab was performed in order to 
180 
investigate the second plateau illustrated in Figure 7.1b between 30 ns and 50 ns of the 
simulation. It was observed that the rise in RMSD occurring at 30 ns was caused by the VH 
domain slightly twisting upwards in the Fab fragment as illustrated in Figure 7.2 where Figure 
7.2a and Figure 7.2b are snapshots taken at the 25 ns and 35 ns timeframes of the simulation 
respectively. The new structural conformation of eldelumab illustrated in Figure 7.2b then 
remained stable throughout the rest of the simulation. In the case of briakinumab, fezakinumab 
and tralokinumab, twisting occurred in all domains where the VH and VL domains packed closer 
to the CL and CH1 domains respectively, thus resulting in a more compact and spherical 
structure (data not shown). The observed conformational change of the structures were gradual 
throughout the simulations which also explains the continued increase of the RMSD values for 
briakinumab, fezakinumab and tralokinumab. 
 
Figure 7.2. Displacement of the VH domain (blue arrow) in the simulation of eldelumab from the domains original 
position captured at (a) 25 ns to its new placement captured at (b) 35 ns. The heavy chain is coloured blue while 
the light chain is coloured red. 
For all simulations except briakinumab, eldelumab, fezakinumab and tralokinumab, the 
structures remained stable throughout the simulation and no conformational changes occurred. 
The last timeframe in each of these simulations was therefore used to generate a PDB structure 
from which descriptors were later generated (see Section 6.6). For eldelumab, the last timeframe 
was used due to that the second plateau remained stable from 30 ns until the end of the 
simulation. Preferably, continued simulation of briakinumab, fezakinumab and tralokinumab 
would be desirable in order to allow the structures to converge to a stable conformation. 
However, due to time constraints within the project, the last timeframe in the simulations (50 
ns) were used to generate the descriptors. Though it introduces some uncertainty regarding 
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briakinumab, fezakinumab and tralokinumab structural stability, it was believed that if the 
simulations were allowed to run further, they would converge to a stable conformation. 
Therefore by selecting the last timeframe in the simulation, it could be assumed that the 
structures would be closer to the stable conformations than they were prior to the simulations.  
7.2.2 Impact of the light chain isotypes 
Similar to the exploratory analysis performed in Chapter 4 on the 273 mAb sequences obtained 
from the IMGT database, the impact of the light chain isotypes, kappa and lambda, on the 
generated 3D structure descriptors described in Chapter 6 was explored with PCA. Only 
descriptors generated from the light chain were used in this exploratory analysis because no 
structural information relating to the heavy chain isotype were present in the structures due to 
all mAbs being expressed as IgG1. The number of principal components (PCs) was 
incrementally increased until approximately 90% of the data variation in the descriptors sets 
had been explained. This was done due to the light chain isotype being expected to have a strong 
impact on the generated descriptors in a similar fashion as was observed in Chapter 4 for the 
primary sequence-based descriptors. 
A clear diagonal separation of kappa and lambda could be observed in the first and second PCs 
in MSD1 (Figure 7.3a), MSD2 (Figure 7.3b) and MSD3 (Figure 7.3c) with an explained 
variation of 81.18%, 72.0.3% and 42.45%, respectively. However, not all of the explained 
variation of the first two PCs can be attributed entirely to the separation of the isotypes which 
also separates the individual samples from each other due to their unique surface properties. It 
is difficult to estimate to what extent the VL and CL domains influence the separation. However, 
a clear contribution from both domains could be observed when investigating the loadings of 
PC1 and PC2, as illustrated in Figure C.7 in Appendix C. The remaining PCs showed no further 
separation of the light chain isotypes and were therefore assumed to capture variation related to 
individual samples instead (data not shown). A short summary of the PCA results is presented 
in Table 7.1. 
The statistical analysis on the response vectors of the HIC retention time and mAb yield 
performed in Section 5.2.2 is still valid due to being independent from the generated descriptors 
and only investigates the behaviour of the responses according to the isotypes. Just as with the 
primary sequence-based descriptors, a strong impact of the isotypes on the generated 3D 
structure descriptors was evident (see Figure 7.3). This can potentially act as a systematic 
variation that is uncorrelated to the response and can have a negative impact on the performance 
of developed regression models (Wold et al., 1998). It is important to remember that the heavy 
chain was modified by Jain et al (2017) where all heavy chain constant domains were expressed 
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as IgG1 regardless of their original conformation. Therefore, no conclusions can be drawn with 
regards to the impact of the original heavy chain isotypes on the responses. For these reasons, 
only IgG1-kappa samples were used for further model development, resulting in 79 samples 
being retained from the previously 128 selected samples.  
As previously described in Chapter 4, the amino acid composition of the primary sequence in 
the VL domain will be different between kappa and lambda due to being expressed from 
separate genes in the VJ recombination (Jung and Alt, 2004). This had a significant impact on 
the generated 3D structure descriptors from the VL domain which had high contributions to the 
loadings of the PC1 and PC2 (see Figure C.7 in Appendix C). This indicates that a fraction of 
residues directly related to the light chain isotype are present on the surface and it further 
highlights the need for an appropriate selection of samples in order to avoid introduction of 
uncorrelated systematic variation prior to model development. 
 
 
Figure 7.3. PCA score plots of the first two components calculated from the light chain descriptors from MSD1 
(a), MSD2 (b) and MSD3 (c) where kappa and lambda samples are coloured red and green, respectively. 
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Table 7.1. PCA exploration summary of light chain descriptors from MSD1, MSD2 and MSD3 where each model 
was developed to capture approximately 90% of the total data variation. The last two columns show information 













Variation (%) by 
selected component 
MSD1 50 4 90.04 1 and 2 81.18 
MSD2 100 6 90.24 1 and 2 72.03 
MSD3 632 26 90.12 1 and 2 42.45 
 
7.2.3 Impact of species origin 
To explore the potential impact of the species origin, classification methods such as PLS-DA 
and SVC were applied to the 79 selected IgG1-kappa samples. All 100 descriptors in MSD1 
were used in the model development due to having been calculated on the full heavy or light 
chains where separation of constant and variable domains is not possible (see Section 6.6.3). 
As for MSD2 and MSD3, only descriptors belonging to the variable domains VH and VL were 
used which resulted in 100 and 644 descriptors being used, respectively. The CADEX algorithm 
was used to split the data into 80/20 for calibration and test, respectively, according to the 
structural information contained in the individual descriptor sets MSD1, MSD2 and MSD3. 
When CADEX was used directly, the algorithm produced a skewed split of species origins in 
the calibration and test sets in all individual descriptor sets. This was especially pronounced for 
the chimeric species origin where only one sample was placed in the test set for MSD2 and 
MSD3 while no samples were placed in the test set for MSD1. Instead, a sample stratification 
strategy was implemented to ensure that all species origins were appropriately represented in 
the test set (Shahrokh and Dougherty, 2013). This was performed by applying the CADEX 
algorithm individually on the three species origins where 80% were retained for training and 
20% for model validation in the test set. A summary of the sample splitting is presented in Table 
C.6 in Appendix C. 
A summary of the performance of the developed PLS-DA and SVC models is presented in 
Table 7.2 for the three descriptor sets. None of the developed models performed well in the 
cross-validation where the error rates were close to 0.4 regardless of modelling method or 
descriptor set, meaning that approximately 40% of the samples were classified incorrectly. The 
corresponding MCC values showed an indication of a weak correlation (0.2-0.3) between the 
generated descriptors and the species origin classes, thus indicating a lack of correlation in the 
data (Jurman et al., 2012). This is further supported through investigation of the individual AUC 
values of the three species origins obtained from the ROC curves illustrated in Figure C.8 in 
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Appendix C. For both PLS-DA and SVC models developed on the MSD1 and MSD2 descriptor 
sets, the AUC values tended to be placed around 0.65 for the chimeric and human species 
origins while the humanised species origin was around 0.75. For PLS-DA and SVC models 
developed on the MSD3 descriptor set, the AUC value of the chimeric species origin tended to 
be around 0.8 while the human and humanised classes had values around 0.7. The AUC values 
are considered to be relative and dependent on the data set used. However, as a rule of thumb 
AUC values above 0.8 can be considered as a reasonable performance while values below 0.8 
can be considered poor (Fawcett, 2006). Thus, none of the developed classification models were 
able to identify an underlaying correlation between the generated 3D structure descriptors and 
the species origins. 
Compared to the cross-validation, the results observed in the test set tended to vary a bit more. 
In general, SVC models tended to have slightly higher MCC values and lower ER values 
compared to PLS-DA.  The best performance was observed in the SVC model developed on 
the MSD3 descriptor set with a MCC value of 0.75 and an ER value of 0.18.  However, due to 
the poor performance in cross-validation this model cannot be considered to produce accurate 
predictions in future samples.  
Table 7.2. Summary of PLS-DA and SVC model performance developed on the descriptor sets: MSD1, MSD2, 
and MSD3. The MCC and ER performance metrics for calibration (Cal), cross-validation (CV) and the external 








Cal   CV   Test  
MCC ER   MCC ER   MCC ER 
PLS-DA 
MSD1 86.68 62.27 0.86 0.08   0.19 0.48   0.29 0.41 
MSD2 76.59 45.97 0.72 0.16  0.20 0.48  0.07 0.53 
MSD3 26.95 57.52 0.78 0.13   0.26 0.42   0.59 0.24 
SVC 
MSD1 - - 0.89 0.06   0.28 0.40   0.48 0.29 
MSD2 - - 0.92 0.05  0.32 0.37  0.37 0.35 
MSD3 - - 0.97 0.02   0.26 0.40   0.75 0.18 
 
When compared to the classification results in Section 4.2.5 where primary sequence-based 
descriptors had a strong correlation to the species origin classes, the 3D structure descriptors 
investigated in this chapter could not be directly linked to the species origin. A plausible cause 
for this could be that the necessary information needed for a reliable classification becomes 
buried inside the protein structure. Compared to the primary sequence-based descriptors, where 
each residue in the VH and VL domains had equal representation, in the 3D structure descriptors 
the species origin related residues might no longer be represented due to having been modified 
to conform to the solvent accessible surface area. Thus, the systematic variation related to the 
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species origins observed in Section 4.2.5 becomes nearly negligible when 3D structure 
descriptors are used.  
It is important to note that there was no significant statistical difference between the means of 
the HIC retention time between the three species origins whereas for the mAb yields, a 
significant statistical difference between the means of the chimeric and humanised samples was 
observed (see Section 5.2.2). However, due to the lack of systematic variation present in the 3D 
structure descriptors related to the species origin, all 79 IgG1-kappa samples were retained for 
further model development presented in Table A.3 in Appendix A. 
7.2.4 HIC model development on IgG1-kappa samples 
The same structured approach for model benchmarking described in Chapter 5 was applied for 
regression fitting with regards to the HIC retention times. The CADEX algorithm was used to 
divide the 79 retained IgG1-kappa samples into a calibration set for training (80%) and a test 
set for model validation (20%). PLS and SVR were used as modelling methods. A first set of 
initial models was developed on all available descriptors in MSD1, MSD2 and MSD3. A second 
set of models was developed with collinearity reduction using the V-WSP algorithm to reduce 
the number of descriptors in MSD1, DS and MSD3. Lastly, a final set of models was developed 
on the retained descriptors from the V-WSP reduction using rPLS, LASSO and GA for variable 
selection to reduce the number of descriptors even further. The model quality metrics on cross 
validation and test set validations for all developed models are presented in Table C.7a in 
Appendix C. These were benchmarked according to the OECD guidelines. 
Models developed on the MSD1 never attained good performance and the cross-validation of 
𝑅2 and 𝑄2 remained below or around 0.2 regardless of the modelling method or the level of 
reduction of the descriptors. Models developed on MSD2 followed a similar trend as MSD1 
but had slightly increased 𝑅2 and 𝑄2 values of 0.39 and 0.34, respectively, in PLS whereas 
values of 0.30 and 0.29 were obtained in SVR after variable selection with GA. Adequate cross-
validation performance was first observed when models were developed on MSD3 in the 
following cases: 1) PLS model after descriptor selection with rPLS, 2) PLS model after 
descriptor selection with GA and 3) SVR model after descriptor selection with GA. Out of these 
three, only descriptor selection with GA demonstrated satisfactory performance in the external 
test with a 𝑅2 and 𝑄2 of 0.66 and 0.65, respectively, for PLS and a 𝑅2 and 𝑄2 of 0.64 and 0.63, 
respectively, for SVR. Neither rPLS nor LASSO performed as well as GA for variable selection 
on the MSD3 descriptor set. LASSO especially had poor performance in both the cross-
validation and test set whereas rPLS had acceptable performance in terms of the OECD 
guidelines in the cross-validation but poor performance in the test set. A potential cause to this 
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might be due to the descriptor sets containing redundant descriptors with differing levels of 
collinearity toward response correlated descriptors. Especially for the LASSO algorithm to 
work properly, only a small degree of collinearity can exist between redundant and response 
correlated descriptors in order for the appropriate selection to be performed (Meinshausen and 
Yu, 2009). In conclusion, only the PLS and SVR models developed using MSD3 (Substructure 
based) and optimised with GA fulfilled the OECD criteria for both cross validation (𝑅2 and 
𝑄2  >  0.5) and external testing (𝑅2 and 𝑄2  >  0.6) (Veerasamy et al., 2011, Alexander et al., 
2015). Due to similar model performance, both the PLS and SVR models can be used for the 
prediction of HIC retention times. However, the PLS model is preferred in an industrial setting 
due to being more straightforward to train where only one model parameter needs to be 
specified. The PLS model also have stronger diagnostic capabilities where the investigation of 
sample and descriptor contribution towards 𝒀 is more intuitive.  
The selected model was developed initially from the original 1163 descriptors available in the 
full MSD3 descriptor set where 319 were retained from the V-WSP reduction, thus effectively 
reducing the number of descriptors by ~70%. The Procrustes index was used to evaluate the 
loss of information when comparing the full and V-WSP reduced MSD3 descriptor sets. A 
value of 0.0638 was obtained, indicating that only a small fraction of the information was lost 
in the reduction step (Ballabio et al., 2014). This can also be observed in benchmark table for 
MSD3 (see Table C3.2a in Appendix C) where the of 𝑅2 and 𝑄2 values in the cross validation 
and the test set remained mostly unchanged after the reduction. Out of the 319 remaining 
descriptors, GA selected a subset of 51 descriptors used to develop the final PLS model. A full 
list of the selected descriptors is presented in Table C.8 in Appendix C. Model predictions of 
the calibration samples (dark circles) and test samples (red circles) are shown in Figure 7.4a as 
a measured vs predicted parity plot. The test samples from Figure 7.4a are further illustrated in 
Figure 7.4b as a bar plot for easier comparison of the measured and predicted values for 
individual mAbs. The model performance is summarised in Table 7.3. 
Y-Randomisation (or Y-Scrambling) was used as a final validation step to evaluate the selection 
of the descriptors (Rücker et al., 2007). A PLS model was trained on a randomised (scrambled) 
HIC response vector while the sample order in the MSD3 descriptor set was kept unchanged. 
This was repeated 50 times and the average of 𝑅2 and 𝑄2 for the cross validation was calculated. 
A resulting 𝑅2 value of 0.03 and a 𝑄2 value of -3.94 was obtained. This indicates that no chance 
correlation is captured by the model and that the selected descriptors are important to describe 
the relationship between the structure of the mAbs and HIC responses. The results are 




Figure 7.4. Predictions of HIC retention times with PLS-GA model developed on the MSD3 descriptor set (LVs 
= 9). (a) Measured versus predicted plot with calibration samples in black and test set samples in red. (b) Measured 
(black) and predicted (red) values of test set samples.  
Table 7.3. PLS model summary developed for HIC retention time prediction using the MSD3 descriptor set. Root 
Mean Square Error (RMSE), R2, Q2 and model bias are listed for Calibration, Cross validation, Test set and Y-
randomisation (Y-scrambled). The Y-randomisation metrics are the average values of 50 randomised models. 
  PLS 
 
RMSE R2 Q2 Bias 
Calibration 0.13 0.98 0.98 0.00 
Cross Validation 0.51 0.75 0.71 0.02 
Test 0.59 0.66 0.65 -0.11 
Y-scrambled 
(Average) 
2.01 0.03 -3.94 -0.01 
 
The developed PLS model has signs of slight over-fitting when observing the calibration 
samples (dark) and the test set samples (red) in Figure 7.4a. The calibration samples showed a 
low RMSE value of 0.13 compared to the test set with an RMSE value of 0.59, which is also 
indicated by a greater distance of these samples from the parity line. This is an indication of 
over-fitting as the RMSE values between the calibration and test set should be ideally similar 
to each other (Lever et al., 2016). A likely reason for this is that a small number of redundant 
or noisy descriptors were selected by the GA algorithm to better fit the calibration samples in 
the cross-validation which in turn resulted in a high calibration fit with 𝑅2 and 𝑄2 values of 
0.98 and 0.98, respectively (Leardi, 2000). However, though not perfect, the underlaying 
correlation between the mAb structures and the HIC retention times has been captured by the 
PLS model as indicated by 𝑅2 and 𝑄2 values greater than 0.6 for the test set (Veerasamy et al., 
2011) 
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A general trend observed in the descriptors was that about 45% of all descriptor belonged to 
the CDR regions, 31% to the framework regions and the remaining 24% belonged to both the 
constant domains of CH1 and CL (see Table C.8 in Appendix C). This indicates the importance 
of the structural information contained in the variable domains. This is sensible as the CDRs 
are the source of the greatest sequence variability in the entire mAb structure which in turn 
affects surface and structure related properties of both the CDRs as well as framework regions 
in the variable domains (Lefranc et al., 2003). The effect will likely not be as pronounced in the 
constant domains of the 79 IgG1-kappa samples due to having identical primary sequence. 
Instead, the variability present in the 3D structure descriptors of the constant domains are likely 
to be related to conformational differences originating from the molecular dynamics 
simulations. However, it is important to note that the  descriptors from the constant domains 
cannot be disregarded due to dynamic interactions between the constant and variable domains 
which in turn will affect the generated descriptors (Feige et al., 2010). 
A closer inspection of the descriptors revealed that selected descriptors describing the polar 
surface areas (Spolar and SASApolar) and non-polar surface areas (Snon-polar and SASAnon-polar) 
belonged almost exclusively to the CDR regions. Representation of the volume (VOLTAE) and 
the electrostatic potential (SIEP) generated as part of the TAE descriptors were also commonly 
found belonging to the CDRs. This is consistent with published research where the CDRs have 
a pivotal role in binding to the HIC column resin with stronger binding usually occurring when 
the CDRs are long and hydrophobic (Hebditch et al., 2018).  
In addition, the stability of the mAb structures played a central role for prediction of the 
retention times represented mostly by energy-based descriptors. 11 of the 24 GA selected 
energy descriptors were related to the conformational entropy Gc(F), which describes the 
stability of the protein with regards to the hydrophobic interactions in the protein core which 
were selected for the CDRs, framework regions and the constant domains. Other important 
energy descriptors of note were the number of estimated water molecules surrounding the 
surface, W(F), and the interfacial free energy, ΔGs, representing the energy contribution from 
interactions between polar residues and surrounding water molecules. This is supported by 
published literature where the protein stability has been reported to play a pivotal role in HIC 
binding (Beyer and Jungbauer, 2018). This is further elucidated when considering that salt is 
added to promote binding in HIC columns and more stable mAbs require higher concentration 
of salt to disrupt electrostatic forces on the surface in order to expose hydrophobic patches 
(Gagnon, 1996a). 
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In retrospect, a replacement for the TAE descriptors might help to improve model performance. 
This is due to the TAE descriptors  consisting of static values for the individual amino acids 
which will be identical regardless of the environment they are in (Breneman and Rhem, 1997). 
Similarly, an alternative to the ProtDCal descriptors describing the energy and stability of the 
structure might also improve model performance due to being based on simplified empirical 
calculations. It was shown that they can provide a fair and often good approximation of stability 
energies when compared to experimental results. However, their applicability was not suited 
for all protein structures where large differences were observed between predicted and observed 
experimental energies in some cases (Ruiz-Blanco et al., 2013). A suggestion would be to 
perform surface properties and energy calculations directly in GROMACS or similar software 
as will be discussed further in Section 8.1. 
7.2.5 mAb yield model development on IgG1-kappa samples 
An identical benchmarking scheme as described at the start of Section 7.2.4 was performed to 
fit the MSD1, MSD2 and MSD3 descriptor sets to the mAb yield response. The cross validation 
and test set validation for all developed models are presented in Appendix C, Table C.7b. The 
developed models behaved similarly to the models for the prediction of the HIC retention times, 
where adequate performance in the cross validation was only achieved after variable selection 
had been performed. GA selection and rPLS achieved acceptable performance with 𝑅2 and 𝑄2 
greater than 0.6 for both PLS and SVR developed using MSD3 descriptor set. Selection with 
LASSO however suffered due to correlation between redundant and response-correlated 
descriptors as explained in Section 2.9.3. 
Unfortunately, none of the developed models had an adequate performance in the external test 
set regardless of which permutation of modelling, reduction or variable selection method was 
used. The predictions from the PLS model developed using MSD3 and optimised with GA is 
illustrated in Figure 7.5a. The test samples (red circles) from Figure 7.5a are further illustrated 
in Figure 7.5b as a bar plot for easier comparison of the measured and predicted values for 
individual mAbs.It can be observed that many of the test set samples have been underpredicted 
which resulted in low 𝑅2 and 𝑄2 values of 0.11 and -0.92, respectively. The model performance 




Figure 7.5. Predictions of mAb yield with a PLS-GA model developed on the MSD3 descriptor set (LVs = 3). (a) 
Measured versus predicted plot with calibration samples (black) and test set samples (red). (b) Measured (black) 
and predicted (red) values of test set samples. 
Table 7.4. PLS model summary developed for mAb yield prediction using the MSD3 descriptor set. Root Mean 
Square Error (RMSE), R2, Q2 and model bias are listed for Calibration, Cross validation and Test set. 
  PLS 
 
RMSE R2 Q2 Bias 
Calibration 20.09 0.90 0.90 0 
Cross Validation 36.42 0.69 0.68 -2.73 
Test 74.25 0.11 -0.92 49.55 
 
It is difficult to identify the true reason for the poor performance in the test set although a 
potential cause may be the lack of necessary variation in the data. Addition of extra samples to 
the data set might aid to better represent the range of 𝒀 responses, but also to introduce more 
structural variation in the 𝑿 block. Noise and descriptor collinearity are also influencing factors 
in the model development where the descriptor selection methods can suffer where the wrong 
descriptors are selected thus leading to fitting of noise uncorrelated to the samples in the test 
set (Fan and Lv, 2010). A nested cross-validation approach might help in improving the model 
generalisation due to using all the available data but at the loss of a dedicated test set (Cawley 
and Talbot, 2010). Another approach would be to try ensemble techniques such as bagging or 
boosting where multiple models are developed on separate sample subsets which have been 
shown to improve model performance and generalisation (Drucker, 1997).  
From a more biological perspective, transcription and translation of the heavy and light chains 
occurs separately within the cell which usually result in a higher concentration of light chains 
being expressed compared to the heavy chains. The structure of the mAbs might therefore not 
be directly related to the mAb yields (Bayat et al., 2018, Bhoskar et al., 2013). In Pybus et al. 
(2014), the authors investigated the mAb expression with regards to the corresponding mRNA 
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structure in CHO cells. They found that expression was significantly impacted by the stability 
of the mRNA structure where less stable mRNA structures resulted in lower yields. The mRNA 
sequence also determines which RNA codons are used during translation which has a 
significant impact on the expression as also reported by the authors. Optimisation of the 
nucleotide sequence is therefore vital in order to have an efficient expression of mAbs. The 
sequence variation in the variable domains has also been shown to impact expression in CHO 
cells which relates back to the mRNA and RNA codons (Mason et al., 2012). The sequence 
variation can impact the protein folding in the endoplasmic reticulum which in turn can become 
overloaded due to the accumulation of unfolded or misfolded proteins, thus leading to lower 
expression rates (Braakman and Bulleid, 2011, Stoops et al., 2012). Based on these facts, it is 
therefore difficult to accurately predict the yields based on the mAb structure alone, but 
information pertaining to the mRNA sequences would be needed as well (Pybus et al., 2014).  
7.2.6 Comparison to primary sequence-based models 
Initially, a model comparison for HIC retention time prediction of the developed primary 
sequence-based model presented in Section 5.2.3 and the developed 3D structure model 
presented in Section 7.2.4 was supposed to be performed with an independent external data set. 
Due to using CADEX, different samples were selected for the test set in the two models which 
meant that an unbiased evaluation using the samples from the data set provided by Jain et al. 
(2017) could not be performed. Instead, HIC retention times for humanised mAbs from the 
Advanced Manufacturing Supply Chain Initiative (AMSCI) data were supposed to be used 
(CPI, 2015). However, due to project time constraint and the lengthy process to draw up 
confidentiality agreements, the AMSCI sequences and HIC retention times could not be 
accessed in time and a direct comparison between the models was therefore no longer possible.  
However, some conclusions regarding the applicability can be made. As was observed in 
Chapter 5, when all species origins were used in model development, none of the resulting 
models had adequate performance with regards to the OECD criteria due to poor performance 
in the test set (𝑅2 and 𝑄2  <  0.6). This was caused by the systematic variation in the primary 
sequence-based descriptors that originated from structural differences between the species 
origins which were uncorrelated to the HIC response (see Section 5.2.2). Adequate performance 
was not reached until only humanised samples had been selected, significantly increasing the 
model performance in both the cross validation and test set when primary sequence-based 
descriptors were used. In comparison, due to the negligible systematic variation present in the 
generated 3D structure descriptors from the species origins, model development could proceed 
with all available IgG1-kappa samples as well as achieving adequate performance in both the 
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cross-validation and test set (see Section 7.2.4). The use of 3D structure descriptors therefore 
increases the applicability of the QSAR model to the point where the species origin can be 
ignored. However, stronger systematic variations originating from the different mab isotypes 
still needs to be considered and therefore the model will only be able to predict accurately on 
IgG1-Kappa samples. 
From the perspective of a pharmaceutical industry, neither the primary sequence-based model 
or the 3D structure descriptor model has adequate performance to be used as a predictive tool 
in QbD risk assessment as of yet. This would require a higher model performance with  𝑅2 and 
𝑄2 values of at least 0.8 in both the cross-validation and test set in order to decrease the offset 
between measured and predicted values thus increasing the confidence in the predictions. 
However, based on the acquired results, both the primary sequence-based descriptors and the 
3D structure descriptors shows promise for further improvements. In this research, the initial 
descriptor sets were developed to capture a wide range of different properties and features in 
although the majority of these were discarded in the model optimisation with V-WSP reduction 
and GA selection. Further model development is therefore recommended by re-evaluating the 
properties of the selected descriptors in order to expand and incorporate more related structural 
properties and features in the descriptor sets. It is important to note that the 3D structure 
descriptors are more flexible than the primary sequence-based descriptors. This is due to that 
process related information regarding the environment e.g. temperature, pH, molality etc can 
be incorporated in the MD simulations and their effects on the protein structure can be 
approximated (see Section 6.5). This is not possible with the primary sequence-based 
descriptors due to being static.  
7.3 Summary 
In this chapter the 3D structure descriptors, developed from mAb structures simulated with 
GROMACS, were explored and used for the development of predictive models for the 
prediction of HIC retention times and mAb yields. 
Exploration of the 3D structure descriptors of the light chain with PCA showed a strong 
correlation to the kappa and lambda isotypes which were present in all of the three generated 
descriptor sets. Based on previous results from the statistical hypothesis testing in Section 5.2.2, 
no correlation between the light chain isotypes and responses of HIC retention times as well as 
mAb yields could be significantly proven. As described in Section 7.1.1, modification of the 
heavy chain was made by Jain et al (2017) as they expressed all IgG2 and IgG4 mAbs as IgG1. 
If the original isotypes were preserved, though unknown, it could have potentially altered the 
measured experimental responses. For this reason, only IgG1 samples were selected due to the 
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uncertainty of the true behaviour of the IgG2 and IgG4 mAbs. Contrary to the previously 
explored primary sequence-based descriptors, only negligible correlation between the 
generated 3D structure descriptors and the species origins was observed through classification 
models based on PLS-DA and SVC. As a result, selection of a subset of 79 IgG1-kappa samples 
of all species origins from the available 128 samples was used in order to reduce harmful 
systematic variation uncorrelated to the response vectors as well as keeping the samples true to 
their original conformations.  
In this chapter, it has been shown that a model for predicting the HIC retention times could be 
developed with 3D structure descriptors generated from the individual substructures (MSD3) 
of a Fab fragment. Both PLS and SVR models developed on the MSD3 descriptor set after 
descriptor selection with GA had similar performance, but the PLS model was selected due to 
more straightforward implementation. The PLS model had adequate performance in accordance 
with the OECD guidelines for QSAR models with a 𝑅2 and 𝑄2 of 0.75 and 0.71, respectively, 
in the cross validation and a 𝑅2 and 𝑄2 of 0.66 and 0.65, respectively, in the test set. Though 
not all variation was explained by the model, it provided valuable insight into important 
descriptors and factors affecting model performance.  
No satisfactory model could be developed for the prediction of mAb yields as indicated by the 
signs of overfitting evidenced by the poor test set results. A potential cause could be that 
structural information alone might not be directly correlated to the yield and other factors 
related to the expression from the cell might be missing. 
Unfortunately, no direct comparison could be made between the selected primary sequence-
based model in Chapter 5 and the 3D structure model in this chapter for prediction of HIC 
retention times as explained above. However, the model developed using the 3D structure 
descriptors showed broader applicability due to being unconstrained in regards to the species 
origins. In comparison, the model developed on the primary sequence-based descriptors was 
trained on humanised samples only and would not be able to reliably predict retention times for 
chimeric and human samples. Further improvement of the developed models is still necessary 






Chapter 8  
 
Conclusions and Future Work 
In this project the QbD framework was reviewed due to being commonly used in process 
development for mAbs and provides a systematic approach to increases process understanding 
through characterisation of process parameters and their effect on the product quality. However, 
due to the numerous process parameters that need to be characterised, the QbD framework still 
faces challenges in implementation. Much research has been focused in areas such as high-
throughput platforms and process optimisation to reduce attrition in the process development. 
However, it was identified that one of the biggest challenges in QbD implementation is the lack 
of knowledge about both the process and product in early process development where the 
manufacturability of an mAb might not be possible. 
In the literature review, it was shown that the QSAR framework for in silico model development 
has become increasingly popular for end point predictions of protein behaviour in different unit 
operations. This makes the QSAR framework a potentially valuable tool which can aid risk 
assessment in early process development to better direct experimental designs and thus reduce 
costs. The use of in silico approaches therefore allows for more informed estimates of the 
potential behaviour of a mAb in different unit operations of the process. This could become 
possible by efficiently making use of historic prosses data from previously established mAb 
manufacturing processes and constructing an expert system. The integration of QSAR into the 
QbD framework was therefore proposed in order to increase product understanding which is 
especially important in early process development.  
In this research, an extensive framework was developed based on QSAR in order to address the 
challenges facing mAb process development. The framework can roughly be divided into three 
parts according to: 1) Generation of descriptors relating both to the primary sequence as well 
as the 3D structure of mAbs. 2) Exploration and statistical assessment of generated descriptor 
and responses, respectively, for elimination of detrimental systematic variation. 3)  Model 
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development and validation coupled with descriptor reduction and selection. The 
implementation of such frameworks is becoming increasingly important in pharmaceutical 
industries in order to speed up development and lower the costs of new biopharmaceuticals. 
Due to the shifts toward high-throughput technology that has occurred during the recent years 
in both upstream and downstream of the mAb process, the increased availability of process data 
introduces and excellent starting point for the implementation of the presented framework. 
In this research, focus was placed on the development of predictive models assessing HIC 
retention times and mAb yields due to these important factors for protein stability and 
productivity assessment in process development. The highlights from the different chapters in 
this thesis and potential improvements are addressed according to the following areas: 1) 
Descriptors, 2) Sample Selection and 3) Model Development and Assessment for easier 
evaluation. 
8.1 Descriptors 
Two different approaches for generating descriptors for development of predictive models was 
reviewed and implemented in this project. The first approach presented in Chapter 3, used the 
primary sequence of the mAbs where descriptors were produced using EMBOSS Pepstats, 
ProtDCal and amino acid scales. These descriptors were designed to capture structural 
variations based on differences in amino acid compositions between mAbs. The second 
approach presented in Chapter 6, was based on development of 3D structure from the primary 
sequences. Due to the lack of published structures, homology modelling was applied to produce 
approximations of the 3D structures for all mAbs used in this research. Molecular Dynamics 
simulations was then performed to relax the homology structures. Descriptors were then 
developed with GROMACS and ProtDCal and captured properties related to the surface and 
stability of the mAbs. 
In both approaches, descriptor sets of different resolutions were generated. For the primary 
sequence-based descriptors, the lowest resolution was attained when descriptors were 
calculated from all residues in an individual domain which meant that each domain could be 
represented individually. The highest resolution was attained when descriptors were generated 
for each individual residue in the primary sequence. For the 3D structure descriptors, the lowest 
resolution was calculated from each individual chain while the highest was calculated from the 
individual substructures present in the mAb structure. By comparing the different resolutions 
in the developed predictive models, a trade-off could be made in order to investigate the 
required resolution for adequate model performance. More explicitly, a too low resolution 
would often confound important structural properties while to high resolution would introduce 
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noise in the form of redundant descriptors into the developed models where in both cases lead 
to poor model performance.  
8.1.1 Suggestion for Improvements 
One of the biggest weaknesses with the generated descriptors is the absence of data on protein 
modifications such as the mAb glycan structure which has a major impact on the mAb stability. 
Due to that the upstream environment was identical for all mAbs in data set acquired from Jain 
et al. (2017), it was assumed that the glycan structure would be similar between the mAbs used 
for model development in this research. However, this assumption cannot be made in an 
industrial setting where the glycan structure is likely to be different between mAbs and therefore 
must be considered as a source of variability and represented in the modelling data. 
In this research atomistic simulations using GROMACS were performed on all mAbs in order 
to relax the structure and capture the structure dynamics. However, as presented in Section 
7.2.1, three mAbs failed to converge to a stable conformation. It was suggested that continued 
simulation would be necessary in order for the structure to converge to a stable conformation. 
In retrospect, a longer simulation time, such as 100 ns as well as multiple runs for each structure, 
would be beneficial for all structures as it allows for more structural variation to be captured 
while at the same time minimises the risk of simulations ending at conformational transition 
points. However, running all simulations at atomistic resolution for 50 ns takes considerable 
amounts of time. An alternative would be to investigate coarse-grained simulations which will 
run much faster due to the protein structure being simplified thus resulting in less particles in 
the simulation system. A comparison would need to be made to ensure that the protein dynamics 
of coarse-grained simulation is representative to that of the atomistic simulation in order to not 
bias the resulting structure. The use of coarse-grained simulation would also allow for longer 
simulations to be run, thus generating a stronger foundation for understanding to structure 
dynamics.   
3D structure descriptor in this research were generated from a PDB structure acquired from a 
single time-frame from the MD simulation. However, due to the structure being dynamic and 
changing slightly over time, only using single time-frame might not accurately represent the 
surface and stability of the structure. An alternative would be to generate descriptors on all 
available time frames from when the structure has reached conformational stability to the end 
of the simulation and then average the descriptors over time. This would probably result in 
more stable and representative descriptors due to conforming to the dynamics of the mAb 
structure.  
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As mentioned earlier in Chapter 7, the calculation of energy descriptor through ProtDCal are 
based on simplified empirical mathematical models which might not accurately represent the 
environment in which the mAbs are simulated. It is therefore proposed that stability and energy 
related descriptors are calculated directly in GROMACS or equivalent software which can take 
into consideration many different interactions between the atoms in the system. GROMACS 
also supports energy calculations of predefined groups of residues, thus allowing for calculation 
of descriptors conforming to the different descriptor set resolutions presented in Chapter 6. 
Though never implemented, a workflow of modifying the titration states of residues in the mAb 
structure as well as adding co-solvents to the system was presented in Chapter 6. It would be 
interesting to see how the descriptors change in response to the change in pH and co-solvent 
concentration. If the HIC elution curves were available for the mAbs in Jain et al. (2017) instead 
of just the end point retention times, several simulations with differing salt concentrations could 
have been performed and linked to the cumulative elution, thus expanding the data set. 
Alternatively, the proposed methodology could be used on published experimental data which 
follows DoE experimental design. 
8.2 Sample Selection 
Selection of samples played a critical role in the model development in order to reduce 
systematic variation uncorrelated to the response vectors where a structured approach for 
investigating sources of variation was proposed. Two sources of variation were identified early 
on where the first originated from the unique structures of the heavy chain isotypes IgG1, IgG2 
and IgG4 whereas the second originated from the unique structure of the light chain isotype 
kappa and lambda. Exploration of the primary sequence-based descriptor with PCA on the 
gathered 273 IMGT sequences presented in Chapter 4 revealed that both the heavy and light 
chain isotypes had a clear and strong separation. Further analysis showed that a significant 
portion of the data variation in the descriptors were used to explain the observed separations. 
Similar results were observed when exploring the 3D structure descriptors of the 128 samples 
acquired from Jain et al. (2017) presented in Chapter 7, where a clear separation of light chain 
isotypes kappa and lambda were observed with PCA. However, due to the alteration of the 
heavy chain constant domains in the original mAb structures which were all expressed as IgG1, 
no conclusive results could be drawn regarding isotypes IgG2 and IgG4. 
The statistical analysis performed in parallel on the response vectors of HIC retention times and 
the mAb yields from the data set provided by Jain et al. (2017) showed that no differences could 
be significantly proven in either of the responses when the heavy or light chain isotypes were 
compared. Important to note is that the statistical analysis performed on the heavy chain 
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isotypes was biased due to all samples being expressed as IgG1 and was therefore not likely to 
show a significant difference between the isotypes. However, due to the clear separation of 
IgG1, IgG2 and IgG4 that was observed in Chapter 4 when exploring the primary sequence-
based descriptors, it was impossible to know if the unaltered mAbs would have an effect on the 
responses.  
A similar analysis of the species origins was performed by exploring data variation in the 
generated descriptor correlated to that of the species origins. These analyses were performed 
with classification methods such as PLS-DA and SVC instead of PCA due to higher degree of 
variability in the explored descriptors.  A strong correlation was observed between the species 
origins and the primary sequence-based descriptors but not with the 3D structure descriptors.   
Elimination of systematic variation uncorrelated to the responses was performed by removing 
groups of samples belonging to a specific isotype or species origin which were strongly 
correlated with the descriptors but where a difference between responses could not be 
significantly proven in the statistical analysis. It is important to mention that the reasoning of 
selecting the IgG1 in this research was based on the assumption that the experimental 
measurements of the response vectors might have been different for the IgG2 and IgG4 samples 
if they were not expressed as IgG1. The IgG1 samples were therefore selected due to their heavy 
chain isotype not having been altered. 
8.2.1 Suggestion for Improvements 
Though it was never followed up due to time constraints, the good classification performance 
observed when predicting the species origins in Chapter 4 might be interesting to look into. It 
is often assumed that there is no intrinsic difference between humanised and human samples. 
However, the prediction accuracy was high in both the cross-validation and the test set, thus 
indicating that a structural difference between human and humanised samples are present. 
Homology models and MD simulations of true IgG2 and IgG4 mAbs were never performed in 
this research. It was shown that only a negligible correlation was present between the 3D 
structure descriptors and the light chain isotypes. It would therefore be interesting to observe if 
the performance of classification models developed on a mix of IgG1, IgG2 and IgG4 mAbs 
where 3D structure descriptors are used as model input would be different. 
8.3 Model Development and Assessment 
Model development on the significantly larger data set provided by Jain et al. (2017) allowed 
for more advanced testing and benchmarking. In Chapter 5 and Chapter 7, predictive models 
for HIC retention times and mAb yields were developed with primary sequence-based 
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descriptors and 3D structure descriptors, respectively. Due to the larger sample sets that were 
retained after samples selection a dedicated test set could be used to validate the developed 
models properly. A model development framework was proposed for testing different 
permutation of modelling methods with descriptor reduction and selection methods. In this 
research, an initial model was developed on the full descriptor set. The unsupervised V-WSP 
algorithm was then applied to decrease the number of collinear descriptors where a new model 
was developed on the reduced descriptor set. A subsequent descriptor selection was performed 
on the reduced descriptor set with supervised descriptor selection techniques such as rPLS, 
LASSO and GA which resulted in three new models being developed. This process was 
performed for all available descriptor sets in order to identify needed resolution for adequate 
model performance in both the cross-validation and the test set. The performance of all models 
was evaluated based on the OECD guidelines for QSAR models. 
Predictive models for HIC retention times were successfully developed for both the primary 
sequence-based descriptors and the 3D structure descriptors. The model developed on the 3D 
structure descriptors had a larger applicability due to having been trained on all chimeric, 
human and humanised samples and passed the OECD criteria. The model developed on the 
primary sequence-based descriptors was more constrained due to having been trained solely on 
the humanised samples due to a poor performance of the model when different samples were 
included into model calibration. The reason for this was due systematic variation originating 
from the species origins which was much more pronounced in the primary sequence-based 
descriptors due to capturing all information from the primary sequence. For the 3D descriptors 
however, due to being buried inside of the protein structure, residue related to the species origin 
class did not translate over to the descriptors due to their SASA values being close to zero (see 
Section 6.6.2). This resulted in 79 mAbs being used to train the 3D structure-based model 
compared to 45 mAbs being used for training the primary sequence-based model. Much more 
structural variability is therefore introduced in the 3D structure based-model which increases 
the model’s robustness when predicting retention times for future samples.  
In the paper of Robinson et al. (2017), a QSAR model was developed for predicting the elution 
salt concentration in a HIC column where the authors developed descriptors generated from 3D 
structures of Fab fragments which was then trained with SVR. The authors reported that a R2 
of 0.60 was observed in the cross-validation while a R2 of 0.44 was observed in the external 
test set. Both the primary sequence-based model and 3D structure-based model presented in 
Chapter 5 and Chapter 7, respectively in this research, attained a higher R2 in both the cross-
validation and external test set compared to Robinson et al. (2017).  
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8.3.1 Suggestion for Improvements 
In this research much focus was placed on developing a single model by splitting all available 
samples once into a calibration set and a test set. However, alternative training approaches for 
model development exist such as nested cross-validation which consist of two validation loops: 
an outer loop for model validation and an inner loop for model training. The available samples 
are often split at random in the outer loop which can be repeated any number of times and have 
shown to produce models with good generalisation (Raschka, 2018). Other alternatives are 
ensemble techniques such as bagging and boosting which have also been shown to produce 
models with good generalisation capabilities. A drawback with these methods is that no 
dedicated test set will be available to substitute as future samples. 
A recommendation from Leardi (2000) was that the GA algorithm should not be used on 
problems with more than 200 descriptors which can result in over-fitting which was observed 
in the mAb yield models. A work-around would be to modify the GA algorithm to generate 
random descriptor subsets based on groups instead of the individual descriptors. The descriptors 
used in this research can all be grouped according to the structure they were generated from e.g. 
chain, domain, substructure etc as well as the type of the descriptor e.g. topological, energy 
based etc. This would not only make GA selection faster but the importance of the individual 
structures of the mAb as well as the descriptor types could be assessed more efficiently. 
As mentioned in this research, the V-WSP algorithm was applied to reduce the number of highly 
correlated descriptors. The implementation however, is very dependent on the data set where 
the correlation thresholds were selected in order to minimise loss of information. The resulting 
reduction might therefore be slightly different if performed on another data set and is therefore 
subjective. However, in both the primary sequence-based descriptors and 3D structure 
descriptors, it was observed that the constant domains generally had a lower correlation 
threshold applied (~0.6-0.7) resulting in less descriptors being retained, while the variable 
domains generally had a higher correlation threshold applied (~0.8-0.9) resulting in more 
descriptor being retained (data not shown). A recommendation would be to use static correlation 
thresholds when reducing the descriptor sets based on the observed values for the constant and 
variable domains. This would in turn lead to a more objective reduction of descriptors 
regardless of the data set used. 
A common problem encountered model development is that the distribution of response data if 
often skewed. This if often true in experimental data of mAbs where the majority of samples 
are well-behaved whereas only a few are flagged as problematic. The CADEX algorithm used 
in this research only takes into account the structural descriptors when selecting samples for 
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training and validation. For a more controlled selection, a stratification strategy with regards to 
the response distribution could be applied in order to split the distribution in to three to four 
equal sample sizes in which the CADEX algorithm is applied individually.  
8.4 Summary 
In summary, the work presented in this thesis has provided an extensive framework for 
generation of structural descriptor and predictive model development that can be applied for 
prediction of mAb behaviour in processing. As was demonstrated, successful model 
development was achieved for prediction of HIC retention times. Though the model 
performance can be further improved, it allows for further study into development of new 
descriptors and approaches for which several suggestions for improvement on the defined 
framework have been given. The framework is therefore very promising due to that only the 
structural information of the mAbs is needed in order to predict chromatographic behaviour. 
The applied descriptor generation and modelling frameworks has therefore the potential to work 
in other chromatographic systems such as AIEX, CEX, etc where column binding is dependent 
on the structural features of the mAbs, which has also been supported by literature. Therefore, 
continued development and implementation of the proposed framework could be used to 
acquire a foundation of risk assessment tools to aid in early process development of new drug 
candidates and used to investigate potential processing behaviour and process route selection. 
This has the added value of increasing the process and product understanding which can 
potentially lower the number of required experiments in order to characterise the process design 
space and in turn lower development costs. As stated by DiMasi et al. (2016), the expected total 
cost from clinical phase I to market release was approximated to $1.460 billion. Even if the 
proposed implementation of QSAR modelling into the QbD framework only reduces cost by 1-
2% at minimum, this is still a reduction of $14.6-29.2 million.  
A continued development and expansion of QSAR risk assessment tools, not only in process 
development, but for clinical safety and biological activity as well, might allow for prediction 
of mAb developability (Zurdo et al., 2015). This means, that based on the potential risk of a 
mAb candidate to fail due to lack of clinical safety, problematic in manufacture or lack of 
biological activity, a more informed decision can be made to either fail or proceed with the 
candidate. This can therefore aid in reducing attrition as well as prevent large investments from 
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Appendix A  
A.1 Marketed mAbs 
Table A.1. List of market approved and withdrawn mAbs in the EU and the US between 1986-2017 with their 
corresponding approval years from EMA and FDA, respectively. mAbs highlighted in blue are biosimilars.  
Trade Name INN EMA Approval FDA Approval Comment 
Amjevita adalimumab 2017 2016 Biosimilar, same as Humira 
Cyltezo adalimumab 2017 2017 Biosimilar, same as Humira 
Imraldi adalimumab 2017 Not approved Biosimilar, same as Humira 
Zinplava bezlotoxumab 2017 2016 
 
Bavencio avelumab Not approved 2017 
 
Dupixent dupilumab Not approved 2017 
 
Imfinzi durvalumab Not approved 2017 
 
Ocrevus ocrelizumab Not approved 2017 
 
Siliq brodalumab Not approved 2017 
 
Cinqair reslizumab 2016 2016 
 
Lartruvo olaratumab 2016 2016 
 
Darzalex daratumumab 2016 2015 
 
Empliciti elotuzumab 2016 2015 
 




infliximab 2013 2016 Biosimilar, same as Remicade 
Ixifi infliximab Not approved 2017 Biosimilar, same as Remicade 
Flixabi (EU), 
Renflexis (US) 
infliximab 2016 2017 Biosimilar, same as Remicade 
Anthim obiltoxaximab Not approved 2016 
 
Tecentriq atezolizumab Not approved 2016 
 
Cosentyx secukinumab 2015 2015 
 
Nucala mepolizumab 2015 2015 
 
Opdivo nivolumab 2015 2015 
 
Praluent alirocumab 2015 2015 
 
Praxbind idarucizumab 2015 2015 
 
Repatha evolocumab 2015 2015 
 
Unituxin dinutuximab 2015 2015 Withdrawn from use in the 
European Union 
Blincyto blinatumomab 2015 2014 
 
Mvasi (US) bevacizumab Not approved 2017 Biosimilar, same as Avastin 
Keytruda pembrolizumab 2015 2014 
 
Cyramza ramucirumab 2014 2014 
 
Entyvio vedolizumab 2014 2014 
 
Sylvant siltuximab 2014 2014 
 
Lemtrada alemtuzumab 2013 2014 
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Trade Name INN EMA Approval FDA Approval Comment 
Kadcyla trastuzumab 
emtansine 
2013 2013 Conjugated antibody 
Perjeta pertuzumab 2013 2012 
 




2012 2011 Conjugated antibody 
Abthrax raxibacumab Not approved 2012 
 
Benlysta belimumab 2011 2011 
 
Vervoy ipilimumab 2011 2011 
 
Xgeva denosumab 2011 2011 
 
Prolia denosumab 2010 2010 
 
Arzerra ofatumumab 2010 2009 
 
Scintimun besilesomab 2010 Not approved 
 
RoActemra tocilizumab 2009 2010 
 
Ilaris canakinumab 2009 2009 
 
Simponi golimumab 2009 2009 
 




2009 2008 PEG conjugated Fab fragment 
Removab catumaxomab 2009 Not approved 
 
Soliris eculizumab 2007 2007 
 
Lucentis ranibizumab 2007 2006 Fab fragment 
Vectibix panitumumab 2007 2006 
 
Tysabri natalizumab 2006 2004 
 
Proxinium catumaxomab 2005 2005 
 
Avastin bevacizumab 2005 2004 
 
Xolair omalizumab 2005 2003 
 
Erbitux cetuximab 2004 2004 
 
Raptiva efalizumab 2004 2003 Voluntarily withdrawn from 
the market in EU in 2009 and 
in US in 2009 
Zevalin ibritumomab 
tiuxetan 
2004 2002 Conjugated antibody 
NeutroSpec fanolesomab Not approved 2004 
 
Humira adalimumab 2003 2002 
 
Bexxar tositumomab Not approved 2003 
 
Campath alemtuzumab 2001 2001 
 
Herceptin trastuzumab 2000 1998 
 
Ogivri trastuzumab Not approved 2017 Biosimilar, same as Herceptin 
Ontruzant trastuzumab 2017 Not approved Biosimilar, same as Herceptin 
Mylotarg gemtuzumab 
ozogamicin 
Not approved 2000 Conjugated antibody. 
Voluntarily withdrawn from 
the market in US in 2010. 
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Trade Name INN EMA Approval FDA Approval Comment 
Remicade infliximab 1999 1998 
 
Synagis palivizumab 1999 1998 
 
Zenapax daclizumab 1999 1997 Withdrawn from the market 
for commercial reasons in EU 
in 2009 and in US in 2009 




rituximab 1998 1997 
 
Rixathon rituximab 2017 Not approved Biosimilar, same as Rituxan 
Truxima rituximab 2017 Not approved Biosimilar, same as Rituxan 
Humaspect votumumab 1998 Not approved Withdrawn from the market in 
EU in 2003 
LeukoScan sulesomab 1997 Not approved 
 
CEA-scan arcitumomab 1996 1996 Withdrawn from the market in 
EU in 2005 
MyoScint imiciromab Not approved 1996 Has been discounted 
ProstaScint capromab Not approved 1996 
 
Verluma nofetumomab Not approved 1996 
 
ReoPro abciximab 1995 1994 Country-specific approval 
(prior to EMA Centralized 
Procedure). 






1986 1986 Country-specific approval 
(prior to EMA Centralized 
Procedure). 
Panorex edrecolomab 1995 Not approved Withdrawn from the market in 
EU in 2006 
Centoxin nebacumab 1991 Not approved Withdrawn from the market in 




A.2 IMGT mAbs 
Table A.2. List of 273 mAbs collected from the IMGT database. The original chain isotypes, species origin and 
development status are given for each antibody.  
INN HC LC Species Origin Development Status 
abituzumab IgG2 kappa humanised Phase I 
abrilumab IgG2 kappa human Phase II 
actoxumab IgG1 kappa human Phase III 
adalimumab IgG1 kappa human Phase M 
aducanumab IgG1 kappa human Phase III 
afasevikumab IgG1 kappa human Phase I 
alemtuzumab IgG1 kappa humanised Phase M 
alirocumab IgG1 kappa human Phase I 
amatuximab IgG1 kappa chimeric Phase II 
andecaliximab IgG4 kappa chimeric Phase II 
anifrolumab IgG1 kappa human Phase III 
anrukinzumab IgG1 kappa humanised Phase II 
aprutumab IgG1 lambda human Phase I 
ascrinvacumab IgG2 kappa human Phase II 
atezolizumab IgG1 kappa humanised Phase III 
atinumab IgG4 kappa human Phase I 
avelumab IgG1 lambda human Phase III 
bapineuzumab IgG1 kappa humanised Discontinued 
basiliximab IgG1 kappa chimeric Phase M 
bavituximab IgG1 kappa chimeric Phase II 
benralizumab IgG1 kappa humanised Phase III 
bevacizumab beta IgG1 kappa humanised Phase III 
bevacizumab IgG1 kappa humanised Phase M 
bezlotoxumab IgG1 kappa human Phase M 
bimagrumab IgG1 lambda human Phase II 
bimekizumab IgG1 kappa humanised Phase III 
bleselumab IgG4 kappa human Phase II 
blosozumab IgG4 kappa humanised Phase II 
bococizumab IgG2 kappa humanised Phase III 
brazikumab IgG2 lambda human Phase II 
brentuximab vedotin IgG1 kappa chimeric Phase II 
briakinumab IgG1 lambda human Phase I 
brodalumab IgG2 kappa human Phase II 
brontictuzumab IgG2 lambda humanised Phase I 
burosumab IgG1 kappa human Phase II 
cabiralizumab IgG4 kappa humanised Phase I 
camrelizumab IgG4 kappa humanised Phase I 
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canakinumab IgG1 kappa human Phase II 
cantuzumab ravtansine IgG1 kappa humanised Phase II 
carlumab IgG1 kappa human Phase II 
carotuximab IgG1 kappa chimeric Phase II 
cergutuzumab amunaleukin IgG1 kappa humanised Phase II 
cetuximab IgG1 kappa chimeric Phase M 
cixutumumab IgG1 lambda human Phase II 
clazakizumab IgG1 kappa humanised Phase II 
clivatuzumab tetraxetan IgG1 kappa humanised Phase II 
codrituzumab IgG1 kappa humanised Phase II 
coltuximab ravtansine IgG1 kappa chimeric Phase II 
conatumumab IgG1 kappa human Discontinued 
concizumab IgG4 kappa humanised Phase I 
cosfroviximab IgG1 kappa chimeric Phase I/II 
crenezumab IgG4 kappa humanised Phase III 
crizanlizumab IgG2 kappa humanised Phase II 
crotedumab IgG4 kappa human Phase I 
dacetuzumab IgG1 kappa humanised Phase I 
daclizumab IgG1 kappa humanised Phase M 
dalotuzumab IgG1 kappa humanised Phase I 
daratumumab IgG1 kappa human Phase M 
dectrekumab IgG1 kappa human Phase II 
demcizumab IgG2 kappa humanised Phase I 
denintuzumab mafodotin IgG1 kappa human Phase I 
denosumab IgG2 kappa humanised Phase III 
dezamizumab IgG1 kappa humanised Phase I 
dinutiximab beta IgG1 kappa chimeric Phase I 
dinutuximab IgG1 kappa chimeric Phase M 
diridavumab IgG1 lambda human Not Stated 
domagrozumab IgG1 kappa humanised Phase II 
drozitumab IgG1 lambda human Phase I 
duligotuzumab IgG1 kappa humanised Phase II 
dupilumab IgG4 kappa human Phase III 
durvalumab IgG1 kappa human Phase III 
dusigitumab IgG2 lambda human Phase II 
efalizumab IgG1 kappa humanised Withdrawn 
eldelumab IgG1 kappa human Phase II 
elezanumab IgG1 lambda human Phase I 
elgemtumab IgG1 kappa human Phase I 
elotuzumab IgG1 kappa humanised Phase M 
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emactuzumab IgG1 kappa humanised Phase I 
emapalumab IgG1 lambda human Phase III 
emibetuzumab IgG4 kappa humanised Phase II 
emicizumab IgG4 kappa humanised Phase M 
enavatuzumab IgG1 kappa humanised Phase I 
enfortumab vedotin IgG1 kappa human Phase I 
enoblituzumab IgG1 kappa humanised Phase I 
enokizumab IgG1 kappa humanised Phase II 
enoticumab IgG1 kappa human Phase I 
ensituximab IgG1 kappa chimeric Phase II 
eptinezumab IgG1 kappa humanised Phase III 
erenumab IgG2 lambda human Phase III 
etaracizumab IgG1 kappa humanised Phase II 
etrolizumab IgG1 kappa humanised Phase III 
evinacumab IgG4 kappa human Phase II 
evolocumab IgG2 lambda human Phase M 
farletuzumab IgG1 kappa humanised Phase III 
fasinumab IgG4 kappa human Phase III 
fezakinumab IgG1 lambda human Not Stated 
ficlatuzumab IgG1 kappa humanised Phase I 
figitumumab IgG2 kappa human Phase I 
firivumab IgG1 kappa human Not Stated 
flanvotumab IgG1 kappa human Phase I 
fletikumab IgG4 kappa human Phase II 
foralumab IgG1 kappa human Phase I 
foravirumab IgG1 kappa human Phase II 
fremanezumab IgG2 kappa humanised Phase III 
fresolimumab IgG4 kappa human Phase I 
fulranumab IgG2 kappa human Phase III 
futuximab IgG1 kappa chimeric Phase II 
galcanezumab IgG4 kappa humanised Phase II 
ganitumab IgG1 kappa human Phase I 
gantenerumab IgG1 kappa human Phase III 
gatipotuzumab IgG1 kappa humanised Phase I 
gedivumab IgG1 kappa human Phase II 
gemtuzumab ozogamicin  IgG4 kappa humanised Phase M 
gevokizumab IgG2 kappa humanised Phase II 
girentuximab IgG1 kappa chimeric Phase III 
glembatumumab vedotin IgG2 kappa human Phase III 
glembatumumab IgG2 kappa human Phase II 
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guselkumab IgG1 lambda human Phase M 
ibalizumab IgG4 kappa humanised Phase III 
icrucumab IgG1 kappa human Phase II 
ifabotuzumab IgG1 kappa humanised Phase I/II 
imalumab IgG1 kappa human Not Stated 
imgatuzumab IgG1 kappa humanised Phase II 
inclacumab IgG4 kappa human Phase II 
indatuximab ravtansine IgG4 kappa chimeric Phase II 
indusatumab vedotin IgG1 kappa human Phase I 
indusatumab IgG1 kappa human Not Stated 
inebilizumab IgG1 kappa humanised Phase II 
infliximab IgG1 kappa chimeric Phase M 
intetumumab IgG1 kappa human Not Stated 
ipilimumab IgG1 kappa human Phase M 
iratumumab IgG1 kappa human Phase II 
isatuximab IgG1 kappa chimeric Phase III 
itolizumab IgG1 kappa humanised Phase II 
ixekizumab IgG4 kappa humanised Phase II 
labetuzumab govitecan IgG1 kappa humanised Phase II 
lacnotuzumab IgG1 kappa humanised Phase II 
lanadelumab IgG1 kappa human Phase III 
landogrozumab IgG4 kappa humanised Phase II 
laprituximab emtansine IgG1 kappa chimeric Phase I 
laprituximab IgG1 kappa chimeric Phase I 
larcaviximab IgG1 kappa chimeric Phase I/II 
lebrikizumab IgG4 kappa humanised Phase III 
lenzilumab IgG1 kappa human Phase II 
lesofavumab IgG1 kappa human Preclinical 
lexatumumab IgG1 lambda human Phase I 
lifastuzumab vedotin IgG1 kappa humanised Phase II 
ligelizumab IgG1 kappa humanised Not Stated 
lirilumab IgG4 kappa human Phase II 
lodelcizumab IgG1 kappa humanised Phase II 
lorvotuzumab mertansine IgG1 kappa humanised Phase I/II 
lucatumumab IgG1 kappa human Phase I 
lumretuzumab IgG1 kappa humanised Phase I 
lupartumab amadotin IgG1 lambda human Phase I 
lupartumab IgG1 lambda human Phase I 
margetuximab IgG1 kappa chimeric Phase II 
mavrilimumab IgG4 lambda human Phase II 
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milatuzumab doxorubicin IgG1 kappa humanised Phase I 
mirvetuximab soravtansine IgG1 kappa chimeric Phase III 
mirvetuximab IgG1 kappa chimeric Phase I 
modotuximab IgG1 kappa chimeric Phase II 
mogamulizumab IgG1 kappa humanised Phase I 
monalizumab IgG4 kappa humanised Phase I 
motavizumab IgG1 kappa humanised Phase III 
namilumab IgG1 kappa human Phase I 
naratuximab IgG1 kappa chimeric Phase II 
narnatumab IgG1 kappa human Phase I 
natalizumab IgG4 kappa humanised Phase M 
navivumab IgG1 kappa human Not Stated 
necitumumab IgG1 kappa human Phase M 
nemolizumab IgG2 kappa humanised Phase II 
nesvacumab IgG1 kappa human Phase I 
nimotuzumab IgG1 kappa humanised Phase M 
nivolumab IgG4 kappa human Phase M 
obiltoxaximab IgG1 kappa chimeric Phase I/II 
obinutuzumab IgG1 kappa humanised Phase M 
ocaratuzumab IgG1 kappa humanised Phase I/II 
olaratumab IgG1 kappa human Phase II 
oleclumab IgG1 lambda human Phase I 
olokizumab IgG4 kappa humanised Phase I 
omalizumab IgG1 kappa humanised Phase M 
onartuzumab IgG1 kappa humanised Phase M 
opicinumab IgG1 kappa human Phase II 
orticumab IgG1 lambda human Phase II 
oxelumab IgG1 kappa human Discontinued 
ozanezumab IgG1 kappa humanised Phase I 
pamrevlumab IgG1 kappa human Phase I 
parsatuzumab IgG1 kappa humanised Phase II 
pateclizumab IgG1 kappa humanised Phase II 
patritumab IgG1 kappa human Phase III 
pembrolizumab IgG4 kappa humanised Phase III 
perakizumab IgG1 kappa humanised Phase I 
pidilizumab IgG1 kappa humanised Phase II 
pinatuzumab vedotin IgG1 kappa humanised Phase I 
plozalizumab IgG1 kappa humanised Phase II 
polatuzumab vedotin IgG1 kappa humanised Phase I 
ponezumab IgG2 kappa humanised Phase II 
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porgaviximab IgG1 kappa chimeric Phase I/II 
prezalumab IgG2 kappa human Phase I 
pritoxaximab IgG1 kappa chimeric Phase II 
quilizumab IgG1 kappa humanised Phase II 
rafivirumab IgG1 lambda human Phase II 
ralpancizumab IgG2 kappa humanised Phase I 
ramucirumab IgG1 kappa human Phase II 
refanezumab IgG1 kappa humanised Phase II 
rilotumumab IgG2 kappa human Phase II 
rinucumab IgG4 kappa human Phase I 
risankizumab IgG1 kappa humanised Phase III 
rituximab IgG1 kappa chimeric Phase M 
robatumumab IgG1 kappa human Preclinical 
roledumab IgG1 kappa human Phase II 
romosozumab IgG2 kappa humanised Phase III 
rontalizumab IgG1 kappa humanised Phase II 
rosmantuzumab IgG1 kappa humanised Phase I 
rovalpituzumab IgG1 kappa humanised Not Stated 
sacituzumab govitecan IgG1 kappa humanised Phase III 
sacituzumab IgG1 kappa humanised Not Stated 
sarilumab IgG1 kappa human Phase M 
satralizumab IgG2 kappa humanised Phase III 
secukinumab IgG1 kappa human Phase M 
selicrelumab IgG2 kappa human Phase I 
seribantumab IgG2 lambda human Phase II 
setoxaximab IgG1 kappa chimeric Phase II 
sifalimumab IgG1 kappa human Phase I 
siltuximab IgG1 kappa chimeric Phase II 
simtuzumab IgG4 kappa humanised Phase II 
sirukumab IgG1 kappa human Phase III 
solanezumab IgG1 kappa humanised Phase III 
suptavumab IgG1 kappa human Discontinued 
suvizumab IgG1 kappa humanised Phase I 
suvratoxumab IgG1 kappa human Phase II 
tabalumab IgG4 kappa human Phase III 
tanezumab IgG2 kappa humanised Phase III 
tarextumab IgG2 kappa human Phase I/II 
telisotuzumab IgG1 kappa humanised Phase I 
teplizumab IgG1 kappa humanised Phase III 
teprotumumab IgG1 kappa human Phase I 
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tesidolumab IgG1 lambda human Phase II 
tezepelumab IgG2 lambda human Phase III 
TGN1412 IgG4 kappa humanised Phase III 
tigatuzumab IgG1 kappa humanised Phase II 
tildrakizumab IgG1 kappa humanised Phase III 
timigutuzumab IgG1 kappa humanised Phase I 
timolumab IgG4 kappa human Phase I 
tisotumab IgG1 kappa human Not Stated 
tocilizumab IgG1 kappa humanised Phase M 
tomuzotuximab IgG1 kappa chimeric Phase II 
tosatoxumab IgG1 lambda human Phase I/II 
tovetumab IgG2 kappa human Phase I/II 
tralokinumab IgG4 lambda human Withdrawn 
trastuzumab emtansine IgG1 kappa humanised Phase III 
trastuzumab IgG1 kappa humanised Phase M 
tregalizumab IgG1 kappa humanised Phase II 
tremelimumab IgG2 kappa human Phase III 
trevogrumab IgG4 kappa human Phase II 
ublituximab IgG1 kappa chimeric Phase I 
ulocuplumab IgG4 kappa human Phase I 
urelumab IgG4 kappa human Phase II 
ustekinumab IgG1 kappa human Phase M 
utomilumab IgG2 lambda human Phase I 
vadastuximab talirine IgG1 kappa chimeric Phase III 
vadastuximab IgG1 kappa chimeric Not Stated 
vantictumab IgG2 lambda human Phase I 
varisacumab IgG1 kappa human Phase I 
varlilumab IgG1 kappa human Phase I 
vatelizumab IgG4 kappa humanised Phase I 
vedolizumab IgG1 kappa humanised Phase M 
veltuzumab IgG1 kappa humanised Phase I 
vesencumab IgG1 kappa human Phase I 
vonlerolizumab IgG1 kappa humanised Phase I 
vorsetuzumab IgG1 kappa humanised Phase I 
vunakizumab IgG1 kappa humanised Not Stated 




A.3 Predictive Modelling mAbs 
Table A.3. List of 137 mAbs from Jain et al (2017) “Biophysical properties of the clinical-stage antibody 
landscape” PNAS. The original chain isotypes and species origin is given for each mAb along with the 
corresponding experimental measurements for melting point (Tm), HIC retention times and mAb yield from HEK 
cell line. The two last columns indicate if either primary sequence-based or MD based descriptors were generated 
for a sample and then used for model development. 
Name HC LC Species Origin Tm HIC Yield Primary MD 
abituzumab IgG2 kappa humanised 75.50 9.23 89.56 ● ● 
abrilumab IgG2 kappa human 71.00 9.41 100.22 ● ● 
adalimumab IgG1 kappa human 71.00 8.82 134.93 ● ● 
alemtuzumab IgG1 kappa humanised 74.50 8.77 144.65 ● ● 
alirocumab IgG1 kappa human 71.50 9.04 69.23 ● ● 
anifrolumab IgG1 kappa human 62.50 8.80 82.05 ● ● 
atezolizumab IgG1 kappa humanised 73.50 13.35 164.09 ●  
bapineuzumab IgG1 kappa humanised 73.00 8.86 151.09 ● ● 
basiliximab IgG1 kappa chimeric 60.50 9.58 107.46 ● ● 
bavituximab IgG1 kappa chimeric 59.50 11.50 45.11 ● ● 
belimumab IgG1 lambda human 60.00 10.46 10.47 ● ● 
benralizumab IgG1 kappa humanised 76.00 9.47 146.71 ● ● 
bevacizumab IgG1 kappa humanised 63.50 11.77 49.98 ● ● 
bimagrumab IgG1 lambda human 72.00 10.13 150.24 ● ● 
blosozumab IgG4 kappa humanised 70.50 9.24 120.01 ● ● 
bococizumab IgG2 kappa humanised 67.00 10.18 95.79 ● ● 
brentuximab IgG1 kappa chimeric 72.00 10.54 268.06 ● ● 
briakinumab IgG1 lambda human 71.50 9.36 121.99 ● ● 
brodalumab IgG2 kappa human 74.50 9.08 150.86 ● ● 
canakinumab IgG1 kappa human 72.00 9.32 45.72 ● ● 
carlumab IgG1 kappa human 69.50 11.17 243.32 ● ● 
certolizumab IgG1 kappa humanised 81.50 11.48 186.71 ● ● 
cetuximab IgG1 kappa chimeric 68.50 10.11 109.16 ● ● 
cixutumumab IgG1 lambda human 73.50 11.76 154.26 ● ● 
clazakizumab IgG1 kappa humanised 69.50 9.57 113.48 ● ● 
codrituzumab IgG1 kappa humanised 73.00 8.84 66.35 ● ● 
crenezumab IgG4 kappa humanised 72.00 10.03 149.27 ● ● 
dacetuzumab IgG1 kappa humanised 68.00 8.47 128.45 ● ● 
daclizumab IgG1 kappa humanised 74.00 9.29 245.11 ● ● 
dalotuzumab IgG1 kappa humanised 77.00 9.89 82.42 ● ● 
daratumumab IgG1 kappa human 71.00 9.51 233.33 ● ● 
denosumab IgG2 kappa human 69.50 8.50 134.17 ● ● 
dinutuximab IgG1 kappa chimeric 69.00 9.83 76.43 ● ● 
drozitumab IgG1 lambda human 63.00 9.29 22.07 ● ● 
duligotuzumab IgG1 kappa humanised 67.50 10.21 192.58 ● ● 
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dupilumab IgG4 kappa human 76.50 10.16 163.55 ● ● 
eculizumab IgG2/G4 kappa humanised 66.00 10.61 226.47   
efalizumab IgG1 kappa humanised 72.50 8.67 166.99 ● ● 
eldelumab IgG1 kappa human 59.50 12.42 89.25 ● ● 
elotuzumab IgG1 kappa humanised 83.50 10.31 213.19 ● ● 
emibetuzumab IgG4 kappa humanised 71.50 9.64 98.75 ● ● 
enokizumab IgG1 kappa humanised 68.00 12.93 239.82 ● ● 
epratuzumab IgG1 kappa humanised 65.00 9.19 78.23 ● ● 
etrolizumab IgG1 kappa humanised 76.00 9.32 173.84 ● ● 
evolocumab IgG2 lambda human 65.00 10.36 260.68 ● ● 
farletuzumab IgG1 kappa humanised 75.50 9.49 220.82 ● ● 
fasinumab IgG4 kappa human 71.00 10.03 110.37 ● ● 
fezakinumab IgG1 lambda human 69.00 11.80 141.45 ● ● 
ficlatuzumab IgG1 kappa humanised 75.00 9.42 249.03 ● ● 
figitumumab IgG2 kappa human 66.50 10.75 119.92 ● ● 
fletikumab IgG4 kappa human 71.50 11.04 220.38 ● ● 
foralumab IgG1 kappa human 66.00 9.84 174.44 ● ● 
fresolimumab IgG4 kappa human 74.00 10.88 166.04 ● ● 
fulranumab IgG2 kappa human 68.50 9.33 142.02 ● ● 
galiximab IgG1 lambda chimeric 67.50 12.20 174.12 ● ● 
ganitumab IgG1 kappa human 78.50 9.33 229.44 ● ● 
gantenerumab IgG1 kappa human 77.50 9.00 162.66 ● ● 
gemtuzumab IgG4 kappa humanised 72.50 12.26 171.30 ● ● 
gevokizumab IgG2 kappa humanised 71.50 8.83 136.36 ● ● 
girentuximab IgG1 kappa chimeric 63.00 9.08 30.72 ● ● 
glembatumumab IgG2 kappa human 70.50 13.68 152.71 ● ● 
golimumab IgG1 kappa human 70.00 11.36 163.24 ● ● 
guselkumab IgG1 lambda human 69.50 11.40 167.34 ● ● 
ibalizumab IgG4 kappa humanised 72.00 10.24 133.28 ● ● 
imgatuzumab IgG1 kappa humanised 71.50 10.09 187.71 ● ● 
infliximab IgG1 kappa chimeric 64.50 10.36 6.58 ● ● 
inotuzumab IgG4 kappa humanised 83.00 9.72 169.77 ● ● 
ipilimumab IgG1 kappa human 73.00 11.57 169.56 ● ● 
ixekizumab IgG4 kappa humanised 83.00 10.94 97.28 ● ● 
lampalizumab IgG1 kappa humanised 67.00 9.25 187.08 ● ● 
lebrikizumab IgG4 kappa humanised 66.00 12.38 61.61 ● ● 
lenzilumab IgG1 kappa human 74.00 8.72 184.74 ● ● 
lintuzumab IgG1 kappa humanised 75.50 10.87 229.97 ● ● 
lirilumab IgG4 kappa human 70.00 25.00 270.48   
lumiliximab IgG1 kappa chimeric 64.50 9.55 86.27 ● ● 
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Name HC LC Species Origin Tm HIC Yield Primary MD 
matuzumab IgG1 kappa humanised 72.00 9.84 224.33 ● ● 
mavrilimumab IgG4 lambda human 68.50 10.30 150.55 ● ● 
mepolizumab IgG1 kappa humanised 78.50 9.24 221.48 ● ● 
mogamulizumab IgG1 kappa humanised 68.50 9.64 89.77 ● ● 
motavizumab IgG1 kappa humanised 86.00 9.69 133.55 ● ● 
muromonab IgG2 kappa chimeric 74.50 8.90 113.52 ●  
natalizumab IgG4 kappa humanised 79.50 9.70 251.75 ● ● 
necitumumab IgG1 kappa human 76.50 10.81 198.60 ● ● 
nimotuzumab IgG1 kappa humanised 65.50 25.00 15.13   
nivolumab IgG4 kappa human 66.00 9.02 178.81 ● ● 
obinutuzumab IgG1 kappa humanised 73.00 10.64 176.44 ● ● 
ocrelizumab IgG1 kappa humanised 70.50 9.91 137.77 ● ● 
ofatumumab IgG1 kappa human 68.00 9.73 249.75 ● ● 
olaratumab IgG1 kappa human 62.50 10.61 141.94 ● ● 
olokizumab IgG4 kappa humanised 69.00 9.91 115.26 ● ● 
omalizumab IgG1 kappa humanised 77.50 9.52 150.45 ● ● 
onartuzumab IgG1 kappa humanised 80.00 9.92 147.93 ● ● 
otelizumab IgG1 lambda 
humanized/ 
chimeric 
75.50 9.08 152.08   
otlertuzumab IgG1 kappa humanised 68.50 10.96 149.60 ● ● 
ozanezumab IgG1 kappa humanised 67.00 10.03 97.07 ● ● 
palivizumab IgG1 kappa humanised 79.50 9.33 243.12 ● ● 
panitumumab IgG2 kappa human 78.50 9.48 179.59 ● ● 
panobacumab IgM kappa human 69.00 9.83 107.60   
parsatuzumab IgG1 kappa humanised 64.50 9.11 40.02 ● ● 
patritumab IgG1 kappa human 71.50 10.15 68.77 ● ● 
pembrolizumab IgG4 kappa humanised 66.00 11.07 64.91 ● ● 
pertuzumab IgG1 kappa humanised 78.50 10.11 31.43 ● ● 
pinatuzumab IgG1 kappa humanised 79.00 9.22 130.58 ● ● 
polatuzumab IgG1 kappa humanised 74.00 8.76 225.06 ● ● 
ponezumab IgG2 kappa humanised 61.00 10.50 16.96 ● ● 
radretumab IgE kappa human 77.00 9.51 151.17   
ramucirumab IgG1 kappa human 66.00 9.43 90.67 ● ● 
ranibizumab IgG1 kappa humanised 65.00 12.14 41.45 ● ● 
reslizumab IgG4 kappa humanised 75.50 9.82 191.57 ● ● 
rilotumumab IgG2 kappa human 79.00 12.63 173.08 ● ● 
rituximab IgG1 kappa chimeric 69.00 10.80 164.14 ● ● 
robatumumab IgG1 kappa human 80.00 9.51 117.12 ● ● 
romosozumab IgG2 kappa humanised 76.00 9.18 227.69 ● ● 
sarilumab IgG1 kappa human 64.00 8.99 181.79 ● ● 
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Name HC LC Species Origin Tm HIC Yield Primary MD 
secukinumab IgG1 kappa human 72.00 11.39 148.96 ● ● 
seribantumab IgG2 lambda human 77.50 10.42 189.98 ● ● 
sifalimumab IgG1 kappa human 67.00 9.65 158.63 ● ● 
siltuximab IgG1 kappa chimeric 64.50 11.00 95.67 ● ● 
simtuzumab IgG4 kappa humanised 66.50 10.41 191.44 ● ● 
sirukumab IgG1 kappa human 68.00 11.26 109.81 ● ● 
tabalumab IgG4 kappa human 64.00 10.85 121.60 ● ● 
tanezumab IgG2 kappa humanised 75.50 12.39 48.86 ● ● 
teplizumab IgG1 kappa humanised 64.50 8.79 150.88 ●  
tigatuzumab IgG1 kappa humanised 64.50 10.02 178.97 ● ● 
tildrakizumab IgG1 kappa humanised 77.50 11.08 181.89 ● ● 
tocilizumab IgG1 kappa humanised 91.50 9.09 139.65 ● ● 
tovetumab IgG2 kappa human 63.50 8.67 277.18 ● ● 
tralokinumab IgG4 lambda human 63.00 10.26 121.43 ● ● 
trastuzumab IgG1 kappa humanised 78.50 9.66 159.48 ● ● 
tremelimumab IgG2 kappa human 75.00 11.56 229.59 ● ● 
urelumab IgG4 kappa human 66.00 11.16 143.92 ● ● 
ustekinumab IgG1 kappa human 69.50 8.78 152.72 ● ● 
vedolizumab IgG1 kappa humanised 80.50 10.94 221.76 ● ● 
veltuzumab IgG1 kappa humanised 70.00 11.09 224.95 ● ● 
visilizumab IgG2 kappa humanised 71.00 9.01 242.01 ● ● 
zalutumumab IgG1 kappa human 72.50 9.34 200.51 ● ● 








Appendix B  
B.1 MATLAB Scripts 
Code B.1. MATLAB script for implementation of OVR classification strategy in SVC function from LibSVM 
toolbox for model fitting. 
function [assignedClass,prob,model] = fitSVC_ovr(X,labels,svmcmd) 
 
nSam = size(X,1); 
labelSet = unique(labels); 
nClasses = length(labelSet); 
 
% MEMORY ALLOCATION 
SVC = cell(nClasses,1); 
prob = zeros(nSam,nClasses); 
decv = zeros(nSam,nClasses); 
     
for i=1:nClasses         
    % MODEL DEVELOPMENT 
    SVC{i} = svmtrain(double(labels == labelSet(i)),pX,svmcmd); 
 
    % PREDICTION OF SAMPLES 
    [~,~,prob(:,i)] = svmpredict(double(labels == labelSet(i)), ...  
                      X,SVC{i},'-q'); 
 
    % DECISION VALUES 
    decv(:, i) = prob(:,i) * (2 * SVC{i}.Label(1) - 1); 
end 
 
% CLASS ASSIGNMENT 
[~,assignedClass] = max(decv,[],2); 
assignedClass = labelSet(assignedClass); 
 
model.SVC = SVC; 




Code B.2. MATLAB script for implementation of OVR classification strategy in SVC function from LibSVM 
toolbox for model prediction. 
function [assignedClass,prob] = predictSVC_ovr(X,labels,model) 
 
SVC = model.SVC; 
nSam = size(X,1); 
labelSet = model.labelSet; 
nClasses = length(labelSet); 
 
% MEMORY ALLOCATION 
prob = zeros(nSam,nClasses); 
decv = zeros(nSam,nClasses); 
     
for i=1:nClasses          
    % PREDICTION OF SAMPLES 
    [~,~,prob(:,i)] = svmpredict(double(labels == labelSet(i)), ...  
                      X,SVC{i},'-q'); 
 
    % DECISION VALUES 
    decv(:, i) = prob(:,i) * (2 * SVC{i}.Label(1) - 1); 
end 
 
% CLASS ASSIGNMENT 
[~,assignedClass] = max(decv,[],2); 




B.2 GROMACS Parameters 
Code B.3. Energy minimisation parameters in EM.mdp. 
integrator   = steep 
emstep   = 0.002 
nsteps   = 50000 
emtol   = 20.0 
 
; Parameters for atom neighbour search and interaction calculations 
nstxout   = 800  
nstlist   = 1 
cutoff-scheme  = Verlet 
ns_type   = grid 
coulombtype  = PME  
rcoulomb   = 1.0 
rvdw   = 1.0 
pbc   = xyz 
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Code B.4. NVT parameters with defined volume and temperature (NVT.mdp).  
title   = NVT equilibration  
define   = -DPOSRES 
 
; Run parameters 
integrator   = md ; leap-frog integrator 
nsteps   = 5000 ; 2 * 5000 = 10 ps 
dt   = 0.002 ; 2 fs 
 
; Output control (saves coordinates, velocities and energies to log file) 
nstxout   = 5000 
nstvout   = 5000 
nstenergy   = 5000 
nstlog   = 5000 
 
; Bond parameters 
Continuation  = no 
constraint_algorithm  = lincs  
constraints  = all-bonds 
lincs_iter   = 1 
lincs_order  = 4 
 
; Neighborsearching 
cutoff-scheme  = Verlet 
ns_type   = grid 
nstlist   = 10 
rcoulomb   = 1.0  
rvdw   = 1.0 
 
; Electrostatics 
Coulombtype  = PME 
pme_order   = 4 
fourierspacing  = 0.16 
 
; Temperature coupling is on 
tcoupl   = V-rescale 
tc-grps   = Protein Non-Protein 
tau_t   = 0.1 0.1 
ref_t   = 300 300 
 
; Pressure coupling is off 
pcoupl   = no 
 
; Periodic boundary conditions 
Pbc   = xyz 
 
; Dispersion correction 
DispCorr   = EnerPres 
 
; Velocity generation 
gen_vel   = yes 
gen_temp   = 300 
gen_seed   = -1 
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Code B.5. NPT parameters with defined pressure (NPT.mdp). Resumes after end of NVT simulation. 
title   = NPT equilibration  
define   = -DPOSRES 
 
; Run parameters 
integrator   = md ; leap-frog integrator 
nsteps   = 5000 ; 2 * 5000 = 10 ps 
dt   = 0.002 ; 2 fs 
 
; Output control (saves coordinates, velocities and energies to log file) 
nstxout   = 5000 
nstvout   = 5000 
nstenergy   = 5000 
nstlog   = 5000 
 
; Bond parameters 
continuation  = yes ; Restarting after NVT  
constraint_algorithm  = lincs  
constraints  = all-bonds 
lincs_iter   = 1 
lincs_order  = 4 
 
; Neighborsearching 
cutoff-scheme  = Verlet 
ns_type   = grid 
nstlist   = 10 
rcoulomb   = 1.0 
rvdw   = 1.0 
 
; Electrostatics 
coulombtype  = PME 
pme_order   = 4 
fourierspacing  = 0.16 
 
; Temperature coupling is on 
Tcoupl   = V-rescale 
tc-grps   = Protein Non-Protein 
tau_t   = 0.1 0.1 
ref_t   = 300 300 
 
; Pressure coupling is on 
pcoupl   = Parrinello-Rahman 
pcoupltype   = isotropic 
tau_p   = 2.0 
ref_p   = 1.0 
compressibility  = 4.5e-5 




Code B.5 Continued. NPT parameters with defined pressure (NPT.mdp). Resumes after end of NVT simulation. 
; Periodic boundary conditions 
pbc   = xyz 
 
; Dispersion correction 
DispCorr   = EnerPres 
 
; Velocity generation 




Code B.6. Production run parameters (MD.mdp). Resumes after end of NPT simulation. 
title   = MD simulation 
 
; Run parameters 
integrator   = md ; leap-frog integrator 
nsteps   = 25000000 ; 2 * 25000000 = 100 ns 
dt   = 0.002 ; 2 fs 
 
; Output control 
nstxout   = 20000 
nstvout   = 20000 
nstenergy   = 20000 
nstlog   = 20000 
 
; Bond parameters 
continuation  = yes ; Restarting after NPT  
constraint_algorithm  = lincs 
constraints  = all-bonds 
lincs_iter   = 1 
lincs_order  = 4 
 
; Neighborsearching 
cutoff-scheme  = Verlet 
ns_type   = grid 
nstlist   = 10 
rcoulomb   = 1.0 
rvdw   = 1.0 
 
; Electrostatics 
coulombtype  = PME 
pme_order   = 4 
fourierspacing  = 0.16 
 
; Temperature coupling is on 
tcoupl   = V-rescale 
tc-grps   = Protein Non-Protein 
tau_t   = 0.1 0.1 
ref_t   = 300 300 
 
; Pressure coupling is on 
Pcoupl   = Parrinello-Rahman 
Pcoupltype   = isotropic 
tau_p   = 2.0 
ref_p   = 1.0 
compressibility  = 4.5e-5 
 
; Periodic boundary conditions 
pbc   = xyz 
 
; Dispersion correction 
DispCorr   = EnerPres 
 
; Velocity generation 




Appendix C  
C.1 Chapter 4 Modelling Results 
 
Figure C.1. PCA exploration of descriptors from VH, CH1, CH2 and CH3 heavy chain domains with a clear 
separation of IgG1 (red), IgG2 (green) and IgG4 (blue) occurred in the scores generated from PSD2 (a), PSD3 (c) 
and PSD4 (e). The vast majority of domain contribution for the HC isotype separation of the scores originated 




Figure C.2. PCA exploration of descriptors from VL and CL light chain domains with a clear separation of kappa 
(red) and lambda (green) occurred in the scores generated from PSD2 (a), PSD3 (c) and PSD4 (e). Both VL and 





Figure C.3. Impact of LC isotype from the VL domain on the PCA exploration with two principal components. No 
clear separation of the species origins: chimeric (red), human (green) and humanised (blue) samples were apparent 
in PSD2 (a), PSD3 (c) and PSD4 (e). Instead, structural features related to the LC isotype from the VL domain had 




Figure C.4. ROC curves and AUC of cross-validation for chimeric (red line), human (green line) and humanised 
(blue line) with PLS-DA developed on (a) PSD1, (c) PSD2 and (e) PSD4 as well as SVC developed on (b) PSD1, 
(d) PSD2 and (f) PSD4. 
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C.2 Chapter 5 Modelling Results 
 
Figure C.5. PLS error for prediction of mAb yields in the calibration (blue line) and the cross-validation (red line) 
with regards to the number of latent variables developed from the V-WSP reduced descriptor sets of (a) PSD1, (b) 




Figure C.6. Impact of species on PLS models developed on the mAb yield where chimeric samples are coloured 
red, human samples in green and humanised in blue. PLS Influence plots for PSD1 (a), PSD2 (c), PSD3 (e) and 
PSD4 (g). PLS scores, 𝑻, for the individual samples for PSD1 (b), PSD2 (d), PSD3 (f) and PSD4 (h). 
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Table C.1. Hypothesis testing of heavy and light chain isotypes using Anderson-Darling Normality Test with a 
significance level of 0.05. H0 represents that the data follows a normal distribution. 
Factor Level Samples 
HIC   Yield 
p Decision   p Decision 
Species 
chimeric 10 0.9900 Keep H0  
0.2387 Keep H0 
humanised 45 0.0007 Reject H0  
0.1195 Keep H0 
human 26 0.0050 Reject H0  
0.8751 Keep H0 
 
 
Table C.2. Hypothesis testing of with a significance level of 0.05. Ho represents that there is no significant 
difference between means of different species origins. Non-parametric tests are referred to as NP and parametric 
test as P. 




HIC Species 3 NP Kruskal-Wallis - 0.3923 Keep H0 








Table C.3. Multiple comparison hypothesis testing with 2-sample T-test with an effective significance level of 
0.0133 according to Bonferroni Correction. H0 represents that no difference between means can be observed. 
First Level Second Level Equal variance p Decision 
chimeric human Yes (p=0.7314) 0.0313 Keep H0 
chimeric humanised Yes (p=0.8420) 0.0093 Reject H0 


















































































































































































































































































































































































































































































































































































































































































































































































C.3 Chapter 7 Modelling Results 
 
Figure C.7. PCA loadings of light chain descriptors from MSD1, MSD2 and MSD3. The first (a) and second (b) 
component of MSD1 calculated from descriptor generated from the entire light chain. The first (c) and second (d) 
component of MSD2 were calculated from descriptors generated individually from the VL and CL domains. The 
first (e) and second (f) component of MSD3 were calculated from descriptors generated from individual 
substructures in the VL and CL domains. Domain specific descriptors are separated by the black vertical dashed 
line in MSD2 and MSD3. 
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Table C.6. 80/20 sample splitting of the 79 selected IgG1-kappa samples. Splitting was performed with the 
CADEX algorithm on the three descriptor resolutions MSD1, MSD2 and MSD3 generated from the variable 
domains VH and VL. The splitting results of a stratified and non-stratified strategy is presented. The implemented 
sample stratification strategy was designed to place approximately 20% of each species origin in the test set for 





Not Stratified  Stratified 








chimeric 10 0 0.00  8 2 0.20 
human 23 3 0.12  20 6 0.23 
humanised 30 13 0.30  34 9 0.21 
MSD2 
chimeric 9 1 0.10  8 2 0.20 
human 23 3 0.12  20 6 0.23 
humanised 31 12 0.28  34 9 0.21 
MSD3 
chimeric 9 1 0.10  8 2 0.20 
human 21 5 0.19  20 6 0.23 





Figure C.8. ROC curves and AUC of cross-validation for chimeric (red line), human (green line) and humanised 
(blue line) with PLS-DA developed on (a) MSD1, (c) MSD2 and (e) MDS3 as well as SVC developed on (b) 
MSD1, (d) MSD2 and (f) MDS3. 
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Table C.7. Model benchmarking table for (a) HIC retention times and (b) mAb yields. Performance of all model 
permutations and descriptor sets in the Cross validation and Test set developed from 79 IgG1-kappa samples have 
been presented. Colouring was applied conforming to the OECD guidelines. Green indicates values higher than 
0.5 and 0.6 in the cross validation and Test set, respectively. Yellow indicates values between 0.3 and 0.5 in the 




Table C.8. List of descriptors from PLS model developed with GA for prediction of HIC retention times (LVs = 
9). The descriptor names and types have been given as well as which domain and substructure the descriptors were 
generated from.  
Index Descriptor Type Domain Substructure 
Regression 
Coefficient 
1 GC(F) Energy VH FW1 0.0673 
2 SIEP TAE VH FW1 -0.0892 
3 W(F) Energy VH CDR1 -0.0867 
4 SASAnon-polar Topo VH CDR1 0.0235 
5 SIEPMax TAE VH CDR1 -0.0898 
6 GC(F) Energy VH FW2 0.1844 
7 ΔGs Energy VH FW2 0.1245 
8 ln(FD) Topo VH FW2 0.0534 
9 Del(K)IA TAE VH FW2 -0.1129 
10 Gc(F) Energy VH CDR2 0.2312 
11 VOLTAE TAE VH CDR2 0.0738 
12 SIEPMax TAE VH CDR2 0.0272 
13 VOLTAE TAE VH FW3 -0.0655 
14 Del(G)NMax TAE VH FW3 -0.0755 
15 GC(F) Energy VH CDR3 0.1747 
16 GW(F) Energy VH CDR3 0.2325 
17 ΔGs Energy VH CDR3 -0.0820 
18 ΔGel Energy VH CDR3 0.1667 
19 SASApolar Topo VH CDR3 0.3130 
20 Spolar Topo VH CDR3 0.0776 
21 Snon-polar Topo VH CDR3 -0.1258 
22 VOLTAE TAE VH CDR3 0.0730 
23 SIEPMax TAE VH CDR3 -0.0948 
24 GC(F) Energy VH FW4 0.0297 
25 SASApolar Topo VL FW1 0.1018 
26 Gc(F) Energy VL CDR1 0.1803 
27 SASAnon-polar Topo VL CDR1 0.0818 
28 Snon-polar Topo VL CDR1 0.0066 
29 ln(FD) Topo VL CDR1 0.1763 
30 Del(Rho)NMax TAE VL CDR1 -0.1068 
31 ΔGs Energy VL FW2 -0.1137 
32 HBd Energy VL FW2 -0.1156 
33 SIDel(K)N TAE VL FW2 -0.1292 
34 ΔGTors Energy VL CDR2 0.2147 
35 SASAnon-polar Topo VL CDR2 0.2519 
36 Snon-polar Topo VL CDR2 0.1550 
37 Gc(F) Energy VL FW3 0.1116 
275 
Index Descriptor Type Domain Substructure 
Regression 
Coefficient 
38 Gc(F) Energy VL FW4 0.2662 
39 ΔGW Energy VL FW4 0.0374 
40 GC(F) Energy CH1 A-Strand 0.1552 
41 Gc(F) Energy CH1 B-Strand -0.1913 
42 SIEP TAE CH1 B-Strand 0.0681 
43 HBd Energy CH1 D-Strand 0.0992 
44 SASApolar Topo CH1 E-Strand -0.2145 
45 Del(K)Max TAE CH1 E-Strand -0.0814 
46 ΔGLJ Energy CH1 G-Strand -0.1064 
47 Del(K)Max TAE CH1 G-Strand -0.1336 
48 Del(K)Max TAE CL A-Strand 0.1670 
49 W(F) Energy CL C-Strand 0.1686 
50 ΔGTors Energy CL F-Strand -0.2348 






Appendix D  
D.1 Eigenvectors and Eigenvalues 
Eigenvectors are a special case of matrix multiplication where a transformation of these vectors 
only changes their magnitude where their original direction is retained. Eigenvectors can only 
be calculated for square matrices, but it should be noted that not all square matrices have them 
(Abdi, 2007). The definition of eigenvectors is presented in eq.(D.1). 
 
 𝑨𝒗 = 𝜆𝒗, 𝒗 ≠ 𝟎 (D.1) 
 
Here, 𝑨 is an arbitrary non-symmetric transformation matrix with 𝑀 rows and 𝑀 columns, 𝒗 is 
the eigenvector and 𝜆 is the eigenvalue. Given the square form of the transformation matrix, 𝑨, 
there will be 𝑚 eigenvectors and eigenvalues. Eq.(D.1) can then be rewritten to include all 
eigenvectors and eigenvalues according to eq.(D.2) and is referred to as the eigen space of 𝑨. 
 
 𝑨𝑽 = 𝑽𝚲 (D.2) 
 
Where, 𝑽 = [𝒗1 … 𝒗𝑀] is the eigenvector matrix and 𝚲 = diag(𝜆1, … , 𝜆𝑀) is a diagonal 
matrix consisting of the eigenvalues. 𝑽 is invertible if, and only if all eigenvectors are linearly 
independent, then the transformation matrix, 𝑨 can be decomposed according to eq.(D.3) which 
is also called the eigen-decomposition of 𝑨. 
 
 𝑨 = 𝑽𝚲𝑽
−1 (D.3) 
 
However, for a special type of matrices often used in statistics called positive semi-definite, the 
eigen-decomposition will always exist. A matrix, 𝑨, is positive semi-definite if obtained as the 
product of some matrix 𝑿 and its transpose according to eq.(D.4).  
 
 𝑨 = 𝑿𝑿
𝑇 or 𝑨 = 𝑿𝑇𝑿 (D.4) 
 
The positive semi-definite matrices are therefore always symmetric which results in all 
eigenvectors becoming orthonormal, meaning that pair-wise eigenvectors are orthogonal, 
eq.(D.5), and that the magnitude of each eigenvector is equal to one, eq.(D.6). The eigenvalues 




𝑇𝒗𝑙 = 0 if 𝑘 ≠ 𝑙, 𝑘, 𝑙 = 1, … , 𝑀 (D.5) 
 ‖𝒗𝑘‖ = 𝒗𝑘
𝑇𝒗𝑘 = 1 (D.6) 
 𝜆𝑘 ≥ 0 (D.7) 
 
The orthogonality of the eigenvectors implies that 𝑽−1 = 𝑽𝑇 and greatly simplifies the eigen-
decomposition of 𝑨 due to that the inverse does not need to be calculated. The expression in 
eq.(D.3) can be rewritten according to eq.(D.8). In statistics, common positive semi-definite 
matrices include the covariance, 𝚺, matrix and the correlation matrix. 
 





D.2 Singular Value Decomposition 
The Singular Value Decomposition (SVD) is another common technique that is used for 
calculating the principal components in PCA where 𝑿 is decomposed according to: 
 
 𝑿𝐶𝑒𝑛𝑡 = 𝑼𝑺𝑽
𝑇 (D.9) 
 
where 𝑼 (N x N) is unitary matrix, 𝑺 = diag(𝑠1, 𝑠2, … , 𝑠𝑚𝑖𝑛(𝑁,𝑀)) (N x M) is a diagonal matrix 
which will contain extra rows or columns of zeros if N > M or N < M, respectively. The matrix 
𝑽 is the eigenvector matrix and is equal to 𝑽 in the eigen-decomposition in eq.(2.12) only when 
𝑿 has been mean centred prior to SVD decomposition (Wall et al., 2003). Through substitution 
of eq.(D.9) into eq.(2.11), the relationship between the eigenvalues and the and the singular 









, 𝑘 = 1,… ,min (N,M) (D.10) 
 
The PC loadings will be the eigenvector matrix as stated in eq.(2.13) which means that the PC 
scores are calculated as the product of 𝑼 and 𝑺 according to: 
 
 𝑻 = 𝑼𝐒 (D.11) 
  
280 
D.3 Lagrange Multipliers in SVC 
Application of Lagrange multipliers is described here for the soft-margin SVC classifier 
covered in Section 2.3.2.2. In its essence the Lagrange multipliers reformulates the primal 






















where the constraints for the class boundaries have been multiplied by 𝛼𝑖 and the constraints 
for the slack variables have been multiplied by 𝛽𝑖. This is necessary in order to formulate the 
dual problem where optimisation is performed with regards to the samples instead of the 
variables. For the SVC algorithm to properly select the optimal solution, the Karush–Kuhn–
Tucker (KKT) conditions must hold true (Kuhn and Tucker, 2014). This means that the 
resulting Lagrangian, ℒ, in expression in eq.(D.9) must be differentiable as presented in KKT 
condition 1. The initial constraints from the primal must also hold true in the solution and is 
represented as KKT condition 2. KKT condition 3 is called the complementary slackness 
condition and is necessary in order to have a strong duality, meaning that the solution of the 
dual is equal to that of the primal.  





= 𝝎 − ∑𝛼𝑖𝑦𝑖𝒙𝑖
𝑁
𝑖=1















KKT condition 2 
 
 𝑦𝑖(𝝎 ∙ 𝒙𝑖 + 𝑏) − 1 ≥ 0 (D.16) 
 𝜉𝑖 ≥ 0 (D.17) 
 
KKT condition 3 
 
 𝛼𝑖(𝑦𝑖(𝝎
𝑇𝒙𝑖 + 𝑏) − (1 − 𝜉𝑖)) = 0 (D.18) 
 𝛽𝑖𝜉𝑖 = 0 (D.19) 
 
Through substitution with eq.(D.13) into eq.(D.12), the expression can be rewritten into the 






















The resulting constraints in eq.(D.17) are formulated based on eq.(D.13) and eq.(D.14) in KKT 
condition 2 as well as eq.(D.15) and eq.(D.16) in KKT condition 3. An example of the potential 
solutions for the Wolf dual is illustrated in Figure D.1 which is only dependent on the values 
𝛼𝑖. For more details on Lagrange multiplier in SVC, refer to the work of Hastie et al. (2009b). 
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Figure D.1. Example of optimisation solutions for the Lagrange dual which is only dependent on the values of 𝛼𝑖 
as well as the samples in the data set. 
